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ABSTRACT 
 
Genetic factors play an important role in the pathogenesis of Paget’s Disease of Bone (PDB). 
The most important predisposing gene is SQSTM1 which is mutated in about 10% of patients, 
additionally common variants at seven other loci have also been shown to predispose to PDB 
as well as environmental factors which are also important in the pathogenesis of PDB. Little 
research has been conducted on the relationship between the genetic variants that predispose 
to PDB and disease severity. Similarly, only limited information exists on the role that gene-
environment interactions play in the pathogenesis of PDB or its severity. The aim of the 
present thesis was to explore these issues in participants of the Paget’s Disease Randomised 
Trial of Intensive versus Symptomatic Management study (PRISM) and other study cohorts. 
In chapter 3, I investigate the relationship between SQSTM1 mutation status, disease severity 
and clinical outcome in 737 patients from the PRISM study. Mutations of SQSTM1 were 
detected in 80/737 (10.9%) patients. Mutation carriers had an earlier age at diagnosis; a greater 
number of affected bones and more commonly had required orthopaedic surgery and 
bisphosphonate therapy than those without mutations. Quality of life was significantly reduced 
in carriers and during the study; fractures were more common although most of these occurred 
in unaffected bone. This study demonstrates that SQSTM1 mutations are strongly associated 
with disease severity and complications of PDB. In chapter 4, I study associations between 
common genetic variants identified by genome wide association (GWAS), clinical severity 
and extent of PDB, alone and in combination with SQSTM1 mutations. This showed that these 
common variants were also associated with severity and extent of PDB in PRISM, but with 
weaker effects than SQSTM1 mutations. The findings were replicated in a multinational study 
involving 1940 subjects from centres in Italy, Spain and Australia. In all cohorts the GWAS 
risk alleles acted in an additive manner with SQSTM1 mutations to regulate disease severity 
and extent. By combining information from SQSTM1 status and the new risk alleles, however, 
we are able to develop a genetic risk score which delineated three distinct groups with 
markedly differing effects on disease extent and severity. 
In chapter 5, I study associations between PDB, severity and extent in relation to circulating 
levels of IgG antibodies against various viruses including Rubella, respiratory syncytial virus, 







   
interaction between viral antibody titres and SQSTM1 in predicting disease severity with the 
notable exception of mumps virus where subjects with the highest levels of antibodies that 
were SQSTM1 positive had in increased age at diagnosis than the other genotype / viral 
antibody groups.  Overall the studies do provide no support for the notion that patients with 
PDB have an abnormal antibody response to paramyxovirus or have had previous infections 
with these viruses more frequently than controls. This of course does not exclude the 
possibility that PDB patients might have a clinically occult slow virus infection which is not 
accompanied by an abnormality in the immune response. . This raises the possibility that 
genetic testing may be of value in identifying individuals at risk of developing severe disease 
and those at risk of complications. I also demonstrate that PBD patients have abnormalities in 
circulating antibodies to various viruses suggesting that the disease may be associated with 
disturbance in the response of the immune system to infectious agents but further investigation 
is required. This, perhaps, could explain the changes in the severity and prevalence of PDB 























   





The function of the bone is to facilitate body movement, to support and protect internal organs 
of the body, to act as a site for haematopoiesis and to act as storage and a reservoir of minerals 
and ions for the maintenance of calcium and phosphate homeostasis.  
 
Bone is a specialized type of connective tissue, which is composed of cells, vessels and extra 
cellular matrix components, which become mineralised with calcium salts in the form of 
hydroxyapatite. The bones also are covered with a thin layer of connective tissue called the 
periosteum and the ends of long bones are covered by articular cartilage. The external or 
periosteal surface of the bone is fibrous and functions as an anchor for the attachment of 
muscles, tendons and ligaments. Some bones (in adults is found only in the vertebrae, hips, 
breastbone, ribs, skull and at the ends) contain haematopoietic tissue in the bone marrow space. 
 
Bones are composed of an outer shell of cortical (compact) bone, which surrounds a network 
of trabecular (plates) or cancellous bone (Fig.1.1)  ( Boyce et al. 2003). Cortical bone is dense, 
and accounts for 80% of the total bone mass in the adult skeleton. Cortical bone is most 
abundant in the shafts of long bones  ( Dempster et al. 2006). It has a slow turnover rate, when 
compared with trabecular bone and a high resistance to bending and torsion. 
 
Cortical bone is composed of structures called osteons or Haversian systems. Each osteon 
consist of a central canal, containing vessels, nerves and possibly lymphatics. Osteons consist 
of concentric layers of mineralized bone. 
 
Trabecular bone, consists of rod-and plate-like elements; joined together to form a spongy 
structure, which contains space for vessels and bone marrow. Trabecular bone is most 







   
accounts for the remaining 20% of the total bone mass in adults, but contains nearly ten times 
the surface of the compact bone. 
 
While not all the bones are equal in size and consistency, on average they comprise about 25% 
water, 45% of mineral and 30% organic matter, mainly collagen and other proteins.  
 
The principal protein of the bone matrix is Type I collagen  ( Lammi et al. 2006), which is a 
fibrillar protein consisting of three individual protein chains wound together in a triple helix. 
Other proteins found in bone matrix include glycosaminoglycans, osteocalcin, osteonectin, 
bonesialo protein and osteopontin. Bone matrix confers properties of elasticity and flexibility 
and plays a role in its structural organization of the skeleton. Added to all the functions 
mentioned above, bones play a central role in calcium and phosphate metabolism, about 99% 
of all calcium in the body is in the bones. Stable levels of calcium in blood are essential to life, 
and bones act as source of calcium, releasing it or taking it up in response to regulatory 








   
 
Figure.1.1: The image is showing the internal structure of bones. A; cortical bone, is 
dense and forms the surface of bones, while B: Trabecular or cancellous bones is spongy 
and makes up the bulk of their interior. Original image taken from: 
http://www.sciencephoto.com/media/198137. 
 
The main minerals that can be found in bone are calcium, magnesium, sodium, and potassium. 
Heavy metals such lead, barium, uranium and strontium  ( Burton et al. 2003;  Garcia-Sanchez 
et al. 2005;  Jaworowski et al. 1985) are also present in low amounts. Bone and minerals are 
constantly being removed and replaced in a process known as bone remodelling  ( Horvath 
2006). 
 
The majority of the bones are formed during embryonic development by endochondral 
ossification, in which they are first modelled from an anlage of cartilage  ( Karsenty and 
Wagner 2002). Blood vessels invade the cartilage, which is resorbed by chondroclast, to form 
a medullary cavity. Subsequently the cartilage is replaced by cortical bone formed by 
periosteal apposition and by trabecular bone, which is laid down within the medullary space 







   
 
In the active skeleton, the integrity of bone is compromised by micro-fractures, excessive 




1.1.1. Bone remodelling 
Bone in the adult skeleton is constantly being renewed and repaired in response to a variety of 
stimuli, through the process of bone remodelling. Bone remodelling can be divided into four 
stages, resorption, reversal, formation and quiescence (Fig. 1.2). During the resorption phase, 
osteoclast precursors are recruited to a specific resorption site where they differentiate to form 
mature osteoclasts. Following retraction of the bone-lining cells, osteoclasts attach to the bone 
surface by forming a sealing zone and create a greatly invaginated secretory surface called the 
ruffled border. The ruffled border creates an acidic and proteolytic environment which results 
in an active bone resorption site in the enclosed space, called a resorption pit or Howship’s 
Lacuna. After osteoclasts have resorbed bone, there is a reversal phase during which the 
osteoclast undergoes apoptosis. Osteoblast precursors are attracted to the resorption pit, where 
they differentiate into mature osteoblast and secrete and deposit bone matrix. As bone 
formation proceeds, some osteoblast become embedded in the bone matrix and differentiate 
to osteocytes. Following bone formation, the osteoid is slowly mineralised to form mature 
bone. This is followed by a period of quiescence.  
 
Under normal conditions the amount of bone removed by osteoclasts exactly equals the 
amount of bone formed by osteoblast. An imbalance in the regulation of bone remodelling, 
can result in bone diseases such osteoporosis, sclerosing bone disease, etc. In Paget’s disease 
for example, there is up-regulation of bone resorption and bone formation, leading to 










   
 
Figure.1.2. Bone remodelling. 
 
 
Relative rates of bone resorption and bone formation relies on complex signalling pathways. 
These signalling pathways that regulate bone remodelling include several hormones, such as 
parathyroid hormone (PTH), vitamin D, growth hormone, cortico-steroids, sex-steroids, 
calcitonin, and several locally produced cytokines and growth factors (summary in Table 1.1). 
Semaphorins are a big family of guidance molecules, secreted, transmembrane, and GPI-
linked proteins, that have important roles in a variety of tissues. Recently published work, 
highlight the role of semaphorins on bone remodelling by a distinct mechanism, where 
Semaphorin 4d expressed by osteoclasts inhibits bone formation; semaphorin 3A exerts an 
osteoprotective effect by suppressing bone resorption and increasing bone formation                      
( Takayanagi 2012). Also we must mention the role of ephrin ligands and receptors, where 
Eph4 signaling into osteoblast enhances differentiation and EphB2 signalling into osteoclast 
precursors suppresses osteoclast differentiation, inducing a shift from bone resorption to bone 



















   
Systemic hormones such as parathyroid hormone (PTH), vitamin D3 and sex hormones affect 
bone remodelling throughout the skeleton and are responsible for increasing or decreasing 
bone remodelling. As an example, PTH, promotes RANKL production by osteoblast/stromal 
cells which accounts in part for the increased osteoclast activity seen in primary 
hyperparathyroidism  ( Boyce et al. 2003;  Suda et al. 1999). In addition to stimulating bone 
resorption, PTH also has anabolic effects on bone through a stimulatory effect as bone 
formation  ( Rubin and Bilezikian 2003). This is associated with intermittent, rather than 
continuous, exposure to PTH, which stimulates bone formation more than resorption. 
Intermittent doses of PTH stimulate bone formation and reduce fracture risk in 
postmenopausal women with osteoporosis.  
 
 
STIMULATES INHIBITS STIMULATES INHIBITS
PTH Oestrogen PTH IL-1
1,25-(OH)2D3 Androgens Oestrogen TNF
IL-1 Calcitonin Wnt SOST






BONE RESORPTION BONE FORMATION
 
Table 1.1: Main systemic and local factors involved in the regulation of bone 
remodelling; systemic hormones, local cytokines and growth factors. 
 
Mechanical loading is also thought to influence local bone remodelling, by regulatory 
secretion of osteotropic factors by the osteocytes, most notably sclerostin (SOST) and RANKL  
( Keller and Kneissel 2005). The osteocytes work as true mechanotransducer being able to 
convert the perceived mechanical strain signal into a biological out-put . In primary osteocytes, 
fluid flow shear stress increases intracellular calcium; promotes the release of nitric oxide 
(NO), ATP, and prostaglandins; induces opening of connexin 43 hemichannels; and enhances 







   
signaling pathways such as the Wnt/β-catenin and protein kinase A (PKA) pathways. The fluid 
flow shear stress also protects osteocytes against apoptosis, activates gene transcription and 
translation, and promotes dendrite elongation. It is still not clear what type of fluid flow shear 
stress occurs physiologically within the lacunocanalicular system ( Dallas et al. 2013). 
 
1.1.2. Osteocytes 
Bone remodelling is carried out by osteoblasts, osteocytes and osteoclasts, which are called 
collectively the bone remodelling unit (BRU), coupled together via paracrine cell signalling   
( Dempster et al. 2006) (Fig. 1. 3). 
 
 
Fig.1.3. Bone Remodelling Unit: A. Transmission electron micrograph of a rat osteocyte. 
B. Scanning electron micrograph of osteoblast on the endosteal surface of a rat long bone. 
C. Scanning electron micrograph of a human osteoclast cultured for 24 hours on a bone 
slice  ( Dempster et al. 2006). 
 
 Osteocytes are star shaped cells with long cytoplasmic processes, found in great numbers in 
compact bone. Osteocytes can be considered as terminally differentiated osteoblasts, which 
become trapped in the matrix they secrete. Osteocytes make up over 90% of the cells in bone  
( Dallas and Bonewald 2010). They are highly active cells, and have a high degree of 
interconnectivity to each other via long cytoplasmic extensions that occupy channels in the 
bone matrix called canaliculi. Osteocytes occupied a space in the bone called a lacuna. 
Osteocytes are known to be responsible for detecting and responding to mechanical loading 








   
 
 Osteocytes are also involved as regulators of phosphate and calcium homeostasis, by 
expression of Dentin matrix Protein 1, Phex, Mepe/OF45  ( Toyosawa et al. 2001;  van 
Bezooijen et al. 2004). Osteocytes also produce fibroblast growth factor-23 (FGF23)  ( Feng 
et al. 2006;  Liu et al. 2006a;  Liu et al. 2003;  Riminucci et al. 2003;  Sitara et al. 2004), which 
is a 32-kDa hormone  ( Quarles 2008) with a crucial role in phosphate (Pi) homeostasis                    
( Shimada et al. 2001). FGF23 is a member of the subfamily of FGFs that act as 
hormones/systemic factors due to their ability to interact with FGF receptor (FGFR) in the 
presence of the Klotho family of proteins  ( Tsujikawa et al. 2003). FGF23 principally 
functions as a phosphaturic factor acting as a counterregulatory phosphaturic hormone to 
maintain phosphate homeostasis in response to vitamin D  ( Larsson et al. 2004;  Liu et al. 
2006b;  Shimada et al. 2001) and counter-regulatory hormone for 1,25(OH)2D production            
( Liu et al. 2006b). An excess of FGF23 causes hypophosphatemia, also suppresses 
1,25(OH)2D  ( Bai et al. 2004;  Larsson et al. 2004;  Shimada et al. 2001). Deficiency of FGF23 
results in the opposite renal phenotype, with hyperphosphatemia and elevated production of 
1,25(OH)2D  ( Liu et al. 2006b;  Sitara et al. 2004). Supraphysiologic FGF23 levels found in 
several genetic disorders (such as autosomal-recessive hypophosphatemic rickets and 
osteoglophonic dysplasia) and in FGF23-producing tumours caused a decreased renal Pi 
reabsorption and hypophosphatemia resulting in osteomalacia and rickets  ( White et al. 2006). 
Parathyroid hormone receptor signalling in osteocytes increases the expression of fibroblast 
growth factor-23 in vitro and in vivo  ( Rhee et al. 2011).  
 
Recent in vitro studies reported that osteocytes support osteoclast formation and activation 
when co-cultured with osteoclast precursors  ( You et al. 2008). Osteocytes are the major 
source of receptor activator of nuclear factor ĸB ligand for osteoclast formation and bone 
remodelling  ( Nakashima et al. 2011). It has also been suggested that mechanical loading 
decreases the osteocyte’s potential to induce osteoclast formation by direct cell to cell contact 
but it is not clear that osteocytes in vivo are able to form direct cell to cell contact with 
osteoclast precursors  ( You et al. 2008). 
 
Mechanically stimulated osteocytes release soluble factors that can inhibit osteoclastogenesis 







   
mechanotransducers by regulating osteoclastogenesis via soluble signals. Negative regulators 
of the Wnt/β-catenin pathway such as Dkk1 and sclerostin are highly expressed in osteocytes. 
Dkk1 is expressed throughout the body but sclerostin is expressed mainly in osteocytes. 
Mature osteocytes have been shown to produce sclerostin, coded by the gene SOST that can 
inhibit osteoblast activity  ( Bonewald 2011). 
 
As well as converting mechanical strain into biochemical signals that regulate resorption or 
formation  ( Gluhak-Heinrich et al. 2003;  Lanyon et al. 1993), osteocytes appear to be 
involved in the deposit or removal of mineral from lacunae in a process called osteocyte 
osteolysis  ( Bonewald 2007;  Lane et al. 2006). 
 
Osteocytes have the ability to move within lacunae and extension and retraction of dendrites 




Osteoblasts are responsible for formation and mineralization of bone matrix. Osteoblasts are 
believed to originate from a common mesenchymal progenitor (Fig. 1. 4) and the 
differentiation pathway is regulated by expression of the runt-related transcription factor 2 
(Runx2)/ core-binding factor α-1 (Cbfa1) and Osterix (OSX) which up-regulate expression of 
osteoblast-specific genes  ( Galindo et al. 2005) and activating transcription factor 4 (ATF4) 
which are known to be crucial for the process  ( Matsuguchi et al. 2009).Bone morphogenetic 
proteins (BMP’s) such as BMP-7/OP-1 are strongly osteoinductive in vivo and in vitro                  
( Takahashi et al. 2005), and cause commitment and differentiation of osteoprogenitor cells 
and pre-osteoblasts into mature osteoblasts. 
 
During differentiation from mesenchymal progenitors various hormones and cytokines 
regulate osteoblast differentiation. Among these, BMPs are the most potent inducers. The 
BMPs also induce non-osteogenic cells to differentiate into osteoblast lineage cells. Sonic and 







   
differentiation. Cbfa1, a transcription factor from the runt-domain gene family, is essential but 
not sufficient for osteoblast differentiation and bone formation  ( Yamaguchi et al. 2000).  
 
Osteoblasts have progenitors in common with chondrocytes, myocytes and adipocytes. 
Primitive osteoprogenitors and related mesenchymal precursors arise in the embryo and some 
persist into adulthood where they contribute to bone remodelling and fracture healing (Fig. 1. 
4).  
Investigations of knockout and transgenic mice models of Wnt pathway components including 
LRP5 and 6, beta catenin, secreted frizzled-related protein 1 and 4, dickkopf-1 and -2, 
sclerotin, axin-2 and T cell factor-1 have shown that canonical signalling modulates many 
aspects of osteoblast physiology including proliferation, differentiation, function, 
mineralization, apoptosis and mechano-sensory perception as well as coupling to osteoclast 
activity. The Wnts are a large family of signalling molecules  ( Bodine 2008). These proteins 
bind to a membrane receptor complex comprised of a frizzled (FZD) G protein coupled 
receptor and a low density lipoprotein (LDL) receptor related protein (LRP). In recent years 
canonical Wnt signalling has been reported to play a significant role in the control of bone 
formation and remodelling. Mutations in LRP5 are associated with low bone mineral density, 
fractures and osteoporosis-pseudoglioma and “high-bone-mass” syndromes  ( Ferrari et al. 
2004). Also some bone forming agents like bone morphogenic proteins (BMP) and parathyroid 
hormone have been demonstrated to interact with and utilize components of the Wnt signalling 
pathway  ( Bodine 2008). 
 
Additionally, the bioactive phospholipids, lysophosphatidic acid (LPA) has been shown to 
induce proliferation of primary rat osteoblast through a pathway that involves Gi proteins and 
cytosolic Ca2+  ( Grey et al. 2001). Studies in vitro have shown that LPA inhibits apoptosis of 
primary rat osteoblasts  ( Grey et al. 2002). It has also been reported that LPA induces 
osteoblastic differentiation of human mesenchymal stem cells by interacting with the receptors 
LPA1 and LPA4  ( Liu et al. 2010). 
 
The mature osteoblast phenotype appears to be heterogeneous with subpopulations of 
osteoblasts expressing only subsets of the known osteoblast markers  ( Aubin 1998a;  Aubin 







   
physiologic signals, meaning that osteoblast from different bone regions, may exhibit different 
response to hormonal, mechanical, and developmental stimulation  ( Lian et al. 2003). 
 
Osteoblasts can also differentiate to become bone lining cells, which form a monolayer on 




Figure.1.4. Osteoblast differentiation; the blue arrows are indicating the place of action 
of some of the factors involved in the different stages of differentiation. BMPs (bone 
morphogenetic proteins), Cbfa1 (core-binding factor  α-1), FGF (fibroblast growth 
factor), IGF (insulin-like growth factor), LPA (lysophosphatidic acid),LRP5 (low 
density lipoprotein receptor related protein 5), OSX (osterix), PTH (parathyroid 
hormone), Runx2 (runt-related transcription factor 2), TGF-β               (transforming 
growth factor beta), VEGF (vascular endothelial growth factor). 
 
 
Mature osteoblasts are mononuclear cells that have a large nucleus, a large Golgi, and 
extensive endoplasmic reticulum. They secrete collagen and other bone matrix proteins which 
mineralise to form mature bone. Mineralization is achieved by release of matrix vesicles, 
which are released by chondrocytes, osteoblasts, odontoblasts, and tenocytes into selected sites 
where matrix calcification will occur. Additionally the osteoblasts produce alkaline 
phosphatase which has an important role in the bone mineralization, by degrading 
pyrophosphate. A substantial amount of bone alkaline phosphatase (ALP) is located at the 









   
1.1.4. Osteoclasts 
Osteoclasts were discovered by Kolliker in 1873 ( Nijweide et al. 1986). This cells are of 
haemotopoietic origin and arise from the monocyte/macrophage cell lineage  ( Suda et al. 
1997;  Teitelbaum 2000). Osteoclast differentiation and activity is crucially dependent on the 
cytokines, receptor activator of NF-ĸB ligand (RANKL), MCSF and osteoprotegerin  
 ( Dugard et al. 2005). Mature osteoclast are large multinucleated cells typically with five 
nuclei and are about 150-200 µm in diameter. Giant osteoclasts can occur in some diseases, 
including Paget's disease of bone and bisphosphonate toxicity. These may have dozens of 
nuclei, and typically express major osteoclast proteins but have significant differences from 
cells in living bone due to the not-natural substrate  ( Basle et al. 1988;  Weinstein et al. 
2009)Osteoclasts are the cells responsible for bone resorption. Bone resorption can be defined 
as a phase of bone remodelling where the osteoclast precursors are recruited to a new bone 
resorption site where they differentiate and polarise to form mature osteoclasts and begin to 
resorb bone (Fig.1.5).  
In bone, osteoclasts are found in pits in the bone surface which are called resorption bays, or 
Howship's lacunae. Osteoclasts are characterized by a cytoplasm with a homogeneous, 
"foamy" appearance, due to a high number of vesicles and vacuoles. These vacuoles include 
lysosomes filled with acid phosphatase. Osteoclast rough endoplasmic reticulum is sparse, and 
the Golgi complex is extensive  ( Holtrop and King 1977;  Vaananen et al. 2000). 
At a site of active bone resorption, the osteoclast forms a specialized cell membrane, the 
"ruffled border," that opposes the surface of the bone tissue. This extensively folded or ruffled 
border facilitates bone removal by dramatically increasing the cell surface for secretion. Once 
activated, osteoclasts move to areas of micro-fracture in the bone by chemotaxis. The sealing 
zone is the attachment of the osteoclast's plasma membrane to the underlying bone. Sealing 
zones are bounded by adhesion structures called podosomes. Attachment to the bone matrix is 
facilitated by integrin receptors, such as αvβ3, via the specific amino acid motif Arg-Gly-Asp 
in bone matrix proteins. The osteoclast releases hydrogen ions through the action of carbonic 
anhydrase (H2O + CO2 → HCO3− + H+) through the ruffled border into the resorptive cavity, 
acidifying and aiding dissolution of the mineralized bone matrix into Ca2+, H3PO4, H2CO3, 
water and other substances. Additionally several hydrolytic enzymes, such as members of the 
cathepsin and matrix metalloprotease (MMP) groups, are released to digest the organic 







   
cathepsin K is secreted from the ruffled border into the resorptive pit. Cathepsin K, along 
with reactive oxygen species generated by TRAP, further degrades the bone extracellular 
matrix. 
Several other cathepsins are expressed in osteoclasts including cathepsins B, C, D, E, G, and 
L. The function of these cysteine and aspartic proteases is generally unknown within bone, 

















   
Figure.1.5. Osteoclast Differentiation and factors involved in osteoclastogenesis. 
Osteoclasts differentiate from a myeloid stem cell; PU-1 is required for determination of 
myeloid stem cells to the monocyte-macrophage lineage. M-CSF is required for 
proliferation and survival of cells in the monocyte-macrophage lineage. 
Osteoblasts/stromal cells are essentially involved in the activation as well as 
differentiation of osteoclasts through a mechanism involving cell-to-cell contact between 
osteoblasts/stromal cells and osteoclast precursors/osteoclasts. Osteoclast differentiation 
factor (ODF, also called RANKL/OPGL/TRANCE) and M-CSF are two essential factors 
produced by osteoblasts/stromal cells for osteoclastogenesis. c-fos is required for 
differentiation to osteoclast precursor. c-src required for polarization to allow bone 
attachment. RANKL is required for fusion and activation. Cathepsin K, carbonic 
anhydrase II, H+ATPase, Tartrate-resistant acid phosphatase and αvβ3 













RANKL is known as a type II membrane protein and is a member of the tumor necrosis factor 
(TNF) superfamily, is an essential cytokine for osteoclastogenesis  ( Boyle et al. 2003;  Suda 
et al. 1995) a protein encoded by TNFSF11; RANKL can be membrane-bound on osteoblasts 
and activated T cells or secreted by  other cell types  ( Cenci et al. 2000;  Suda et al. 1999;  
Theill et al. 2002). It has been recently reported that purified osteocytes express RANKL at 
higher levels than osteoblasts or bone marrow stromal cells  ( Nakashima et al. 2011). This 
raises the possibility that RANKL secreted by osteocytes may also regulate bone resorption    
( Xiong et al. 2011). 
 
 RANKL exists in two forms, a soluble form  (sRANKL) and a membrane bound form thought 
to be responsible for initiating osteoclast formation  ( Boyle et al. 2003;  Theoleyre et al. 2004;  
Xiong et al. 2011). RANKL interacts directly with its cognate receptor, RANK, on the surface 
of cells in the osteoclast lineage  ( Suda et al. 2002). 
 
 RANK does not possess innate kinase activity to mediate downstream signalling. Like other 
members of the TNF superfamily it recruits TNF receptor –associated factors (TRAFs), which 
bind other proteins that play a role in signal transduction.  
 
RANKL is necessary and sufficient, in the presence of small amounts of M-CSF, for the 
differentiation, maturation and activation of osteoclast from precursors in the 
osteoclast/macrophage lineage  ( Lacey et al. 1998;  Quinn et al. 1998;  Tsukii et al. 1998). 
Together with DC-STAMP, RANKL is responsible for promoting fusion of mononuclear 
committed osteoclast precursors, to form mature osteoclasts. Furthermore, RANKL promotes 
activation of osteoclast by enhancing polarization, ruffled border formation, and by preventing 
apoptosis  ( Boyce et al. 2003). RANKL knockout mice develop severe osteopetrosis which is 
due to a total absence of osteoclasts  ( Kong et al. 1999). Osteopetrosis, also known as marble 
bone disease and Albers-Schönberg disease, is an extremely rare inherited disorder whereby 







   
osteosclerosis  ( Lam et al. 2007). The cause of the disease is understood to be malfunctioning 
osteoclasts  ( Coudert et al. 2015); in osteopetrosis, the number of osteoclasts may be reduced, 
normal, or increased. Most importantly, osteoclast dysfunction mediates the pathogenesis of 
this disease  ( Askmyr et al. 2008). The disease is caused by underlying mutations that interfere 
with the acidification of the osteoclast resorption pit  ( Sobacchi et al. 2013). 
RANKL is also expressed in lymph nodes, thymus, mammary glands and lung and at low 
levels in a variety of other tissues including spleen and bone marrow  ( Kearns et al. 2008). It 
is expressed by synovial cells and activated T cells in joints of patients with inflammatory 
arthritis and contributes at least in part, to the joint destruction seen in patients with rheumatoid 
arthritis. RANKL also stimulates the release of osteoclast precursor into circulation and 
apparently osteoclast themselves regulate the egression of hematopoietic stem cells from 
niches within the marrow under the control of RANKL  ( Kollet et al. 2006). Thus, RANKL-
induced osteoclast activation appears to regulate haematopoietic stem cell mobilization as part 
of homeostasis and host defence mechanism linking bone remodelling with the regulation of 
haematopoiesis  ( Boyce and Xing 2008b). RANKL is also expressed in epithelial cells in 
mammary gland lobules during pregnancy and is required for hyperplasia of this cell during 
lactation and milk production in mice  ( Fata et al. 2000). 
 
 T cell production of RANKL also induces expression of IFN β by activated osteoclasts which 
acts through c-Fos to negatively regulate osteoclast formation; IFN β inhibits the 
differentiation by interfering with the RANKL—induced expression of c-Fos  ( Takayanagi et 
al. 2002b). This may be enhanced by T cell produced INFγ which degrades TRAF6, an 
essential adapter protein for RANK signalling  ( Takayanagi et al. 2002a). IFN-γ has been 
reported to be a strong suppressor of osteoclastogenesis in vitro through inhibition of RANKL 













   
1.1 6. RANK 
RANK is a member of the TNF receptor superfamily, protein encoded in humans by 
TNFRSF11 gene. It is widely expressed at mRNA level by osteoclast-like cells and 
mononuclear cells in contact with the cortical and trabecular bones surface  ( Ikeda et al. 2001).  
It is also expressed by skeletal muscle, thymus, liver, colon, small intestine, adrenal glands 
and by several human cell lines  ( Anderson et al. 1997). It appears to be expressed in fewer 
tissues than RANKL at the protein level. However, in addition to osteoclast precursors, RANK 
is expressed by mature osteoclasts, pre-osteoclasts, dendritic cells, breast and prostate cancers 
cells  ( Kim et al. 2006), CD14+ (monocytoid), CD19+ (B-lymphoid), CD56+ (NK cell), giant 
cell tumour of bone (GCT), and glycophorin A+ erythroid progenitors. Minor populations of 
T lymphocytes and bone marrow hematopoietic progenitors also expressed cell surface RANK  
( Atkins et al. 2006). 
 
In 2000 activating mutations (activating mutations refers to a substitution of one amino acid 
residue by another that confers a new higher activity upon the protein) in exon 1 of RANK 
have been reported in humans to account for the increased osteoclast formation, activity and 
osteolysis seen in some patients with familial Paget’s disease and familial expansile osteolysis 
(FEO) again underlying the importance of the system for osteoclast regulation in humans             
( Hughes et al. 2000). Familial Paget’s disease is the cases of Paget’s with a positive family 
history; the line is blurry to define Sporadic cases, which literally mean scattered or isolated, 
but mainly sporadic Paget’s disease are the cases where it is not family history of the disease. 
In 2004 a deletion mutation was reported that causes a lethal autosomal recessive 
osteopetrosis, confirming the importance of RANK for osteoclastogenesis  ( Kapur et al. 
2004). 
 
Targeted deletion of RANK causes osteopetrosis in mice. RANK -/- mice has increased 
numbers of CD11b+ osteoclast precursors in their spleen and peripheral blood, meaning that 
the defect is caused by failure of differentiation rather than a defect on survival of precursors. 
In RANK -/-   mice the teeth fail to erupt and the growth is reduced in comparison with 









   
1.1. 7.  Osteoprotegerin   
Osteoprotegerin (OPG) is a decoy receptor for RANKL and a member of the TNFR 
superfamily. It is a protein encoded by the tumour necrosis factor receptor superfamily 
member 11B (TNFRSF11B) gene  ( Hofbauer et al. 2001).   
 
Osteoprotegerin is homologous to RANK and acts as a decoy receptor for RANKL. By binding 
RANKL, OPG prevent the RANKL-RANK interaction and signalling inhibiting of osteoclast 
formation, differentiation and survival  ( Hofbauer et al. 2001). 
 
OPG is secreted by multiple cells and tissues, including osteoblasts, B cells, heart, kidney, 
liver, and spleen. It is mainly produced by B cells in bone marrow in normal mice  ( Boyce 
and Xing 2008a) . Osteoclast numbers and activity may increase if there is a change in the 
RANKL/OPG ratio due to either an increase, decrease or a change in both that leads to a 
change in the ratio in favour of RANKL. 
 
The osteo-protective role of OPG in humans has been confirmed by the report of homozygous 
partial deletions of TNFRSF11B in patients with juvenile Paget’s disease, an autosomal 
recessive disorder in which affected individuals have increased bone remodelling, osteopenia, 
bone expansion, deformity and fractures  ( Whyte et al. 2002). The expression of OPG is 
regulated in osteoblasts by a variety of cytokines, hormones, growth factors                ( 
Theoleyre et al. 2004), and Wnt/β-catenin  ( Glass et al. 2005).  Additionally, autoantibodies 
against osteoprotegerin have been described in a male patient with celiac disease who 
presented with severe osteoporosis and high bone turnover  ( Riches et al. 2009). The 
antibodies are able to block the inhibitory effect of the osteoprotegerin on signalling by the 
receptor activator of nuclear factor (NF)-κB (RANK); also the autoantibodies have been 
described in some additional cases with severe osteoporosis and patients with celiac disease    











   
1.1.8. M-CSF 
Macrophage Colony-Stimulating Factor (M-CSF) is a cytokine required for the survival and 
proliferation of osteoclast and macrophage precursors until their complete maturation (Fig. 1. 
4). The active form of M-CSF is found extracellularly as a disulphide-linked homodimer, and 
is thought to be produced by proteolytic cleavage of a membrane-bound precursor. M-CSF 
has been shown to be essential for differentiation of osteoclast precursors in mice and humans 
in vitro and in vivo  ( Fujikawa et al. 1996;  Sarma and Flanagan 1996;  Suda et al. 1995;  
Tanaka et al. 1993). 
 
Reflecting the fact that M-CSF is essential for differentiation, mice with a point mutation in 
the M-CSF gene (op/op mice) have severe osteopetrosis due to absence of osteoclasts                     
( Yoshida et al. 1990). 
 
Macrophage colony-stimulating factor is produced by many cell types, including fibroblast, 
bone-marrow stromal cells, osteoblasts, and activated monocytes/macrophages. M-CSF 
expression by osteoblasts and stromal cells is required for progenitor cells to differentiate into 





Dendritic Cell-specific Trans membrane protein (DC-STAMP) is a member of the trans 
membrane 7 superfamily of receptors and is encoded by the TM7SF4 gene. The protein is 
expressed specifically by antigen presenting dendritic cells and osteoclast precursors. Human 
and murine DC-STAMP proteins are highly conserved and localized to the endoplasmic 
reticulum of immature dendritic cells and translocate towards the Golgi compartment upon 
maturation  
 ( Eleveld-Trancikova et al. 2005;  Sanecka et al. 2011). 
 








   
 
Inhibition of DC-STAMP produces defects in osteoclast multinucleation, suppresses the 
formation of multinucleated osteoclast-like cells and reduces bone-resorbing activity causing 
osteopetrosis. Osteoclast fusion and multinucleation is controlled by DC-STAMP. 
Experiments in knock-out mice lacking expression of DC-STAMP, confirmed the function of 
DC-STAMP, as a critical regulator of the fusion of osteoclast precursors  ( Yagi et al. 2005).  
 
Additionally the lack of DC-STAMP also affects foreign body giant cell formation by 
macrophage cell fusion. The immunological and biological processes where DC-STAMP is 
involved in, are only recently emerging. Some data have suggested involvement of DC-
STAMP in phagocytosis and antigen presentation, which has been demonstrated by the fact 
that aged DC-STAMP knock-out mice show symptoms of autoimmune diseases  ( Hwang et 
al. 2014;  Sanecka et al. 2011;  Sawatani et al. 2008). 
 
 
1.1.11. Parathyroid hormone, Ca2+ and Calcitriol 
Parathyroid hormone (PTH) is an 84 amino acid peptide secreted by parathyroid glands. PTH 
is one of the two major hormones modulating calcium and phosphate homeostasis, the other 
being calcitriol  ( Potts 2013). The major regulatory signal for PTH secretion is serum calcium; 
which inversely affects PTH secretion. High levels of PTH, as seen in primary and secondary 
hyperparathyroidism, increase octeoclastic bone resorption. Low levels of PTH, delivered in 
an intermittent manner, seem to increase osteoblastic bone formation. PTH paradoxically can 
stimulate resorption when administered in a continuous fashion, or bone formation when 
administered intermittently  ( Kroll 2000). Bone resorption can be triggered by PTH in 
response to hypocalcemia; 99% of the body’s Ca2+ is present in bones. 
 
Low plasma calcium as already mentioned, stimulates PTH release, and PTH acts to resorb 
Ca2+ from the pool in bone and to enhance renal re-absorption of Ca2+. . A high level of calcium 
in plasma, stimulates calcitonin secretion which lowers plasma calcium by inhibiting bone 
resorption. Ca2+ is highly involved in mechanical loading signal transduction which is also 







   
bone cells is critical for enabling intracellular calcium fluxes to occur in osteoblast in response 
to loading  ( El-Haj et al. 1990). Patch clamping measurements have revealed the presence of 
several types of calcium channels, both voltage-sensitive and voltage-independent. These 
calcium channels, often coupled with intracellular calcium release, can respond to hormonal, 
cytokine and especially mechanical stimulation  ( Duncan et al. 1998). In addition, it has been 
shown that the production of matrix proteins, such as osteopontin and osteocalcin, are elevated 
in response to mechanical loading and that this response is strongly inhibited by the calcium 
channel blocker, nifedipine, and enhanced by the calcium channel agonist Bay K8644  ( 
Walker et al. 2000).  
 
Calcitriol, also called 1, 25-dihydroxycholecalciferol or 1, 25-dihydroxyvitamin D3, is the 
hormonally active form of vitamin D. Calcitriol increases the level of calcium in the blood by 
increasing the intestinal calcium absorption, specifically by increasing the calcium uptake 
through the brush border membrane of the enterocyte. Vitamin D also regulates skeletal 
metabolism through the RANK pathway. Additionally vitamin D promotes the mineralization 
of osteoid and stimulates bone resorption by mature osteoclast, indirectly by promoting cell 
recruitment and interaction with osteoblast and the fusion of monocytic precursors to 
osteoclast. Vitamin D also regulates the expression of several bone proteins, as osteocalcin. It 
promotes the transcription of osteocalcin and has bidirectional effects on type I collagen and 
alkaline phosphatase gene transcription  ( Adams et al. 1989;  Zaloga et al. 1984). 
 
 
1.1.12. Other factors involved in bone resorption 
Many other factors play a role in the regulation of osteoclast differentiation and function. There 
are two critical steps in the generation of mature osteoclast: step one is the commitment of the 
progenitor cells to osteoclast precursor cells, which involves the activation of osteoclast 
marker genes such as Tartrate-resistant acid phosphatase (TRAcP) and the calcitonin 
receptor; Step two, which is the fusion of TRAcP-positive mononuclear cells to form 
multinucleated osteoclasts. Pathological disruption of osteoclastic bone resorption leads to a 







   
( Balemans et al. 2005). Analysis of mice with mutations that result in the osteopetrotic 
phenotype have provided insights into the important factors involved in the differentiation of 
myeloid stem cells into active osteoclasts (Fig. 1. 5). 
 
Src tyrosine kinase plays an essential role, because its expression is required for the 
cytoskeletal protein rearrangement that results in formation of the ruffled border, which 
attaches the cell tightly to the bone surface  ( Boyce et al. 1992;  Boyce et al. 1993). Within 
this sealing zone, hydrogen and chloride ions are secreted through proton and chloride pumps 
and combine to form hydrochloric acid, which dissolves the mineral in the bone matrix. Src or 
other Src family members also appear to mediate RANKL-mediated osteoclast survival in a 
signalling pathway that involves phosphorylation of PI3 kinase, Akt, BAD and caspase 9, 
where caspase 9 prevents activation of the apoptosis pathway  ( Wong et al. 1999;  Xing et al. 
2001). 
 
The transcription factor PU-1 is essential for differentiation cells to cells of the 
osteoclast/macrophage lineage and PU.1 knockout mice are not only devoid of osteoclasts 
leading to osteopetrosis, but also lack macrophages within the marrow, lungs and liver                  
( Tondravi et al. 1997). C-fos is also an essential transcription factor in osteoclast 
differentiation and mice lacking c-fos develop severe osteopetrosis  ( Wang et al. 1992) 
 
Cathepsin K is another essential protein involved in bone remodelling and resorption. This 
protein, which is member of the peptidase C1 protein family, is predominantly expressed by 
Osteoclasts. Osteoclasts synthesize and secrete cathepsin K into the space between the 
osteoclast and the bone surface, where it degrades bone collagen. RANKL signalling via the 
calcineurin-calcium-NFAT signalling cascade plays an important role in the regulation of 
cathepsisn K expression  ( Troen 2006). 
 
The nuclear factor of activated T-cells (NFAT) is a family of transcription factors where 
NFATc1, in particular, is crucial for multiple seemingly unrelated biologic processes, 
including heart valve formation  ( Wu et al. 2011), T-cell activation, osteoclast development 
and the mitigation of hair follicle stem cell proliferation  ( Aliprantis and Glimcher 2010). 







   
osteoclast but not their survival  ( Ikeda et al. 2006); NFAT, Mitf and various components of 
AP-1 enhance osteoclast formation and bone resorption, while IFN-gamma, calcitonin, 
estradiol, and calcium have an inhibitory effect  ( Troen 2006). 
 
The fusion of osteoclast precursors to become a multinucleated bone resorbing active cell, 
require RANKL, DC-STAMP  ( Yagi et al. 2005) as mention before. 
 
Bone resorption relies on the extracellular acidification function of vacuolar (V-) ATPase 
proton pump(s) present in the plasma membrane of osteoclasts. Atp6v0d2, is an essential 
component of the osteoclast-specific proton pump that mediates extracellular acidification in 
bone resorption ( Wu et al. 2009), is a subunit of v-ATPase, is a component of the V-type H+ 
ATP6i osteoclast proton pump complex that secretes H+ from the osteoclast  ( Lee et al. 2006). 
Vacuolar ATPases, in the osteoclast plasma membrane, pump protons onto the bone surface 
which is necessary for bone resorption. They are also responsible for acidifying a variety of 
intracellular compartments in eukaryotic cells. Vacuolar-type proton transporting ATPase (V-
ATPase) is a multi-subunit complex and an enzyme  ( Finbow and Harrison 1997;  Nelson 
1992). The TCIRG1 gene through alternate splicing  ( Smirnova et al. 2005), encodes two 
proteins with similarity to subunits of the vacuolar ATPase, the encoded proteins seem to have 
different functions; mutations in the TCIRG1 locus, cause severe autosomal recessive 
osteopetrosis (ARO) in humans (Kornak et al. 2000). Osteopetrosis is an inherited disorder of 
impaired bone resorption, where the most commonly affected genes are CLCN7 and TCIRG1, 
encoding the Cl-/H+ exchanger CLC-7 and the a3 subunit of the vacuolar H+-ATPase, 
respectively  ( Barvencik et al. 2013). Significant association has been reported between 
CLCN7 polymorphisms with the variance of modulate bone density and bone resorption 
marker levels in postmenopausal women and with the variability of the autosomal dominant 
osteopetrosis type II phenotype  ( Kornak et al. 2006). 
 
As is evident, bone remodelling is a complex process regulated by multiple factors involving 
a number of cells and their differentiation and in this work I will not claim to mention and 
describe them all, but we need to underline the fact that while PDB is characterised by 
increases osteoblast and osteoclast activity, the primary cellular abnormality is generally 







   
 
 
1.2. Paget’s Disease of Bone 
 
1.2.1. Historical Aspects: Sir James Paget 
Paget’s disease was classically described by Sir James Paget, who studied medicine at St 
Bartholomew’s Hospital in London in 1834.  He was hard working, brilliant and dedicated 
student. 
 
In 1847 he was accepted as a surgeon at Barts and in 1858 he was Appointed Surgeon 
Extraordinary to Queen Victoria. In 1874 he received an honorary degree from the University 
of Cambridge (Paget, Sir James, Bart in Venn, J. & J. A., Alumni Cantabrigienses, Cambridge 
University Press, 10 vols, 1922-1958) at the age of sixty-one he is universally accepted as one 
eminent men of his profession. 
 
 In November 1876 Sir James Paget published a paper regarding a form of chronic bone 
disease which he called osteitis deformans. This paper described five cases of this disease, 
which had previously gone largely unrecognized. The main case described, was that of a 46 
year old coachman who first visited St Bartholomew’s Hospital in 1854 suffering from pain 
in his lower limbs. James Paget described the disease as “a chronic form of inflammation of` 
the bones”. Paget observed that the patient’s left shin bone and his left thigh bone were 
enlarged and deformed. No other abnormality was noted. It was an unknown condition and he 
was therefore unable to make a diagnosis. In the years that followed the bones of the man’s 
right leg also became enlarged and eventually his legs became bowed to such an extent that he 
could not bring his knees together. Simultaneously his skull became so large and deformed 
that he had to buy increasingly larger hats. The patient was so stooped that his head sank onto 
his chest and his height was reduced by over four inches. 
 
Twenty years after his first consultation the patient developed a rapidly enlarging bone mass 
in his left forearm which was diagnosed as bone cancer and possibly caused his death two 







   
dramatic aberration in the bone remodelling process that normally continues throughout life 
which Paget thought was inflammatory in nature so he called it osteitis deformans. This is the 
disease now known as Paget’s Disease of Bone. 
 
It was a remarkable feat of observation and diagnostic skill which brought about this diagnosis 
as another forty years elapsed before the development of X-rays allowing the whole skeleton 
to be examined in living patients for the first time. It was at this time that doctors realized that 
PDB was not the rare condition they had thought it to be, and that many older people have one 
or more bones affected by the disease, even though they may not be experiencing any 
symptoms. Paget’s original description of the condition is so accurate that not much has been 






1.2.2. Paget’s Disease of Bone 
Paget’s Disease of Bone (MIM 167250, 602080) is a focal disorder of the skeleton, 
characterized by increased and disorganised bone remodelling affecting one or more sites 
throughout the skeleton. This results in the deposition of abnormal bone which is mechanically 
weak. It is thought to be primarily a disorder of osteoclasts, although bone formation is also 
abnormally increased. 
 
 The main abnormality is a marked increase in the rate of bone resorption caused by large 
multinucleated osteoclasts. Radiologically, these areas are seen as an advancing osteolytic 
wedge in long bones or as osteoporosis circumscripta in the skull. The elevated bone turnover 
causes a subsequent compensatory increase in bone formation, leading to osteosclerosis and 
bone expansion (Fig. 1.6). Accelerated deposition of bone in a disorganized fashion, produces 
a “mosaic” pattern, rather than the normal linear lamellar pattern. The marrow spaces are filled 
by an excess of fibrous connective tissue with a marked increase in blood vessels, causing the 







   
 
PDB it is not a new disease. It has been described in various ancient skeletal remains, one of 
those being an Anglo-Saxon skeleton dated around 950AD, which was dug up at Jarrow 
Monastery, and is still available for examination  ( Wells and Woodhouse 1975). Other 
archaeological studies demonstrated the occurrence of the disease around 1500AD  ( Rogers 














   
Figure. 1. 6: Panel a; Osteosclerosis, bone expansion and osteolysis caused by elevated 
bone turnover and the compensatory increase in bone formation. Panel B; compared 
with the normal side. Radiograph kindly provided by Prof. Stuart Ralston. 
 
The abnormal remodelling processes disrupt normal bone architecture and can lead to the 
development of several complications including bone pain, deformity, secondary 
osteoarthritis, nerve compression syndromes and pathological fractures  ( Visconti et al. 2010). 
Although sarcomatous degeneration is a rare complication of Paget disease (reportedly less 
than 0.1%), a high number of osteosarcomas in adults occur in patients with PDB            
 ( Merkow and Lane 1990;  Moore et al. 1991). Some patients have severe disease which has 
a major impact on quality of life  ( Gold et al. 1996;  Langston et al. 2007a;  van Staa et al. 
2002b) but others are completely asymptomatic  ( van Staa et al. 2002b). The determinants of 




The prevalence of PDB differs markedly between countries. It is common in the populations 
of England, France, Italy, and Spain and also in European emigrants to Australia, New 
Zealand, Netherlands, USA and South Africa. It is rare throughout Asia and in Scandinavia  
  ( Barker et al. 1980;  Barker et al. 1977;  Detheridge et al. 1982;  Gardner et al. 1978;  Guyer 
and Chamberlain 1980). Estimates of the prevalence in individual British areas showed that in 
England and Wales’s hospital discharge rates for PDB are higher in the north and west when 
compared with the south and east. This can even be shown inside Scotland, where the 
discharge rates for the areas around Glasgow are higher than in the Highlands and Borders       
( Barker and Gardner 1974). 
 
Paget’s disease in New Zealand, England and Wales, is slightly more common in men than in 
women  ( Bastin et al. 2009;  van Staa et al. 2002b). The disease clearly increases in prevalence 
with age and more than 90% of patients are older than 40 years of age. The prevalence 








   
According to data from US National Health and Nutritional Examination Survey, based on X-
ray of the hip, pelvis and spine, the prevalence of PDB has been estimated at 1.3 per 100 
women and men age 45-74. In the US it has been estimated that there are over a million 
affected individual  ( Altman et al. 2000). On the other hand, many Pagetic patients are 
asymptomatic and as a consequence they pass undetected by health care professionals, which 
means that the prevalence of clinically diagnosed cases of PDB is much less. It has been 
estimated that about 7% of patients with the disorder (apparent on radiographs) reached 
clinical diagnosis  ( van Staa et al. 2002b). 
 
There is some evidence that the incidence and severity of Paget’s disease is falling  ( Tiegs et 
al. 2000) in countries such as Britain and New Zealand  ( Cooper et al. 1999;  Corral-Gudino 
et al. 2013a;  Corral-Gudino et al. 2013b;  Doyle et al. 2002;  Poor et al. 2006b). In Italy and 





1.2.4. Clinical Presentation and Diagnosis 
 The clinical features of PDB may vary from patients being asymptomatic (involving a single 
bone) to patients having severe, multiple bone involvement with systemic disease. The most 
common sites of involvement are pelvis, vertebra and femur. Skeletal complications 
attributable to PDB included bowing deformities, fractures of affected bones and rarely 
osteosarcoma. Osteoarthritis is common and about 7% of the cases in the PRISM study 
required hip or knee replacement  ( Langston et al. 2007c). Other complications related to PDB 
included cranial nerve, peripheral nerve and nerve root compression, basilar invagination, 
hypercalcemia, and congestive heart failure. Also hearing loss may occur           ( Wermers et 
al. 2008). 
 
Paget Disease of Bone may present in a wide variety of ways. PDB is often diagnosed 
incidentally on X-rays obtained for other purposes, in patients who are undergoing 







   
unusual for patients to present to the rheumatologist, orthopaedic surgeon or ENT specialist 
with symptoms specifically related to the disease, such as bone pain, bone deformity, fractures 
and deafness. 
 
A common manifestation is pathologic fractures, they occur most frequently in the long 
weight-bearing bones of the lower extremities such as the femoral neck and sub-trochanteric 
region of the femur and tibia  ( Merkow and Lane 1990). PDB may also present with pain, 
increasing deformity, and tenderness over the affected bone. There may be night pain unrelated 
to change of position. When the spine is affected, neural compression may be the source of 
presenting problems. When the skull is affected (Fig.1.7), headache and deafness may be 
observed. Hat size may increase. The cardiovascular system can be involved, due to high 
output cardiac failure caused by increased blood flow through Pagetic bone. 
 
The diagnosis of PDB is based on the typical features on an X-ray. There may be an increase 
in serum alkaline phosphatase level, which reflects increase in bone formation, but population 
based radiologic surveys  ( Eekhoff et al. 2004b) have shown that about 86% of PDB patients 
have normal ALP. Hypercalcemia may occur in patients that have been immobilized. Uric acid 
level may be increased. Hydroxyproline levels are an indicator of bone resorption and lysis, 
they are found elevated in PDB. Urinary pyridinium/pyridinoline peptides can also be used as 
markers of bone resorption in PDB. Other biochemical markers such as osteocalcin (OC), C-
terminal telopeptide of type I collagen (CTX), deoxypyridinoline (DPD) and procollagen type 
1 N-terminal propeptide (P1NP)  are found in PDB and can be used to assess bone formation 
and the response to treatment  ( Shankar and Hosking 2006). More usually, however, ALP 
levels are used to assess activity and treatment response in PDB. 
 
Bone turnover markers nay provide an assessment of the rate of bone turnover (for bone 
turnover markers summary see table 1.2 A and B), they are proteins originating from osteoclast 
and osteoblast activity or fragments released during the formation or degradation of type I 
collagen. Some of these peptides are sufficiently small to be filtered into urine, while larger 
fragments may be detected in blood  Bone turnover markers are released during normal bone 
turnover. The concentrations may rise in metabolic bone diseases (as osteoporosis), other 







   
growth spurts. They cannot be used for screening or diagnosis of specific bone diseases. Their 
concentrations and patterns may be used by specialist units to monitor treatment response and 
disease progression in metabolic bone diseases including Paget’s disease of bone (Sunethra 
Devika C Thomas, 2012.www.australianprescriber.com).  
 
Current evidence suggest that bone turnover markers may be useful for monitoring the 
response to antiresorptive therapy  ( Bonnick and Shulman 2006;  Compston 2009). 
Intravenous and oral bisphosphonate therapy respectively lead to a decrease in bone resorption 
markers within days and weeks. The decrease in resorption markers is followed by a decline 
in bone formation markers. The decrease in the bone turnover markers may be sustained for 
years after cessation of therapy in patients who have been treated for several years. 
 
 However a significant change in bone turnover markers after starting therapy confirms 


















C-terminal propeptide of type I procollagen PICP RIA, ELISA Serum
N-terminal propeptide of type I procollagen PINP RIA, ELISA Serum
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PANEL A                                                                           PANEL B 
Figure.1. 7: A 63 year’s old man with a long history of sinusitis and 3 weeks of frontal 
headache. The physical examination was ordinary. The alkaline phosphatase level was 
elevated at 434 IU per litre (upper limit of the normal range is 129). The serum calcium 
level was within normal limits. Radiography of the skull (Panel A) showed thickening of 
the outer and inner tables of the cranial bones, widening of the diploe, and a "cotton 
wool” appearance caused by irregular areas of sclerosis (arrows). Computed 
tomography of the skull (Panel B) confirmed bony expansion, cortical bone thickening, 
and irregular areas of sclerosis (arrows). These imaging findings reflect the mixed 
osteolytic and osteoblastic phases of PDB, resulting in accelerated bone turnover with 
bone deposition and expansion. The patient was treated with alendronate, which resulted 
in improvement in frontal headache  ( Bhargava and Maki 2010). 
 
Radionuclide bone scans are more sensitive than plain X-rays in detecting PDB. Bone scans 
are used to screen for PDB and evaluate skeletal involvement of the disease. The bone scan 
appearance in PDB is usually pathognomic, but is recommended to confirm the diagnosis by 












In the case of PDB, a cure  is not available. Treatment is intended to reduce or stabilize the 
symptoms, suppress bone turnover, reduce pain and improve the patient’s quality of life. 
 
 The general recommendation is that medication should be given when the patient is 
experiencing bone pain which appears to be directly associated with the disease. It has also 
been suggested that prophylactic treatment should be considered for patients who will require 
surgery, those with active symptoms in skull, long bones or vertebra involvement; also for 
those patients with disease located in bones in close proximity to major joints, with a risk of 
developing osteoarthritis and in patients with several bones affected. There is no evidence this 
is beneficial however. 
 
Many antiresorptive therapeutic agents have been used over the years for the treatment of PDB 
including mithramycin (plicamycin), glucagon, actinomycin D, calcitonin (porcine, salmon, 
or human) and gallium nitrate. Most of them have been replaced by bisphosphonates which 
are the current treatment of choice. The aim of these therapies is to improve symptoms 
controlling the metabolic activity of the disease  ( Merkow and Lane 1990). 
 
Calcitonin was the first osteoclast inhibitor to be used in the treatment of PDB. It was proven 
to be effective in suppressing bone turnover and improving bone pain in PDB  ( Martin 1980). 
Comparing with bisphosphonates, calcitonin is more expensive, generally less effective in 
suppressing bone turnover and has shorter duration of action. Additionally, some patients 
develop side-effects such as nausea, vomiting and flushing. Resistance may also occur with 
continued use due perhaps to down-regulation of calcitonin receptors on the osteoclast or 
development of antibodies  ( Dube et al. 1973). 
 
Bisphosphonates are drugs that inhibit osteoclast. They are called bisphosphonates because 







   
Bisphosphonates were developed in the 19th century as water softening agents, but were first 
investigated in the 1960’s for use in disorders of bone metabolism.  
 
Bisphosphonates inhibit osteoclast activation and bone resorption by causing apoptosis, or cell 
death, thus slowing bone loss  ( Weinstein et al. 2009). 
 
 Bisphosphonates work according to one of two main mechanisms of action, depending on the 
chemical nature of the side chain attached to the bisphosphonate core (fig.1.8). Non-nitrogen 
bisphosphonates (such as etidronate, clodronate, and tiludronate) (Fig. 1.9) inhibit bone 
resorption by generating a toxic analog of adenosine triphosphate, targeting the mitochondria  
( Rogers 2003). The second mechanism of action occurs with the nitrogen-containing 
bisphosphonates (as alendronate, ibandronate, pamidronate, risendronate and zoledronic acid); 
they are more potent, and act by targeting pyrophosphatase synthase enzyme in the mevalonate 





























Bisphosphonates: Basic structure and structure of Zoledronate 
Figure.1.8. The figure shows at the left side, “simple Bisphosphonate” with two 
additional chains (R1 and R2). R1 structure together with the P-C-P are primarily 
responsible for binding to bone mineral and for the physicochemical action of the 
molecule, an hydroxyl group in this position, provides optimal condition for this function. 
R2 is believed to be responsible for the antiresorptive action, small modifications in this 
group, translate into marked differences in antiresorptive potency. The presence of a 
nitrogen molecule in an alkyl chain or in a ring structure, in R2 greatly enhances the 
antiresorptive potency and specificity of the bisphosphonate. As in the right side we have 
a molecule of zoledronate, one of the newer potent bisphosphonates containing nitrogen 
in the R2 chain and a hydroxyl group on R1  ( Michou and Brown 2011;  Papapoulos 
1997;  Russell 2007). 
 
As well as being used in PDB, bisphosphonates are used in the prevention and treatment of 
osteoporosis, bone metastase (with or without hypercalcemia), multiple myeloma, primary 









   
Additionally, radio-labelled bisphosphonates are used in scintigraphy to demonstrated disease 
distribution and activity of PDB, since these compounds are taken up by bone in proportion to 
local turnover  ( Reid and Hosking 2011). 
 
 
Figure.1.9: Etidronic acid. Didronel (the bisphosphonate used for treatment) contains 
etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid for 
oral administration, basically is sodium added in one of the OH group for each P. 
 
While several potent bisphosphonates have been licensed for the treatment of PDB  ( Miller et 
al. 1999;  Reid et al. 2005;  Siris 1996) clinical trials of these agents have mainly been focused 
on evaluating the short term responses of biochemical markers as ALP  ( Altman et al. 1973;  
Langston et al. 2007b;  Miller et al. 1999;  Recker et al. 2008;  Reid et al. 1996;  Reid et al. 
2005). Therefore, in most of these studies, ALP has been the primary end-point. While ALP 
is a marker of metabolic activity in PDB, it has not been shown that patients with lower levels 
of ALP have a more favourable clinical outcome  ( Langston et al. 2007b;  Langston et al. 
2007c). Indeed, the PRISM study showed that intensive bisphosphonate therapy conferred no 
clinical advantage over symptom-driven management in patients with established PDB. It was 
also shown that either management strategy had a significant beneficial impact on pain, quality 









   
Zoledronic acid (marketed by Novartis under the trade names Zometa, Zomera, Aclasta and 
Reclast) is the most potent licensed bisphosphonate. It has been shown to be effective in the 
treatment of osteoporosis and in the prevention of skeletal related events in malignancy          ( 
Black et al. 2007;  Lyles et al. 2007;  Reid et al. 2002). It is also used to prevent recurring 
fractures in patients with previous hip fracture  ( Craig et al. 2011;  Zidrou et al. 2010). It is 
given as a single dose of 5mg intravenously  ( Michou and Brown 2011;  Reid et al. 2005)  
Comparative trials have been published evaluating the relative efficacy of the bisphosphonates 
in the treatment of PDB with differing protocols. These trials still showed that zoledronic acid 
5 mg could give an extended biochemical remission in 98% of the patients with one single 
dose, compared with 57% for risedronate  ( Michou and Brown 2011;  Reid et al. 2005;  Reid 
and Hosking 2011). Resistance has not been observed so far                ( Papapoulos et al. 2006), 
which is common with etidronate and pamidronate. Also normalization of serum total alkaline 
phosphatase was achieved at six months in 93%              ( Martini et al. 2007;  Merlotti et al. 
2007). A post infusion syndrome (a flu-like illness) occurring in about 15% of patients treated 
(mostly at the first infusion) is the main adverse effect  ( Reid et al. 2005;  Reid and Hosking 
2011). 
 
Zoledronic acid has the highest affinity for hydroxyapatite in vitro and is the most potent 
inhibitor of the bisphosphonate target enzyme farnesyl diphosphate synthase, also known as 
farmesyl pyrophosphate (FPPS)  ( Dunford et al. 2001;  Nancollas et al. 2006). Also zoledronic 
acid produces sustained response, allowing arrest of bone turnover for many years in most 
patients with only a single infusion  ( Reid et al. 2011). After 5-6 years the therapeutic response 
is still maintained in 87% and 38%, respectively, with improvement in quality of life scores in 




















1.2.6. Role of Genetics in Paget’s Disease of Bone 
In 1876 when Sir James Paget first described the disease, he did not note a genetic 
predisposition since his index case had no other family members affected. 
 
Subsequently here have been many reports of familial aggregation in PDB. In 1883 Pick made 
the first report of the occurrence of Paget’s disease in more than one member of a family. He 
described a father-daughter pair with Paget’s disease  ( Pick 1883). After that, Lunn reported 
in 1885 a case where two sisters had PDB  ( Lunn J.R. 1885).  
 
In 1947 Boyd suggested that PDB may be familial, and added that he knew of two families in 
each of which three cases occurred  ( Boyd 1947;  Montagu 1949). Additionally Montagu 
suggested that: “the predisposition to Paget’s disease, when inherited, is transmitted as an 
incompletely dominant gene carried on a X-chromosome”  ( Boyd 1947;  Montagu 1949). We 
know now this was incorrect and his report was consistent with autosomal dominant 
transmission. In 1983 Sofaer et al reported that Paget’s disease shows a degree of familial 
aggregation  ( Sofaer et al. 1983). Siris reported that risk in siblings of cases was higher when 
a parent was affected (22.1+/-8% SEM) compared with the situation when both parents were 
unaffected (6.7 +/-1.1%SEM)  ( Siris et al. 1991). Migrant studies have shown that the risk of 
the disease remains high in subjects who move from high-prevalence regions to low-
prevalence regions, supporting the influence of a genetic component to the pathogenesis               
( Gardner et al. 1978). It has been estimated that between 15-40% of patients have a positive 
family history of the disease  ( Morales-Piga et al. 1995;  Siris et al. 1991;  Sofaer et al. 1983), 
this cases are described as familial cases of PDB 
 
Furthermore, the risk of developing PDB is 7-10 times higher in relatives of PDB patients 
compared with controls  ( Siris et al. 1991;  Sofaer et al. 1983). Patients with PDB, with a 







   
presentation, polyostotic involvement and bone deformity, compared with those patients 
without family history  ( Morales-Piga et al. 1995;  Siris et al. 1991). 
 
 We can defined “familial Paget’s disease of bone” as the disease inherited in an autosomal 
dominant manner, with incomplete penetrance, 15% to 20% of Pagetic individuals have a first-
degree relative with the disease  ( Seton et al. 2003a;  Siris et al. 1991;  Sofaer et al. 1983). 
Several families have been described in which Paget’s disease affects several generations. The 
cases with family history tent to have an earlier age of onset, a trend to a higher incidence of 
bone deformity was observed and an increased fracture rate  ( Seton et al. 2003b). Many 
individuals do not have a positive family history of the disease  ( Hocking et al. 2000) or have 
not being discovered, in this case they are called “sporadic cases”. 
 
Paget’s disease of bone have been reported as being very rare in the Chinese population                
( Thomas and Shepherd 1994), In 2011 an study characterized the clinical manifestations and 
features of 13 Chinese patients with “sporadic Paget’s disease of bone”, the finding include 
similar features to those reported in Western countries. The most common lesion sites were 
the pelvis, the femur and tibia; after those most common were the spine and skull. Most 
patients got elevated serum alkaline phosphatase level. Treatment with bisphosphonates was 
effective and within the group characterized they found the first reported SQSTM1 genetic 
mutation that contributes to the pathogenesis of PDB in Chinese patients  ( Gu et al. 2012) 
 
 
1.2.6.1. Family studies 
A variable percentage of patients (5-40%) have a positive family history of PDB with an 
autosomal dominant transmission pattern and incomplete penetrance  ( Haslam et al. 1998;  
Morales-Piga et al. 1995;  Singer and Leach 2010). Although multiple families have been 
reported with PDB, the average number of affected individuals in these families is three.  A 
study performed in New Zealand  ( Tilyard et al. 1982), identified two additional families that 
seemed to segregate the disease in an autosomal dominant fashion. Each family had four 








   
 A positive family history of PDB was reported in nearly 15% of patients in two large studies. 
In Spain, it was reported that 40% of patients had a least one first degree relative with PDB 
after screening with bone scans  ( Morales-Piga et al. 1995). In the same study, they reported 
that PDB seemed to be transmitted through either parent, suggesting an autosomal dominant 
mode of inheritance.  
 
Linkage studies in PDB have shown evidence of genetic heterogeneity. Chromosome 18 has 
been extensively studied in relation to Paget’s disease based on the fact that Familial expansile 
osteolysis (FEO) was linked to that chromosome. This is a rare bone dysplasia that shares 
some features with PDB and is also transmitted as an autosomal dominant disorder; it is caused 
by constitutive activation of RANK due to an 18-bp tandem duplication in the first exon of the 
TNFRSF11A gene  ( Hughes et al. 2000). FEO exhibit several histological similarities to 
Paget’s disease such as the existence of woven bone, large osteoclasts and the presence of 
microcylindrical inclusions in osteoclast nuclei  ( Dickson et al. 1991;  Wallace et al. 1989). 
FEO is recognized as being distinct from PDB since it has a predominantly peripheral 
distribution, with an onset in the second decade. There is also a progressive osteoclastic 
resorption accompanied by medullar expansion which leads to severe, painful, disabling 
deformity and a tendency to pathologic fracture. In many cases FEO is associated with early 
onset deafness and loss of dentition as a result of unique middle ear and jaw abnormalities. 
Some families with Classical PDB were linked to chromosome 18q21 but linkage studies and 
mutation screening have excluded the involvement of RANK in the majority of patients with 
PDB  ( Good et al. 2001). The connection between chromosome 18, FEO and Paget’s disease 
still has not been established  ( Haslam et al. 1998;  Hocking et al. 2000;  Nance et al. 2000). 
On the other hand FEO has certainly be linked to chromosome 18  ( Hughes et al. 1994). 
 
Another disease that shows phenotypic overlap with PDB is Early onset familial PDB, also 
inherited in an autosomal dominant trait. Although some features are shared with classic PDB, 
there are several distinguishing features such as the early onset and hearing impairment 
occurring in the late teens or early 20s. As in the case of FEO individuals with the disease 
experienced premature tooth loss (second and third decades of life)  ( Nakatsuka et al. 2003). 







   
expansion and osteosclerotic lesions. Like FEO, this disease is caused by an insertion, a 
mutation of the TNFRSF11A  ( Hughes et al. 2000;  Nakatsuka et al. 2003). 
 
Expansile skeletal hyperphosphatasia (ESH) is another metabolic bone disease, inherited as 
a highly penetrant autosomal-dominant that is characterized by early-onset deafness, 
premature tooth loss and involvement of the skeleton with progressive hyperostotic expansion 
of the long bones affecting the fingers, distinguishing from the other disorders due to the 
episodic hypercalcaemia and widespread diffuse bone involvement without focal osteolytic 
lesions  ( Ralston 2008;  Whyte et al. 2000). This disease is also due to a 15bp insertion 
mutation in the TNFRSF11A gene  ( Whyte et al. 2000). 
Inclusion body myopathy, Paget’s disease and Frontotemporal dementia (IBMPFD) are 
autosomal dominant disorders characterized by 3 main features: disabling muscle weakness 
(in 90%), osteolytic bone lesions consistent with Paget’s disease (in 51%), and frontotemporal 
dementia (in 32%) manifested by prominent language and behaviour dysfunction with a mean 
age of onset at 54 years old  ( Kimonis and Watts 2005;  Weihl et al. 2009); In IBMPFD 
myopathy is the most prominent feature (occurring in 90% of the cases) and death occurs 
typically at a mean age of 58 years due to respiratory and cardiac failure       ( Ralston 2008).  
 
The last, but not less important disease is Idiopathic hyperphosphatasia (IHH) or juvenile 
PDB. This is a rare autosomal-recessive condition characterized by a generalized increase in 
bone turnover, skeletal deformity, bone expansion, bone pain and an increased risk of 
pathological fractures. The disease is caused by a deficiency of osteoprotegerin (OPG) due to 
the loss of function mutation in the TNFRSF11A gene and chr8q24  ( Cundy et al. 2002;  
Whyte 2006). The most distinguishing features include early age onset  ( Ralston 2008;  Whyte 
et al. 2002). Other features include expanded and bowed extremities. Alkaline phosphatase 
levels are elevated in parallel with other markers of bone turnover, long bones are greatly 
expanded with osteoporosis and coarse trabeculations and calvaria markedly thickened with 
islands of increased bone density; there is premature loss of teeth, dwarfism, enormously 
increased turnover of subperiosteal bone  ( Eyring and Eisenberg 1968), progressive 
sensorineural deafness, kyphosis and acetabular protrusion with an increase severity during 







   
relationship have been described, where the severity of the disease is depending of the 
mutation causing the disorder  ( Cundy et al. 2002;  Ralston 2008).  
 
 
1.2.6.2. Genes and Loci for PDB 
The classical approach for finding the particular gene responsible for any given human disease 
is linkage analysis. More recently genome wide association studies (GWAS), have been used 
to identify disease genes. Both approaches have been used in PDB. 
 
Linkage analysis has been used to identify the genes for familial Paget’s disease. Few larger 
kindreds have been used for linkage analysis. One study in 1977 used haplotype data obtaining 
a maximum LOD (logarithm of the odds ratio of a particular locus being linked or not linked 
to the disease locus) score of 2.44 with 11% recombination (LOD score of 3 is considered 
linkage), which was considered as “suggestive”  ( Fotino et al. 1977). A later study in New 
Zealand identified two additional families in which the disease seemed to segregate with HLA 
in an autosomal dominant fashion (each family with four affected members). The combined 
linkage analysis from both studies resulted in a maximum LOD score of 3.69 with 10% 
recombination. 
 
In 2001 a Genome wide linkage analysis of 319 individuals, from 62 kindreds with familial 
PDB (predominantly British descent) identified three chromosomal regions with LOD scores 
above the threshold for suggestive linkage. These were on chromosomes 2q36, 5q35, and 
10p13 (where 2q36 and 10p13 had a lower LOD score). These studies indicated the presence 
of three susceptibility loci for PDB and identified a strong candidate locus for the disease, on 
chromosome 5q35  ( Hocking et al. 2001). 
 
Laurin in 2001 performed genetic linkage analysis in 24 large French Canadian families (479 
individuals) in which Paget’s disease was segregating as an autosomal dominant trait. After 
excluding linkage to the PDB2 locus, they performed a genome-wide scan on the three most 
informative family nuclei. LOD scores greater than 1.0 were found at 7 locations. The disorder 
in 8 of the families showed strong linkage to chromosome 5q35-qter, and the disease locus 







   
families, suggesting a founder effect. The disorder in the 16 other families, with very low 




Subsequently, several genetic loci (PDB1-PDB7) have been reported to predispose to late-
onset PDB. Seven loci have been reported and they are referring to the following chromosomes 
respectively: 6p21.3, 18q21.1-22, 5q35, 5q31, 2q36, 10p13, 18q23                    ( Daroszewska 
and Ralston 2005). At present PDB3 (5q35) is the only locus where a gene, sequestosome1 
(SQSTM1), has been identified. Mutations in SQSTM1 have been associated with both sporadic 
and familial PDB in different populations, Rhodes et al reported that about 28.8% of families 
with a history of PDB have a mutation in the SQSTM1 gene, which maps to chromosome 5  ( 
Rhodes et al. 2008), Cundy reported a 26% of patients with familial PDB in New Zealand had 
disease-associated mutations in the SQSTM1 gene  ( Cundy et al. 2011) and Hocking reported 
that SQSTM1 mutations occurred in 15% to 40% of the pagetic individuals have an affected 
first degree relative  ( Hocking et al. 2002). At least 28 gene mutations have been identified in 
exon 7 and exon 8 of SQSTM1, most of which are in the ubiquitin-associated domain. 
 
In a search for additional loci associated with PDB Albagha et al  ( Albagha et al. 2010) 
performed a genome-wide association study comparing genetic variants in patients with PDB 
(without SQSTM1 mutations) to healthy individuals. In this work three different genomic 
regions at chromosome 1p13, 10p13 and 18q21 have been associated with PDB. In each of 
these regions a putative predisposition gene associated with susceptibility to PDB was 























Table 1.3: Candidates genes proposed by Albagha et al as predisposition genes associated 
with susceptibility to PDB. 
Candidate genes Chr …encodes Related Diseases 
CSF1 1p13 M-CSF Osteopetrosis. 
TNFRF11A 18q21 RANK 
Familial expansile osteolysis, Early 
onset PDB, ESH. 
OPTN 10p13 Optineurin Glaucoma 
PML 15q24 PML Promyelocytic leukemia 
RIN3 14q32 
Ras and Rab 
interactor 





TM7SF4 8q22.3 DC-STAMP PDB 
 
In a subsequent study three new loci and their association with PDB were identified                 ( 
Albagha et al. 2011). 
 
Genetic studies in patients with apparent sporadic Paget disease are difficult to interpret and it 
is possible misclassification. Lucas et al  ( Lucas et al. 2005) found that most SQSTM1 
mutations are carried on one of two common haplotypes in patients classified as having 
sporadic PDB suggesting that these patients are probably misclassified. Common haplotypes 
suggest that these “sporadic” patients have had a family history that was unreported and were 
misclassified. As clinical screening of other family members is not always possible, these 








   
 
 
1.2.6.3. Pro/Cons of linkage and GWAs in the identification of genetics variants 
After almost 2 decades of relatively unsuccessful attempts to identify genes for complex 
genetic diseases by means of linkage mapping, the application of genome-wide association 
studies (GWAs) over the past 5 years has identified a wealth of novel disease associations. 
Where GWAs investigate common diseases using case-control or cohort studies rather than 
extended or nuclear families for rarer diseases. Microarray technologies enable fast and 
accurate genotyping of millions of single nucleotide polymorphisms (SNPs) in a short time. 
In contrast, genome-wide family-based linkage studies had much lower resolution, with 
standard panels including only hundreds of microsatellite markers. The success of the GWAs 
has been overwhelming; but unexpectedly, many of the identified associations do not map to 
genes but to genes deserts, and the biology underlying these discoveries is rarely immediately 
apparent; that just show the importance and value of functional studies following the detection 
of association in GWAs ( Ziegler and Sun 2012). 
 
Specifically as mention on an study in 2015, previous genome-wide association studies 
identified a locus on chromosome 14q32 tagged by rs104986 which was significantly 
associated with susceptibility to PDB in several European populations. Fine-mapping of the 
candidate locus confirmed that the association was confined to RIN3 gene, some variants have 
been also described which are over represented in case compared with controls, the biology 
underlying these discoveries is rarely immediately apparent as we said before, the link to the 
disease translate so far as a susceptibility to PDB mediated by a combination of common and 
rare coding variants in RIN3 ( Vallet et al. 2015). 
 
The success of GWAs using a large number of unrelated individuals has only made possible 
by the advancements in microarray technology. However, it also required new developments 
in statistical methodology, novel study designs and new methods for analysis to complement 
the established study designs and methods because of the complexity in genetics. 
 
It is clear that the future success of genetic studies will require well-defined, interpretable, and 







   
sequence does not tell us what that sequence does. Finding genomic variants that differ 
between those who have and those who do not have disease will not automatically help us to 
understand and treat the many diseases to which humans are prone; neither will do with Paget’s 
disease of bone. We should clarify that the common disease-common variant GWAs approach 
fails to identify rare variants, although we know that “multiple rare variants in disease gene 
can play an important role in disease susceptibility” ( Ziegler and Sun 2012).  
 
Still family information is relevant to refine the genetic model and for estimation of disease 
risk. The large pedigree design is practical, efficient, and well suited for investigating rare 
variations. Also unless the sample sizes are very large, rare functionally relevant variants with 



























   
1.3. SQSTM1 and PDB 
 
 
There have been many advances in understanding the role of genetic factors in the 
pathogenesis of PDB over recent years and several genetic variants have been identified that 
predispose to the disease  ( Ralston et al. 2008). The most important of these is SQSTM1 which 
was initially identified in patients with familial PDB by positional cloning  ( Laurin et al. 
2002). Subsequent studies showed that SQSTM1 mutations occur in up to 40% of patients with 
familial PDB and up to 10% of patients with “sporadic” PDB  ( Hocking et al. 2002). 
 
Mutations of SQSTM1 are thought to play a causal role in the pathogenesis of PDB  ( Ralston 
et al. 2008). They have been found to segregate with the disease in families and have an overall 
frequency of between 5-10% in PDB patients as compared with less than 0.07% in unaffected 
controls  ( Eekhoff et al. 2004a;  Hocking et al. 2004;  Laurin et al. 2002). It should be noted 
however, that at least one subject has been described who had not developed PDB by the 
seventh decade despite being a carrier of the P392L mutation of SQSTM1 indicating that 
penetrance is incomplete  ( Morissette et al. 2006). Previous studies have shown that patients 
with mutations of SQSTM1 tend to have an earlier age of onset than those without mutations  
( Eekhoff et al. 2004a;  Hocking et al. 2004;  Laurin et al. 2002); but the relationship between 
SQSTM1 mutations and clinical outcome of PDB is still unclear. 
 
As the disease is focal, rather than systemic, additional local factors may in some cases act as 
disease triggers, although the nature of these is unclear. Adding the occurrence of somatic 
mutations, mutations that are present in bone but not in circulating blood. Somatic mutations 
are often found in the pagetic bones of patients with sporadic PDB and pagetic osteosarcoma  
( Merchant et al. 2009). 
 
 
Mutations in the Sequestosome 1 gene (SQSTM1) are an important cause of PDB. Most of the 
mutations identified until now, affect the ubiquitin-associated (UBA) domain of SQSTM1, a 
region of the protein that binds non covalently to ubiquitin  ( Layfield and Hocking 2004). 







   
or deletion of the ubiquitin binding-associated (UBA) domain (Fig.1.10 and Fig.1.11). At 
present, around 30 different mutations have been identified in the gene encoding sequestosome 
1(Table 1.4). The abnormalities on UBA domain may be responsible for the elevated 




Figure.1.10: Sequestosome 1 Gene structure; SQSTM1 (SQSTM1)/p62 (440 amino acids). 
(5q35.3). Interaction with LCK (aa 1-50). Int.: Interaction with PAWR (aa 50-80). Zinc 
finger (ZZ-type) (aa 122-167). LB; LIM-binding (aa 228-233). PEST (aa 266-294). 
Interaction with NTRK1 (aa 269-440). L: LIR motif (SGGDDDWTHLSS) (aa 332-343). 
PEST (aa 345-377). UBA (aa 389-434). 
 
 
The protein encoded by the human SQSTM1gene, is a cytoplasmic scaffolding/adaptor protein 
and has been implicated in diverse cellular functions  ( Geetha and Wooten 2002) as the 
modulation of potassium channel function, control of transcriptional activation  ( Ciani et al. 
2003), protein recruitment to endosomes and in close relation with PDB, control of NFkB 
signalling and autophagy  ( Layfield and Hocking 2004).  
 
Some of the mutations, denoted A390X, K378X, E396X, Q400X, E394X, Y383X, D423X, 
and D408X, disrupt translation of the p62 UBA domain via introduction of stop codons, 
resulting in premature termination of the protein (Fig. 1.11). Recent evidence indicates that 







   
with point mutations  ( Hocking et al. 2004;  Rea et al. 2006). The most common mutation is 
P392L, substitution of proline by leucine on position 392, modifies the structure of the UBA 
domain by extending the N terminus of helix 1, do not affect multi-ubiquitin chain binding by 




Figure.1.11: PDB causing mutations of SQSTM1 in relation to UBA domain structure. 
(A) Sequencing traces for novel PDB causing mutations in relation to the ribbon 
structure of the UBA domain. (B) Surface representation of the SQSTM1 UBA domain 







   
Table 1.4: Mutations described on exon 7 and 8 of the UBA domain. Other missense 
mutations are label as other m. 
 Nucleotide Protein 
Mutation 
type Author/Notes 
 T1085A S349T missense  ( Michou et al. 2011) 
 C1090T P364S missense  ( Rea et al. 2009) 
 C1205C A390X truncating  ( Beyens et al. 2006) 
 IVS7+1G>A   truncating  ( Hocking et al. 2002) 
 A1132T K378X truncating  ( Rea et al. 2006) 
 C1215T P392L missense  ( Laurin et al. 2002) 
 1225insT E396X truncating  ( Hocking et al. 2002) 
 delT1210 L394X truncating  ( Johnson-Pais et al. 2003) 
 C1238T Q400X truncating  ( Visconti et al. 2010) 
 A1250G M404V other m.  ( Hocking et al. 2004) 
 T1251C M404T other m.  ( Eekhoff et al. 2004a) 
 G1271A G411S other m.  ( Hocking et al. 2004) 
 T1290A L417Q Other m.  ( Michou et al. 2011) 
 T1311G I424S other m.  ( Visconti et al. 2010) 
 G1313A G425R other m.  ( Hocking et al. 2004) 
 1348insC   extra 48 aa  ( Visconti et al. 2010) 
 C1200T P387L other m. 
 ( Johnson-Pais et al. 2003) 
 1215delC L394X truncating 
 C1277T L413F other m. 
 ( Collet et al. 2007) 
 C1182T A381V other m. 
 T1235C S399P other m.  ( Eekhoff et al. 2004a) 
 A1241G M401V other m. 
(Gennari et al. 2010) 
 C1320A A427D other m. 
 T1085A S349T other m. 
(Michou et al. 2010) 







   
 T1290A L417Q other m. 
 T1046A D335E other m. 
(Falchetti et al. 2009) 
 C1190A Y383X Truncating 
 T1229G S397A other m. 
 1307insT D423X Truncating 
 G1312A G425E other m. 
 
SQSTM1/p62 is an adapter protein which binds ubiquitin and regulates signalling cascades 
through ubiquitination. Ubiquitin is best known for its function in targeting proteins for 
degradation by the proteosome  ( Sun and Chen 2004). This multifunctional protein regulates 
the activation of nuclear factor kappa-B (NFKB) by TNF-alpha, nerve growth factor (NGF) 
and interleukin-1. More recently, a role for SQSTM1/p62 in macroautophagic removal of 
intracellular protein aggregates has also been proposed. Studies involving the cellular 
depletion of SQSTM1/p62 have indicated a need for its association with LC3 and the aggregate 
proteins in order to facilitate correct formation of the autophagosome. The protein 
SQSTM1/p62  was initially identified as a phosphotyrosine-independent ligand of the Src 
homology 2 (SH2) domain of p56lck, SQSTM1/p62  functions to link signalling molecules such 
as RIP, TrkA, and TRAF6 to atypical protein kinase C (aPKCs) in response to various stimuli, 
including tumour necrosis factor-α, interleukin-1, NGF, and RANKL.Earlier studies have 
shown that SQSTM1/p62  non-covalently binds ubiquitin at its C-terminus, suggestive of 
functioning as a storage compartment for ubiquitinated proteins. In addition, SQSTM1/p62  
binds specifically to lysine-63 (K63)-polyubiquitinated substrates, acting as a putative 
ubiquitin chain-targeting factor that shuttles these substrates for proteosome degradation via 
its UBA domain. 
 
SQSTM1/p62  has been implicated in the regulation of osteoclast formation; deletion of the 
UBA domain of SQSTM1/p62  potentiates RANKL-Mediated Osteoclast formation and 
multinucleation, it also disrupts SQSTM1/p62  co-localization with TRAF6  ( Yip et al. 2006). 
Additionally SQSTM1/p62  appears to function as an adaptor recruiting CYLD to TRAF6 and 







   
that CYLD mediate the negative signalling function of SQSTM1/p62  by deubiquitinating 
TRAF6  ( Jin et al. 2008). 
 
Mice lacking SQSTM1/p62 exhibit modified osteoclastogenesis in vivo and reduced IKK 
activation and nucNF-κB) translocation. The protein functions in concert with TNF receptor-
associated factor 6 to mediate activation of NF-kB in response to upstream signals. 
Alternatively spliced transcript variants encoding either the same or different isoforms have 
been identified for this gene. 
 
In the study made by Yip, K, H, M et al, over expression of the SQSTM1/p62 UBA domain 
deletion mutant (p62ΔUBA) significantly boosted osteoclastogenesis in vitro compared to 
controls. Over expression of p62ΔUBA increased the formation of abnormally large 
multinucleated osteoclasts and resorption of bone (as in PDB) and also increased RANKL-
induced activation of NFκB, NFAT, and ERK phosphorylation. Deletion of the SQSTM1/p62 
UBA domain reduced the association of SQSTM1/p62  with TRAF6 in the proteasomal 
compartment. These observations suggest that the UBA domain encodes essential regulatory 
elements required for receptor activator of NF-κB ligand-induced osteoclast formation and 



















   
1.4. Environmental Triggers for PDB 
 
 
Both genetic and environmental factors are thought to be involved in the pathogenesis of PDB. 
The environmental factor which has been most widely studied is paramyxovirus infection  ( 
Roodman and Windle 2005) although the role of paramyxovirus infection in the pathogenesis 
of PDB remains controversial  ( Rima et al. 2002). Other potential risk factors for PDB include 
low calcium intake during childhood  ( Siris 1994), vitamin D deficiency during childhood  ( 
Barker and Gardner 1974), repetitive mechanical loading of affected bones  ( Solomon 1979) 
and environmental exposures to toxins  ( Lever 2002).  
 
The changes in severity and also occurrence of the disease that have been found coupled with 
variable penetrance of Paget’s disease within families, demonstrating that an environmental 
factor may be operative. The concentration of cases in Lancashire, England      ( Barker et al. 
1980) and in Australia  ( Gardner et al. 1978) has been use to suggest an important 
environmental factor in the aetiology but could also be due to a “founder effect” with clustering 
of people who carry predisposing genetic variation. Additionally high prevalence areas have 
been seen and reported in Spain and Italy  ( Corral-Gudino et al. 2012;  Gennari et al. 2005;  
Gua+¦abens et al. 2008). 
 
The focal nature of Paget’s is still unexplained, which has led to the hypothesis for an 
infectious aetiology in Paget disease of bone, slow virus infection theory. Also the detection 
of somatic origin mutations in sporadic PDB and in cases with pagetic osteosarcoma suggests 
a modification of the pattern  ( Merchant et al. 2009), which could be explained by the viral 
infection. It is not possible to completely explain the etiology of PDB by SQSTM1 alone. If 
SQSTM1 mutations were sufficient to initiate PDB, all patients with the inherited form of the 
disease would develop the same form of the disease than the sporadic form of the disease. 
Moreover are clear differences between inherited or familial form of the disease and the 
sporadic form of the disease, leading to the hypothesis of other factors involved in the 
presentation of the disease.Perhaps the occurrence of viral infections could affect the aging 







   
time could modify its functioning making them permissive to the clinical expression of PDB  




1.4.1. Mechanical Loading 
The skeletal changes in PDB disease could have unusual distribution and the reason for a 
variation on the sites affected is unknown. A number of cases have been reported where 
mechanical loading may determine the sites affected. In 1969 a case with extensive Paget’s 
disease was described, where a leg paralysed by poliomyelitis was described as free of Paget’s  
( Barry 1969). Also in 1979 a short report described a case of a champion billiards player who 
developed Paget’s disease in his hands with a pattern that clearly corresponded to lines of 
pressure created by aligning his cue  ( Solomon 1979). Also in 1979, Gasper described in a 
letter a case of a 79 years old lady with PDB in her right leg associated with her occupation as 
a maker of wrist bands on a machine that she used to operate pushing with her right foot a foot 
operated lever; in this particular case the absence of PDB in her left leg, suggested that the 
repeated physical trauma triggered the onset of Paget’s disease in the affected site  ( Gasper 
1979). 
On a recent review of the literature, not new information have been added to the influence of 
mechanical loading, recently a study tried to characterize the alterations to the structure and 
composition as well as the mechanical properties of bone from healthy patients and those with 
PDB. The study indirectly confirm that mechanical loading may not be a relevant factor on the 
pathology of the disease. The alterations to the structure in PDB produce bowing/deformities, 
namely from the low mineral content, but may also improve the mechanical integrity of the 
tissue by promoting plastic deformation to stop the growth of cracks, leading to the presence 












   
1.4.2. Nutrition 
On 1994, Siris carried out an interesting epidemiological study based on questionnaires 
completed by 864 pagetic patients and 500 controls; where one of the findings was that the 
dietary calcium intake in cases was much lower than in controls. The calcium intake in this 
particular study was assessed by milk intake during childhood  ( Siris 1994). Also linked with 
the diet, the broad geographical association between the current distribution of PDB and that 
of Rickets at the beginning of the century leads to the hypothesis that another trigger for PDB 
is vitamin D deficiency in childhood. The secular trends for a decreased incidence of PDB 
appears to follow the secular trends of rickets disease, but the evidence for an association 





1.4.3. Environmental Toxins 
Another possible trigger of the disease that has been suggested is exposure to environmental 
toxins. In 1974 a survey in PDB showed a cluster of towns in Lancashire with the highest 
prevalence of PDB. They were former cotton mill towns and a link was reported between the 
use of calcium arsenate pesticide and the high-prevalence findings. The suggestion in that 
study was that geochemical arsenate was widespread in the environment and may account for 
geographic variations in PDB prevalence  ( Lever 2002). As today, it is not recent evidence of 
the environmental toxins been a trigger for PDB, not further studies had reported cases or 
further studies on the subject. 
 
 
1.4.4. Other Risk factors 
Many environmental factors have been suggested, including rural life style  ( Merlotti et al. 
2005). In Italy they suggested a link between PDB and contact with animals in rural districts. 
The study of Merlotti et al. showed a correlation between having pets, living in rural areas and 
being in contact with pigs with the prevalence of PDB; also a correlation was shown 







   
of animal viscera has been linked with PDB aetiology  ( Lopez-Abente et al. 1997;  Merlotti 
et al. 2005). More recently Gennari et al  ( Gennari et al. 2010) reported on a study with 
patients from Campania-Italy that PDB patients exposed to animal contacts showed an 
increased number of affected sites and a higher prevalence of familial disease than patients 




1.4.5. Infections-Viral Aetiology 
As mentioned above, epidemiological studies indicate that environmental factors may also 
play a role in regulating susceptibility of the disease or perhaps even a link with the severity 
or sites affected. A viral cause for PDB was first proposed in the 1970's when electron 
microscope studies pointed to the occurrence of inclusions in the osteoclasts of patients with 
Paget’s disease which were thought to resemble viruses  ( Rebel et al. 1974).  
After that other studies confirmed the occurrence of nuclear inclusions, consisting essentially 
of striated filaments around 110 to 150 A in diameter, often organized in bundles and 
sometimes in paracrystalline arrays  ( Harvey et al. 1982;  Howatson and Fornasier 1982;  Mills 
et al. 1980;  Mills and Singer 1976;  Rebel et al. 1974); Viral budding-like structures containing 
these inclusions were found at the peripheral cytoplasm or cell processes in the ruffled border 
of some pagetic osteoclast of some fresh tissues from patients with Paget’s disease  ( Abe et 
al. 1995). While inclusions are typical of Paget’s disease, they are not specific and similar 
structures have been found in the osteoclasts of patients with osteopetrosis  ( Mills et al. 1988)  
and pycnodysostosis  ( Beneton et al. 1987) and also in macrophages from patients with 
primary oxalosis  ( Bianco et al. 1992) and also in osteoblastsfrom patients with otosclerosis  
( McKenna et al. 1986;  McKenna and Mills 1990). 
 
Previous studies have reported the presence of measles RNA by in situ hybridization and also 
the presence of measles antigens by immunostaining in Pagetic tissue  ( Basle et al. 1986;  
Rebel et al. 1980a). Respiratory syncytial virus antigens have been identified by immune 







   
Pringle et al. 1985). Simian virus 5  ( Basle et al. 1985) and parainfluenza virus type Type 3 
antigens have been also detected by fluorescent antibody technique.  
 
In 1985 an apparent relationship between PDB and dog ownership  ( O'Driscoll et al. 1990;  
O'Driscoll and Anderson 1985) was reported. Keeping in mind that canine distemper virus 
(CDV) is also a paramyxovirus and it is closely related to measles, this led to the hypothesis 
that CDV may be a trigger for the disease. In 1991 CDV RNA was reported to be detected in 
osteoclasts, osteoblasts and osteocytes in PDB cases, but not in controls, by in situ 
hybridisation and by reverse transcription PCR  ( Gordon et al. 1991;  Gordon et al. 1992). 
Further studies confirmed these findings  ( Gordon et al. 1993).  
 
Evidence for measles virus antigens in the osteoclast of pagetic patients was found using 
antimeasles antisera and sera from patients with subacute sclerosing panencephalitis  ( Basle 
et al. 1979;  Basle et al. 1981;  Rebel et al. 1980a;  Rebel et al. 1980b). Also Barbara Mills 
reported in 1984 that antigens of two viruses, measles and respiratory syncytial virus were 
found in the same osteoclast  ( Mills et al. 1984). In 1985 Pringle et al had surveyed the 
presence of neutralising and immunoprecipitating antibodies to respiratory syncytial virus and 
parainfluenza virus type 3 in 177 patients attending a bone disease clinic. Thirty-six of the 
patients had confirmed PDB. All the samples tested possessed neutralising activity for both 
viruses but not significant differences were reported in this study between Paget and non-Paget 
patients. In summary the serological results in this study highlight that persistent infection with 
respiratory syncytial virus can occur  ( Pringle et al. 1985). 
 
In 1996 Reddy et al detected measles virus nucleocapsid transcripts in circulating blood cells 
from patients with Paget’s disease by RT-PCR  ( Reddy et al. 1996). It was later reported that 
measles virus nucleocapsid protein gene transduction to normal human osteoclast precursors 
results in formation of osteoclast that were reported to have pagetic phenotype  ( Kurihara et 
al. 2000). Also, measles virus infection of osteoclast precursors from CD46 transgenic mice 
formed osteoclast with a pagetic phenotype in vitro  ( Reddy et al. 2001). Most recently, a 
team of researchers lead by the University of Pittsburgh School of Medicine, published results 
based on the bone marrows of 12 pagetic patients and 8 controls, finding viral proteins 







   
 
All previous positive reports, suggested that there may be an association between Paget’s 
disease and persistent viral infection following an initial focal infection 20 to 30 years 
previously. For the virus to remain present after this length of time following the original 
infection any number of mechanisms may be involved to enable the virus to persist and escape 
detection by the immune system. We can mention as an example, the chronic infection of the 
brain caused by measles subacute sclerosis panencephalitis (SSPE), where the virus persist 
by producing either incomplete or mutated viral proteins  ( Cattaneo et al. 1988). Another 
example is the chronic necrotising mumps encephalitis where it is the host failure to produce 
an adequate immune response which explains a low grade infection in the brain. 
 
On the other hand, osteoclasts are part of the monocyte/macrophage system and share many 
characteristics and functions. As the mononuclear phagocytic system is one of the primary 
defences against infection, elimination of viruses can also play a role on the persistence or 
latency of the virus and monocytes and macrophages can harbour virus, then osteoclast might 
possibly act as reservoirs, permitting paramyxovirus replication, latency and persistence              
( Gordon et al. 1991;  Ohmann and Babiuk 1986). 
 
Immunosuppressive measles virus V protein is able to suppress NF-ĸB activity by preventing 
nuclear translocation of p65  ( Schuhmann et al. 2011). Measles virus P protein is able to 
suppress NF-ĸB by up-regulation of ubiquitin-modifying enzyme A20  ( Yokota et al. 2008); 
also canine distemper virus induces human osteoclastogenesis through NF-ĸB and 
SQSTM1/P62  activation  ( Selby et al. 2006). All the reported interactions open the possibility 
of regulation of bone remodelling via viral infection in different pathways. 
 
In contrast, there have been several studies where the results do not support the hypothesis that 
measles or other paramyxoviruses play a role in the pathogenesis of Paget’s disease                        
( Ralston et al. 1997;  Ralston and Helfrich 1999). Birch also failed to find paramyxovirus 
RNA in cultures of pagetic bone-cells and in pagetic bone  ( Birch et al. 1994). Absence of 
measles virus and canine distemper virus transcripts in long-term bone marrow cultures from 







   
to detect measles virus RNA, by RT-PCR in bone cells cultures from patients with PDB  ( 
Matthews et al. 2007;  Matthews et al. 2008). 
  
Many of the reported studies have been done in cultured cells. However Helfrich in 2000 failed 
to find evidence of measles or canine distemper viral sequences, using RT-PCR, in situ 
hybridization and immunocytochemistry in a wider selection of samples including bone biopsy 
specimens, bone marrow and peripheral blood mononuclear cells. Also they reported that the 
inclusion bodies, as described previously in Paget’s disease, differed in appearance from those 
in Subacute Sclerosing Panencephalitis (SSPE)  ( Helfrich et al. 2000). 
 
 The conflicting results may be due to the differences in samples, techniques, sensitivity and 
specificity. In 2007 a multicentre blinded analysis by RT-PCR was applied to the detection of 
paramyxoviruses in PDB samples and control material. This study showed no evidence of viral 
mRNA in PDB samples, it also showed that one laboratory that previously had detected CDV 
mRNA in PDB samples, also detected CDV RNA in control (negative) samples. The results 
of this study suggested that the technique used was not the best technique for detection due to 
the high-sensitivity which varied from lab to lab; also there is a risk of contamination which 
may have explain why positive results occurred in some studies  ( Ralston et al. 2007). 
 
 
1.4.5.1.  Paramyxovirus 
The Paramyxoviridae, have been the most widely studied family of viruses related to PDB. 
They are pleomorphic, enveloped negative strand RNA viruses which share a high degree of 
genetic and structural homology in the order Mononegavirales. The family is divided into two 
subfamilies, Paramyxovirinae and Pneumovirinae, according to several features such as 
morphology, genomic organization, role of the encoded viral proteins and the sequence 
relationship between these proteins  ( Loney et al. 2009). 
 
In this thesis we are going to focus on the subfamily Paramyxovirinae which consist of five 
genera: Respirovirus, Morbillivirus, Rubulavirus, Avulavirus and Henipavirus. Some of the 
well-studied viruses belonging to this subfamily include human parainfluenza virus types 1 







   
and distemper virus (Morbillivirus), and human respiratory syncytial virus (RSV) a 
member of the subfamily Pneumovirinae. 
 
Paramyxoviruses contain no segmented negative-strand RNA genomes containing 6-10 
tandem linked genes. Viral mRNAs are transcribed monocistronically, meaning one protein 
being expressed from a single mRNA, with the exception of the P gene. 
 
Viral RNA is encapsulated with nucleocapsid (N) protein which is associated with a 
polymerase complex composed of phosphoprotein (P) and large (L) protein. The virion 
contains a lipid bilayer envelope that is derived from the plasma membrane of the host cell. 
The envelope is studded with glycoproteins necessary for virus egress, attachment, and entry 
and is lined internally by the matrix protein (M). 
 
Structural investigation of paramyxovirus biology has proven difficult, due to disordered 
regions in some of their proteins, conformational flexibility in the nucleocapsid, and the 
pleomorphic nature of the paramyxovirus virion. An example is found in measles virus where 
the nucleocapsid protein has been found to bind several viral and host proteins             ( Loney 
et al. 2009). This is linked to the C-terminal domain of the measles virus nucleoprotein which 
is intrinsically disordered and folds upon binding to the C-terminal moiety of the 
phosphoprotein  ( Longhi et al. 2003). Paramyxovirus virions are highly pleomorphic and are 
shown to range in diameter from approximately 120 to 450nm in diameter  ( Terrier et al. 
2009).  
 
In 1994, a new member of the family Paramyxoviridae isolated from fatal cases of respiratory 
disease in horses and humans was shown to be distantly related to morbilliviruses and 
provisionally called equine morbillivirus. To facilitate characterization and classification, the 
virus was purified, viral proteins were identified, and the P/V/C gene was cloned and 
sequenced  ( Wang et al. 1998). The accessory proteins expressed from the P/V/C gene are 
major factors in the pathogenesis of the viruses, because of their ability to disrupt various 
facets of type I interferon (IFN) induction and signalling. Most of the paramyxoviruses share 
the ability to antagonize innate immunity by blocking IFN induction and the Jak/STAT 











Amongst the paramyxoviruses the most studied in association with PDB had been measles 
virus. Ultra structural and immunological studies suggested measles or measles-related virus 
as the main agent involved in the pathogenesis of PDB. It has been reported that the expression 
of measles virus nucleocapsid gene in mice, with or without a mutation on the SQSTM1/p62  
gene (P392L), develops pagetic like osteoclasts and increased Interleukin 6 levels in bone 
marrow dependent on p38MAPK activation. The same group reported that mice co-expressing 
measles virus nucleocapsid gene and P392L mutation on SQSTM1/p62  develop dramatic 
Paget’s-like bone lesions  ( Kurihara et al. 2011) suggesting that measles virus plays a key role 
in PDB. 
 
Interestingly, the potential of measles virus to interfere with some pathways in close 
relationship with bone formation, bone cells and bone remodelling has been reported. The key 
players of the measles virus-mediated immune evasion, are three phosphoprotein gene 
products P, V and C. By a process called RNA editing, additional G is inserted into the mRNA 
of the phosphorprotein gene transcript producing the V protein  ( Cattaneo et al. 1988). Measles 
virus essential P protein and the accessory proteins V and C appear to prevent NF-ĸB –
dependent gene expression by retaining p65 in the cytoplasm  ( Schuhmann et al. 2011). It has 
also been reported that measles virus P protein suppresses Toll-like receptor signal through 
up-regulation of ubiquitin-modifying enzyme A20  ( Yokota et al. 2008). 
 
The annual incidence of measles has been reported as around 100 cases from 1998 to 1999 in 
the USA, but now is greatly reduced by the MMR vaccination program; this is an incidence 
rate of approximately 1 in 2,720,000; by extrapolation 96 per year, 8 per month, and 2 per 
week. Corresponding figures in Canada were 6.5 cases per 1,000,000 people for 2000, and 
two/million in Australia for 2002. After the introduction of the vaccine in Spain, in 1978, the 
incidence decreased from 4290 cases/million in 1977 to 1.8 cases/million in 2002  ( Mosquera 
et al. 2005). The World Health Organization reported that the global figures for 2009 were 
222,408 reported cases and 164,000 estimated deaths in 2008. Measles vaccine was introduced 







   
Initially the coverage was poor and during the 1970s, fewer than 60% of children were 
vaccinated by the age of 2. In recent times vaccination has risen to almost 80% coverage but 
measles still continues to circulate and cause substantial morbidity and mortality  ( Miller 
1989). 
 
 Indeed measles has recently reappeared in the United Kingdom, with 449 confirmed cases to 
the end of May 2006 compared with 77 in 2005, and the first death since 1992  ( Perviz and 
Eithne 2006). In 2008, measles was declared endemic in the UK, meaning that the disease was 
sustained within the population. This was the result of a decade’s low MMR vaccination rates, 
which created a population of susceptible children who could spread the disease. In May 2008. 
A British 17 year old with an underlying immunodeficiency dies of measles (as reported by 
Smith Rebecca, Medical Editor at the Telegraph. 20th June 2008. Retrieved 21st April 2013). 
An outbreak centered on the Swansea area of Wales started in November 2012; as of 22nd April 
there have been 886 cases (NHS WALES. Public health Wales Outbreak data November-July 
2013). 
 
Vaccination may eventually eradicate measles. However, controversy regarding the combined 
vaccine measles, mumps, rubella (MMR) vaccine, has led to reduced vaccination coverage in 
some countries during the last decade. In 2010, around 30.367 cases were reported from across 
the 32 European countries reporting to euvac.net (72% from Bulgaria, and 17% from France), 
and 21 measles related deaths (EUVAC annual measles report 2010. 
http://www.euvac.net/graphics/euvac/pdf/annual_2010.pdf . After the MMR vaccine negative 
publicity, associating the vaccine with autism and bowel disease  ( Wakefield et al. 1998), 
compliance dropped sharply in the UK, from 92% in 1996 to 84% in 2002  ( Simon 2003). 
Measles cases continued to be reported in 2006 at incidence rates 13 times greater than 1998 
levels. In 2008, measles was declared endemic in the UK, meaning that the disease was 
sustained within the population and the incidence rates 24 times greater than 1998 
(“Confirmed cases of measles, mumps & rubella”. Health Protection Agency 2007-03-22. 
Retrieved 2007-09-05). All this, may be the result of a low MMR vaccination rate which 
created a population of susceptible children who could spread the disease; also in some years 








   
Susceptible groups in the UK include: unvaccinated children, young adults born in the UK 
between 1970 and 1979 (single measles vaccine) which in a few years also could be at risk of 
PDB, recipients of a single dose of measles containing vaccine, children aged less than 12 
months who have not yet been vaccinated and immune-compromised people in whom live 
vaccines are contraindicated  ( Perviz and Eithne 2006). 
 
The serology of measles is quite well established and can be summarized as follows: In 
individuals with acute measles four-fold or greater increases in measles-reactive antibodies 
are detectable by CF, HAI, IFA, and EIA. IgM antibodies to measles virus, the test of choice, 
are often detectable with onset of the rash and typically persist for 4 weeks  ( Helfand et al. 
1997); at least 80% will be positive for measles IgM at 6 days and 100% at 16 days after onset 
of symptoms  ( Ozanne and Dhalewyn 1992). Over 50% of patients with recent measles will 
become IgM-negative at 4 months with the first negative results recorded around 9 weeks            
( Helfand et al. 1997). Maximal titers are reached between 15 to 19 days after rash onset               
( Helfand et al. 1997;  Oshitani et al. 1997) False-positive measles IgM may happen due to 











   
 
Figure.1.12. The diagram is showing a general behaviour of Inmunoglobulins after 
vaccination, where the inside vertical line, parallel to the Y axis, is indicating the time of 
vaccination. 
 
Patients with failed vaccination for measles often develop measles virus reactive IgM when 
infected  ( Ryall et al. 1996). Exposure to measles virus often leads to a secondary immune 
response in IgG-positive individuals but neither immune response nor prior vaccination 
ensures protective immunity  ( Ozanne and Dhalewyn 1992). 
 
Additionally, increased intrathecal synthesis of IgG against measles virus is often seen in 
multiple sclerosis  ( Albrecht et al. 1983;  Dhibjalbut et al. 1990). Also profound increases of 
intrathecal synthesis of measles virus-reactive IgG in sub-acute sclerosing panencephalitis 
(SSPE) has been reported  ( Patrick et al. 1990). Smaller increases are common in multiple 
sclerosis as part of the MRZ reaction  ( Felgenhauer and Reiber 1992). Increases of measles-
reactive IgA and IgD in cerebro-spinal fluid (CSF) have also been reported in SSPE, as well 
as antibodies to mumps virus  ( Patrick et al. 1990;  Persson et al. 1989). 
 
The introduction of vaccination programs for measles in 1968  ( Miller 1989) has been 







   
highlighted that this occurred too recently to account for reduction in prevalence and severity 
of PDB patients born in the 1930s and 1940s  ( Doyle et al. 2002;  Poor et al. 2006a). If the 
theory is correct the reduction in the incidence of PDB will be seen in the years to come and 
onwards. 
 
Another virus that belongs to the family paramyxovirus, and has been mentioned as a possible 
candidate for viral trigger on PDB is Canine distemper. Gordon reported canine distemper 
virus as the predominant paramyxovirus associated with PDB in the North West of Britain  ( 
Gordon et al. 1991;  Gordon et al. 1992;  Gordon et al. 1993); Distemper is most commonly 
associated with domestic animals such as dogs and ferrets. It is a single-stranded RNA virus  
( McCarthy et al. 2007) very similar to the measles virus. Canine distemper virus (CDV) seems 
to have appeared more recently with the first case described in 1905 by French veterinarian 
Henri Carre  ( Pomeroy et al. 2008). The virus can cause systemic infection in the host 
carnivore. Puppies from 3-6 months old are particularly susceptible. CDV spreads through 
aerosol droplets and through contact with infected bodily fluids including nasal and ocular 
secretions, faeces and urine. It can be also spread by food and water contaminated with these 
fluids. Canine distemper tends to orient its infection towards the lymphoid, epithelial, and 
nervous tissues  ( Fankhauser 1982). 
 
1.4.1.3. Other Virus 
In addition to the paramyxoviruses, other viruses have been studied for this thesis in 
association with PDB. That is the case for varicella-zoster virus and rubella virus.  
 
Rubella has been chosen due to its similarity to paramyxoviruses. It is the only member of the 
genus Rubivirus and belongs to the family Togoviridae. It is similar to the paramyxovirus 
because it is a single stranded RNA of positive polarity enclosed by an icosahedral capsid. 
Additionally Rubella is part of the vaccine Measles, Mumps, and Rubella (MMR). Supporting 
our decision to include Rubella in the study is a report of bone changes after double vaccination 
with rubella and measles vaccine  ( Peters and Horowitz 1984). This article described a drastic 








   
Varicella-zoster virus, more commonly known as chickenpox and herpes zoster, are known 
clinical manifestations of infection with varicella-zoster virus. A primary infection with 
Varicella-Zoster Virus, usually produce the clinical syndrome known as chicken pox which is 
highly contagious, characterized by widely spread vesicular eruptions and fever. It most 
commonly affects children from 5 to 8 years of age. Herpes zoster is mainly a disease of adults, 
with most cases appearing in patients around fifty years of age or older. Evidence suggest that 
this manifestation of VZV infections results from a reactivation of virus which has remained 
latent in the sensory spinal ganglia after a primary infection rather than a reintroduction of the 
virus into the host. The capability of the virus to remain dormant in the nervous system is well 
known. Variola, vaccinia, varicella, and the Epstein-Barr virus have been associated with 
arthritis  ( Silverman 1976). This virus was selected as a non-related control due to his 
capabilities (similar to the paramyxoviruses) and the fact that belongs to a completely different 







   
1.6. Aims 
 
The aim of my project is to investigate the relationship between the genotype and the 
phenotype of PDB patients and the interactions between genotype and environmental variables 
such as diet, occupation, previous musculoskeletal injury and extend of Paget’s disease. The 
hypothesis in this case was that the different genotypes could be related with the presentation 
of Paget’s Disease of Bone, genotypes could be associated with the severity of the disease and 
extend. 
 
Additionally, another aim is to investigate the role of virus infection in PDB by serology 
searching for viral prints or circulating antibodies in affected patients and controls. To 
investigate the hypothesis where measles virus infection might act as a trigger for disease 
occurrence and severity in people genetically predisposed to develop PDB. 
 
A third aim is the exploration of the possibility of mutations in other genes that have not been 
investigated. For the purposes of answer to the last query, I used results from the genome-wide 
association study and genotyped all samples available for other genes indicated in the results 




















   
Chapter 2: General Materials and Methods 
 
 
2.1. PRISM Patients/Samples 
 
The study was based on participants of the Paget’s disease, Randomised Trial of Intensive 
versus Symptomatic Management (PRISM) study (ISRCTN12989577) which was a 
randomised comparative trial of two treatment strategies for PDB  ( Langston et al. 2010).  
PRISM Study population was a total of 2110 patients that were screened for possible inclusion 
in the study between December 2001 and June 2004 in 39 referral centres throughout the 
United Kingdom. In brief, the PRISM trial involved 1324 patients with PDB attending 
secondary care referral centres in the UK. Recruitment was based in the 39 secondary referral 
centres in the United Kingdom included in table 2.1. Patients were invited to take part in the 
study if they were known to have PDB diagnosed by standard clinical criteria  ( Selby et al. 
2002), were considered by the attending clinician to be able to adhere to the study protocol, 
and have a life expectancy greater than 1 year. An overview of the trial profile is shown in 
figure 2. 1 and demographic characteristic of the study population are shown in Table 2.2 
 
They were randomised to receive either “symptomatic” therapy in which treatment was 
administered only in patients who had bone pain or “intensive” bisphosphonate therapy in 
which the aim of treatment was to suppress and maintain serum alkaline phosphatase levels 
within the normal range by use of bisphosphonate therapy. The bisphosphonate of choice in 
the “intensive” group was risedronate since the trial was initiated in 2001 prior to the licensing 
of zoledronic acid for the treatment of PDB. The present report is based on a subgroup of 
737unrelated study participants who consented to provide a blood sample for genetic analysis. 
 
The enrolment criteria for the PRISM study were as follow: 
 PDB, diagnosed by standard clinical radiographic criteria. 
 Age greater than 18 years. 
 Life expectancy greater than 12 months at the time of enrolment. 







   
 Able to provide written informed consent. 
In addition, non-pagetic controls were recruited. The controls were volunteers (members of 




































   
Table 2.1: Referral Clinical Centres 
Clinical Centre Location 
Aberdeen Royal Infirmary Aberdeen 
University Hospital Aintree Aintree 
Royal National Hospital for Rheumatic Disease Bath 
Musgrave Park Hospital Belfast 
Queen Elizabeth Hospital Birmingham 
Royal Bolton Hospital Bolton 
Ninewells Hospital Dundee 
University Hospital of North Durham Durham 
Medway Maritime Hospital Gillingham 
Western Infirmary Glasgow 
Huddersfield Royal Infirmary Huddersfield 
Raigmore Hospital Inverness 
Airedale Hospital Airedale 
Leicester Royal Infirmary Leicester 
Leicester General Hospital Leicester 
Royal Liverpool University Hospital Liverpool 
Llandudno General Hospital Llandudno 
Guy’s Hospital London 
King’s College Hospital London 
Manchester Royal Infirmary Manchester 
The James Cook University Hospital Middlesbrough 
Freeman Hospital Newcastle 
Norfolk & Norwich University Hospital Norwich 
City Hospital Nottingham 
Robert Jones & Agnes Hunt Orthopaedic Hospital Oswestry 
Nuffield Orthopaedic Centre Oxford 
Llandough Hospital Penarth 
Derriford Hospital Plymouth 







   
Harold Wood Hospital Romford 
Oldchurch Hospital Romford 
Hope Hospital Salford 
Northern General Hospital Sheffield 
Southhampton General Hospital Southhampton 
Royal National Orthopaedic Hospital Stanmore 
The Great Western Hospital Swindon 
Queen Elizabeth II Hospital Welwyn Garden City 
Arrowe Park Hospital Wirral 
Yeovil District Hospital Yeovil 
Western General Hospital Edinburgh 
 
2.1.1. Additional Cohorts 
 
On Chapter 4, for replication, we used four separate clinic-based cohorts of PDB 
patients. The GenePage cohort comprised 384 unrelated Italian patients with Paget’s 
disease recruited from 13 Italian centers as previously described  ( Falchetti et al. 
2009); the Naples/Siena cohort comprised a non-overlapping cohort of 363 unrelated 
Italian patients with Paget’s disease recruited from northern, central, and southern Italy 
as described  ( Gennari et al. 2010); the Salamanca cohort comprised 191 unrelated 
patients attending a specialist clinic for Paget’s disease in Salamanca, Spain  ( Corral-
Gudino et al. 2013b), and the Western Australian cohort comprised 232 unrelated 













   
2.2. Laboratory Investigations 
 
All participants had a radionuclide bone scan prior to entering the study and the extent of 
skeletal involvement was assessed by counting the number of affected sites. Routine 
biochemistry and haematology, including measurement of total serum alkaline phosphatase 
(ALP) was performed at baseline and during the study according to standard techniques. 
 
 
2.3. Clinical Assessments 
 
Health-related quality of life was assessed by the SF-36 questionnaire  ( Langston et al. 2007a). 
Deformity was assessed by the attending physicians who were asked to assess whether the 
patient had clinical evidence of bone deformity using a three-point scale as follow: 0= no 
deformity; 1= mild or moderate deformity and 2= severe deformity. The presence of bone pain 
was recorded and physicians were asked to assess if they thought the pain was caused by PDB. 
Information was collected on previous fractures and whether they had occurred in affected 
bone; on orthopaedic surgical procedures; on the use of a hearing aid for deafness; on age at 
first diagnosis of PDB; and family history of PDB. 
 
 Information was recorded on whether or not the patient had previously received 
bisphosphonate treatment, and if so, the number of treatment courses given. 
 
 We devised a disease severity score taking several clinical features into account; giving a 
point for the number of bones affected on the bone scan (range 1-26); the presence of bone 
pain thought to be due to PDB (0= no or 1 = yes), previous fractures (0 = no or 1 = yes), 
previous orthopaedic surgical procedures (0= no or 1 = yes), bone deformity (0 = no deformity 
to 14 = severe deformity in 7 bones); and use of a hearing aid if the patient had PDB of the 
skull (0= no or 1 = yes). The score could theoretically range from 1 (monostotic PDB with no 
complications) to 43 (PDB affecting all skeletal sites with multiple complications and multiple 








   
We also collected information on occupation and categorised occupations according to the UK 
Office for National Statistics Standard Occupation Classification 2000. Occupations were 
classified into three groups: those that were sedentary (for example, office workers); those that 
involved moderate physical activity (for example, factory workers, delivery workers, nurses 
and care assistants); and those that involving heavy physical activity (for example, farmers, 
miners and manual labourers). Milk consumption (as a surrogate for dietary calcium intake) 
was assessed by asking whether the patient took the equivalent of at least a glass of milk once 
a day; one a week or less than once a week as previously described  ( Visconti et al. 2010) . 
Previous episodes of musculoskeletal injury that were serious enough for the patient to seek 
medical advice were recorded and patients categorised into those that had suffered such an 
injury (score =1) and those that had not (score =0).  
 
 
2.4. DNA Extraction 
 
DNA was extracted from patient’s blood prior to the start of this project for the purpose of 
several studies. Extraction was carried out using the Nucleon BACC3 DNA Extraction Kit 
from Gen-Probe, according to the manufacturer’s instructions. All samples concentrations 
were analysed by Pico green (using UV transparent plates and a plate reader). Subset of 
samples (8 out of 92) also runs on a UV spectrophotometer. The purity of the extracted DNA 
was determined from the OD260/OD280 ratio. Extracted DNA was stored in solution at -40C. 
Stock DNA prepared at a concentration of 50ng/ul and working stock at a concentration of 




2.5. Mutation Screening 
 
For the screening of the subject for novel mutations and known SQSTM1 mutations; Genomic 
DNA was extracted from peripheral blood using standard procedures, as described above. 







   
chromosome 5, focusing on exons 7 and 8 and the intron exon boundaries since all previously 




2.5.1. Primer design 
Primer sequences were designed for two exons of SQSTM1 using OLIGO 3.4 Primer Selection 
Software (Rychlik and Rhoads, 1989). Exon 7 is suitably short to be accommodated by one 
automated sequencing run so primer pairs were designed to include the entire exon 7 and the 
exon-intron boundaries. Exon 8 is also a suitable size to be sequenced in one run. After initial 
selection just a pair of primers that amplify the reading frame have been used for the 
continuous genotype of the exon 8. The oligonucleotides used in PCR amplification were 
purchased from Invitrogen and are shown in Table 2.1. These were received in a freeze-dried 
state, suspended in sterile water to a storage stock concentration of 100M and diluted to a 
PCR working stock concentration of 10M for PCR use and working stock concentration of 
3.3M  for sequencing use. 
 
Table 2.1: Primers used for SQSTM1 exon 7 and 8 amplification. 
PRIMER NAME FORWARD &REVERSE SEQUENCE Amplified Region 











Genotyping of samples was carried out by PCR analysis of genomic DNA. All PCR reactions 
were performed in AB-Gene 96-well plates. The volume for each reaction was adjusted to 25ul 








   
 
Table 2.2: PCR Reaction. 
Volume 
(microliters) 
Solution Suppliers Notes 
 
2.5 10X Taq buffer mix Qiagen Catalogue#201207 
2.0 dNTPs Promega Catalogue#U1420 
5.0 
Q solution 




Invitrogen 1.5ul of each in a concentration 
of 10uM 
0.125 Taq polymerase Qiagen Catalogue#201207 




2.5 Genomic DNA  10ng/ul 
25 Final volume for PCR reaction 
 
 
2.5.2. PCR Amplification 
All the PCRs and genotyping was done by the candidate. PCR amplification was carried out 
in 25l reactions (as described in table 2.2) in 96-well skirted plates (AbGene, 0.2ml per well, 
cat. No. AB-0600-L). 2.5l of genomic template DNA (20ng/l) was mixed with 10.375l 
sterile distilled H2O (GIBCO distilled water DNase/RNase free. Cat No.10977-035 500ml), 
1.25l each of forward and reverse primer (10M), and PCR reagents from the Qiagen Taq, 
PCR Core Kit (2.5l of 10x PCR Buffer containing 15mM MgCl2; 5l of 5x Q-Solution; 
0.125l of Taq DNA Polymerase at 5 units/l concentration. Cat. No.201225) and 2l dNTP 
Mix containing 10mM of each dNTP. PCR thermocycling was carried out in a DYADTM DNA 
Engine (Peltier) and the thermocycling conditions for each primer pair are given in Table 2. 
 
 To identify any mutation on exon 7, a 454bp fragment was generated, using the primers 
previously described. For identification of any mutation on 







   
 
Amplification of both fragments was performed in a MJ Research thermocycler. The thermal 
cycling protocol is described on Table 2.3.  
 
Table 2.3: Thermocycling condition for PCR of exon 7 and 8. Cycle 2 is repeated for 34 
cycles. 
Step Action Temperatures Duration 
Cycle 1 Denature template 94°C 3:10min 
Cycle 2 to be 
repeated 34 times 
Denature template 94°C 0:50min 
Anneal primers 60°C 1:00min 
Extend primers 72°C 1:30min 
Cycle 35 Extend primers 72°C 8:30min 
 Storage   4°C 1hour 
 
 
2.5.3. Agarose Gel Electrophoresis 
The PCR products were visualised on a 2% agarose gel (Bioline cat# BIO41025) to confirm 
successful amplification of the correct product size. The gel was prepared with 1.60gr of 
agarose and 80ml of TBE ( Tris Borate EDTA buffer) adding 8ul of  SYBR safe gel stain 
(Invitrogen cat# S33102). As a reference for the size of the products obtained I used a low 
molecular weight ladder (New England Biolabs, cat# N3233S). 
  
Tris Borate EDTA buffer  was prepared from 20X TBE, which was made with 242g Tris base, 
123.4g Boric acid and 14.88g Sodium EDTA (BDH) dissolved in distilled water to make a 
final volume of 1 litre. 5ul of PCR product was mixed with 3ul of orange G gel loading dye 
(0.2g orange G (Sigma) dissolved in 100ml of 30% glycerol) and later loaded into the gel wells 
(Fig. 2. 1). 
  
 
2.5.4. DNA sequencing 
The PCR products were sequenced using the same primers in both forward and reverse 







   
purification system. 1l of ExoSAP-IT was mixed with 6l of PCR product and this mixture 
was incubated at 37C for 30 minutes to accommodate enzymatic digestion and at 80C for 
15 minutes to deactivate the enzyme. This enzymatic purification allowed the removal of all 
molecules except target double-stranded PCR product from the working solution. This mixture 
was diluted 1:2 by adding 7l of sterile H2O, mixed thoroughly and split into two 7l aliquots; 
one each for automated sequencing in the forward and reverse direction. 
 
Amplified and labelled DNA fragments were sequenced using a MegaBACETM 1000 DNA 
Sequence Analyser (Amersham). This system uses fine-bore capillaries filled with 
MegaBACETM Long Read Matrix to provide a homogeneous, gelatinous medium in which 
molecules of different sizes can be resolved by electrophoresis. Amplified and precipitated 
target DNA samples were re-suspended in 8l of Loading Solution (DYEnamic ET Dye 
Terminator Kit, Amersham) and vortexed. Samples were dissolved at 50C for 2 minutes, 
vortexed, denatured at 95C for one minute and placed on ice. Automated sequencing using a 




2.5.5. Nucleotide Sequence Analysis 
Automated sequencing data were imported into Chromas which produces a sequence 
chromatogram for each sample. This output was analysed manually for polymorphic variation 
in each exon among all members of the sample group. 
 
 The traces were analysed by Chromas-pro software and compared with the reference sequence 









   
 
















Figure 2.1: Gel electrophoresis analysis of SQSTM1 PCR. Lane 1: Low molecular 
weight DNA ladder; lane 2-5: Samples from patients amplified using exon 7 
primers; lane 6: Low molecular weight DNA ladder ; lane 7-10: Samples from 







   
2.6. Enzyme immune Linked ImmunoSorbent Assay for viral IgG 
(ELISA) 
 
2.6.1. Serum for viral studies 
Blood from patients was obtained on red top tubes, which contained serum clot activator. The 
serum was obtained by centrifugation of the whole blood at 1500g, serum removed and stored 




For viral testing enzyme linked immunosorbent assays (ELISA) was used for the detection 
and quantitative determination of IgG antibodies to Measles, Rubella, Mumps, Varicella-
Zoster Virus (VZV), Respiratory syncytial virus (RSV) and Canine Distemper Virus. 
 
For Measles virus, Mumps, Rubella and Varicella-Zoster, we used the kits mentioned in the 
Table 2.6.1. All these kits share the same protocol; also serum diluent buffer, 
Chromogen/Substrate Solution, wash buffer and stop solution are not kit lot number dependent 
and may be used interchangeably within the Trinity Biotech ELISA IgG assays. All the tests 

















   
Table 2.6.1: ELISA kits use for Measles, Mumps, Rubella and Varicella-Zoster, 
Respiratory syncytial virus and Canine Distemper. 
Virus Manufacturer Catalogue number 
Measles Trinity Biotech Captia TM 2326000 
Mumps Trinity Biotech Captia TM 2325900 
Rubella Trinity Biotech Captia TM 2325300 
Varicella-Zoster Trinity Biotech Captia TM 2325600 
Respiratory syncytial  MP Biomedical 071-516002 
Canine Parvovirus Distemper Biogal 11CPD200 
 
 
Briefly, the samples, calibrator and controls (positive and negative) were diluted 1:21 (10ul of 
the sample in 200ul of diluent) in a 96 well plates specific for each ELISA. To individual 
wells, 100ul of the appropriate diluted calibrator, controls and patient sera was added. Each 
plate was incubated at room temperature (21 to 25° C) for 25min (+/- 5 min). After incubation 
the liquid from the wells was discarded by inverting the plate. The washing solution was added 
for a total of 3 washes. After the final wash, the plate was blotted on paper towelling to remove 
all the liquid from the wells. The conjugate was added, 100ul, and incubated for 25min at room 
temperature, after that another 3 washes followed. 100ul of chromogen/substrate was added 
and incubated at room temperature for 10-15minutes. Finally the reaction was stopped adding 
100ul of stop solution (1N H2SO4). The plates were read on an ELISA plate reader (BIO-TEK; 
Synergy HT) equipped with a 450nm filter. The antibody titers were calculated for each well, 
by blanking all the samples, calibrators and controls; using the calibrators value to calculate 
the Immune Status Ratio (ISR), and for most of the virus the values are transformed into 









   
 
Figure 2.2: Trinity Biotech Captia Elisa. 
For Respiratory syncytial virus, we use the MP Biomedical RSV IgG ELISA (catalogue 
number 071-516002). In this case the principle of the test was the same as the other ELISAs 
performed, but the protocol, was slightly different.  
The assay steps were as follow: The washing buffer needed to be diluted 1 in 9 with distilled 
water. The samples were diluted 1 in 100 with the buffer provided (2ul in 198ul); the controls 
for the standard curve are ready to use and 5 standards are supplied with the kit. The samples 
were added to the ELISA plate (100ul) and incubated for 60 minutes. After the first incubation 
the plate was washed 3 times with 300ul of diluted washing buffer. The conjugate was added 
to each well (100ul) and incubated for 30 minutes, this was followed by 3 washes with 300ul 







   
minutes in the dark and the stop solution was added (100ul). The plate was read within 60 min. 
at 450nm and a reference wavelength of 620nm was used.  
 
For Canine Distemper IgG test, ImmunoComb® Canine Parvovirus and Distemper IgG 
Antibody Test Kits were used. The ImmunoComb® test is a modified ELISA, which can be 
described as an enzyme labelled “dot assay”. In this case the assay is slightly different to the 
other ELISA’s performed. 
 
The kit contains 2 main components: a comb shaped plastic card, hereafter referred to as the 
Comb and a multi compartment developing plate. The comb has 12 teeth, sufficient for 12 
tests or samples. Each tooth contains 3 dots, one of the dots is purified parvovirus and a second 
dot is purified distemper virus, the upper most spot is a positive control. Purified CPV antigen 
is attached at the middle spot and purified CDV antigen is attached at the lowest of the 3 spots 








   
Figure 2.3: Biogal Laboratories, ImmunoComb®. 
 
The first step of the test is to add 5ul of serum in a well in row A of the multi-compartment 
developing plate (diluting the samples in sample buffer 1 in 100). After adding the 12 samples 








   
exposed to the antigen attached to the comb). For mixing during incubation, the comb is dipped 
up and down at the start of each incubation; this motion is repeated at least twice in all the 
remaining rows. Next, tweezers were used to pierce the foil of the next well (row B) as a wash 
step and the comb is inserted for 2 minutes; before transferring the comb from one well to the 
next, we pierced the foil of the next well and gently shook off excess liquid from the comb 
teeth onto a tissue. The comb will be in row C for 5 minutes (the secondary antibody was in 
those wells), after will be in row D & E for 2 minute in each well (washing step and fixation) 
and the last well (row F) for 5 minutes (substrate step). Upon completion of the colour 
development in row F, the comb is moved back to row E for 2 minutes for colour fixation and 
to stop the reaction. When the comb is out, it needs to be allowed to dry for 1-10 minutes. The 
test can be read manually with the comb scale or by an image developer matching the positive 
reference spot with Immune Response Status 3 or S3, which is the “cut-off” point. Anything 
≥3 is positive meaning the titer is high enough to be protected against the virus, ≤3 mean 
inadequate immunity (low level of antibodies), ≥5 is high Positive which mean that you may 























   




Statistical analysis was performed using SPSS version 13.0. Differences between mean score 
were analysed for significance by one-way analysis of variance (ANOVA) followed by 
Dunnett’s post hoc test. Significant differences between groups were assessed using general 
linear model ANOVA followed by Turkey’s post hoc test (for equal variances) or Games-
Howell post hoc test (for unequal variances). Differences between cases and controls groups 
were analysed by independent-samples t test. The used of General Linear Model was justified 
by the need of determining whether the means of two groups differ (with or without 
SQSTM1/p62 mutations) procedure in which the calculations were performed using a least 
squares regression approach to describe the statistical relationship between some predictors 
and a continuous response variable. On GLM we choose to use a binary coding scheme (0, 1). 
 
In general, variable transformation was used or apply to the data which didn’t follow a 
normal distribution, as the viral titer (chapter 5), where the immune status ration were 
transform on tertiles. Similar approach was used on chapter 4, for the risk allele score. 
 
On chapter 3 the Student’s t test was used to look at the differences between two groups (with 
SQSTM1 mutations or without) and Chi Square was used to compares observed frequencies to 
expected frequencies all in categorical data. Univariate and Multivariate regression analysis 
was used to study the association of the mutations with the composite severity score, described 
on more detail in the corresponding chapter. In this case multivariate linear regression was 
used as an approach for modeling the relationship between a scalar dependent variable 
(severity) and some explanatory variables (age of diagnosis, family history, mutations, calcium 
intake, occupation, previous musculoskeletal injury). In linear regression, data are modeled 
using linear predictor functions, and unknown model parameters are estimated from the data. 
The goal in this case was prediction, or forecasting. For the regression analysis the 
Normality was tested to determine if the data set was well mode lled by a normal 
distribution and an informal approach to testing the normality was used by 
comparing a histogram of the sample to a normal probability curve, also the normal 







   
data against the standard normal distribution. For multivariate regression, adding 
and subtracting variables to the model one at a time and t esting them individually 
or in small groups with t test allow us to decide on appropriate variable inclusion. 
 
For the regression analysis the Normality was tested to determine if the data set 
was well modelled by a normal distribution. Comparing histogram of the sample to 
a normal probability curve, was an informal approach used on this case as well as 
normal probability plot where the standardized data against the standard normal 
distribution was tested. 
 
Software was used for the data analysis (Minitab and SPSS). We use Regression to assess how 
independent predictors of disease are collectively associated with the severity Score. Given 
the potential for correlation among the predictors, we’ll have Minitab display the variance 
inflation factors (VIF), which indicate the extent to which multi-collinearity is present in a 




On chapter 4: The meta-analysis was performed by Dr. Omar Albagha. In this case meta-
analysis was used for comparing, contrasting and combining results from different studies or 
cohorts, in the hope of getting results on a wider group or population, identifying patterns 
among study results, sources of disagreement among those results, or other interesting 
relationships that may come to light in the context of multiple studies. Data were synthesized 
across cohorts by the meta-analysis using Review Manager software, we use the results from 
5 different cohorts to examine the relation between risk allele score and markers of disease 
severity in the study group as a whole. No heterogeneity was found. The total size on this study 
adding all the cases used for each study is N=1940; but more specific details of the cohorts are 
in the table 4.1.  
 
As will be mention on chapter 4, on figure 4.1 case we used the fixed effects model. The figure 
is referring to Standard mean difference which is calculated using the means from tertile 1 and 







   
figure 4.1 is showing that it is not heterogeneity between the results or in other words, the 
results are similar between the cohorts. The total size on this study adding all the cases used 
for each study is N=1940; but more specific details of the cohorts are in the table 4.1. The 
Mantel-Haenszel method was used to calculate odds ratios and confidence intervals for 
categorical variables, and the inverse variance method was used to calculate standardized 
mean differences for continuous variables. 
 
On the same chapter, for each individual in each cohort, we assigned a score of 0, 1, or 2 to 
genotypes at the different 7 loci, depending on whether subjects carried the wild-type allele or 
were heterozygous or homozygous for the allele that was associated with PDB. Also a 
cumulative allelic risk score was created as described on previous publication  ( Albagha et al. 
2013). A cumulative risk allele score was constructed by adding the variants together and 
relating this to markers of disease severity, alone and in combination with SQSTM1 mutations. 
The use of tertiles is justified also by the need of summarizing the data. Tertiles split the data 
into three (approximately) equally sized groups. This approach is particularly useful because 
the data was not symmetrically distributed.  
 Analysis of variance (ANOVA) and general linear model ANOVA were used to evaluate the 
differences between the genotyped groups for continuous variables, and the chi-square test 
was used for categorical variables. Post hoc tests were run to confirm where the differences 
occurred between groups, used just because an overall significant difference in group means 
was observed. 
 
Statistical analysis on chapter 5 is based on the study of the differences between the levels of 
antibodies in cases and controls, and the differences were assessed by analysis of variance 
when the data were normally distributed or by Mann-Whitney test when the data were not 
normally distributed. Differences in the proportion of PDB patients and controls that tested 
positive for antibodies were assessed by the chi-square test. The relation between viral 
antibody concentrations and markers of disease severity was assessed by analysis of variance 
after categorising patients into tertiles of low, medium and high antibody levels for each virus.  
Additional analyses were performed in which the relationship between genotype and disease 
severity were analysed in relation to circulating viral antibodies. This analysis employed a 







   
gender and age into the model with calculation of least square means for the categorical 
variables. The significance level was set at 0.008 to account for the fact that antibodies against 
six different viruses were tested.  
 
All data are presented as means ± standard error of means (SEM) unless stated otherwise. 
Values of p less than 0.05 were considered significant, except on chapter 5 were we explained 
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Chapter 3: 
Mutations of Sequestosome 1 are Associated with Severity 
and Clinical Outcome in Paget Disease of Bone 
ABSTRACT 
Genetic factors play an important role in the pathogenesis of PDB and the most important 
predisposing gene is SQSTM1 which is mutated in about 10% of patients. Here we investigated 
the relationship between SQSTM1 mutation status, disease severity and clinical outcome in 
737 patients who took part in a randomised study of two different management strategies for 
the disease. Mutations of SQSTM1 were detected in 80/737 (10.9%) patients. Mutation carriers 
had an earlier age at diagnosis (59.4 ±11.5 vs. 65.0±10.4 years, p<0.0001); a greater number 
of affected bones (3.2±1.2 vs. 2.1±1.2, p<0.001) and more commonly had required orthopaedic 
surgery (26.2% vs. 16.1%, p=0.024) and bisphosphonate therapy (86.3% vs. 75.2%, p=0.01) 
than those without mutations. Quality of life as assessed by the SF36 physical summary score 
was significantly reduced in carriers (34.0±11.3 vs. 37.1±11.4; p=0.036) and during the study 
fractures were more common (12.5% vs. 5.3%, p=0.011) although most of these occurred in 
unaffected bone. This study demonstrates that SQSTM1 mutations are strongly associated with 
disease severity and complications of PDB.  
 
 
3.1. Materials and Methods 
All the work in this chapter, practical work, and design of the experiment, results, statistics 
and calculations was performed by the candidate. PCR, genotyping by chromatograms 
analysis all performed by the candidate. The sequencing of the PCR products was done by the 
MRC sequencing service and the results were analysed by the candidate. 
 
3.1.1. Genotyping for SQSTM1 mutations (exon 7 and exon 8) 
Genomic DNA was extracted from peripheral blood using standard procedures, as described 
previously. The PCR methodology used as described previously  ( Barille et al. 1995)and is 







   
 
 
3.1.2. Amplifying Exon 7 and Exon 8 
 To identify any mutation on exon 7, a 454bp fragment was generated using the following 
primers: Forward, 5’TTAAAGTCACGCTGGGAACCTGCT3’; Reverse, 
5’AGGGCAGGATGCTCTAAAGGG3’. To identify any mutation on exon 8, a 421bp 
fragment was generated, including entirely the encoding region, using the following primers: 
 Forward, 5’TCTGGGCAGGCTCGGACACT3’; 
 Reverse, 5’CCCTAAATGGCTTCTTGCACCC3’. 
 
Amplification of both fragments was performed in a MJ Research thermocycler, conditions 
described in detail under Materials and Methods. 
 
The PCR products were sequenced using the same primers in both forward and reverse 
directions.   The traces were analysed by Chromas-pro software and compared with the 
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3.1.4. Statistical analysis 
Student’s t test was used to evaluate differences between patients with and without SQSTM1 
mutations for continuous variables, and the chi-square test was used for categorical variables. 
Univariate and multivariate regression analyses were used to evaluate predictors of disease 












Patients who consented to provide DNA samples for analysis (n=737) were about 1 year 
younger than those who declined or were not asked to provide samples (n=578). (Mean ± SD 
= 73.2 ± 7.8 vs. 74.8 ± 7.9; p<0.001). They had an earlier age at diagnosis by about 3 years 
(64.4 ± 10.6 vs. 67.5 ±10.8, p<0.001), but their gender distribution was similar (46% male vs. 
48% male; p=0.43) and the number of affected sites was similar (2.22 ± 1.3 vs. 2.22 ±1.4; 
p=0.92). 
Mutations of SQSTM1 were identified in 80/737 (10.9%) of the patients studied as summarised 
in Table 3.1. The most common mutation was P392L but several other mutations were found, 
including 7 novel mutations (Fig.3.1 and Fig.3.2); T1311G, causing an amino acid change 
from isoleucine to serine at codon 424 (I424S); C1238T, causing a premature stop codon at 
position 400 in place of a glutamine residue (Q400X) and an insertion in position 1348 of an 
C, which produced a frameshift with 48 extra aminoacids; an insertion of an G in position 
1254, causing a premature stop codon at position 408 (D408X); a missense C1214T, which 
produce an aminoacid change from proline to serine  at codon 392 (P392S); a missense 
mutation A1331G, causing an aminoacid change at codon 431, an isoleucine to valine (I431V); 
T1290C, causing an aminoacid change from leucine to proline at codon 417 (L417P); C1208G, 
causing an aminoacid change at codon 390 (A390G) an alanine to a glycine. All mutations 
were present in heterozygous form, with the exception of one patient who was a compound 





























C1215T P392L  Missense 60 75 
1225insT E396X  Truncating 2 2.5 
C1238T Q400X  Truncating 1 1.3 
T1251C M404T  Missense 1 1.3 
A1250G M404V  Missense 4 5 
G1271A G411S  Missense 1 1.3 
T1311G I424S  Missense 5 6.3 
G1313A G425R  Missense 5 6.3 
G1313A/T1311G G425R/I424S  Missense 1 1.3 
TOTAL    80 100 
 
   







   
 
Figure 3.1: Some of the new mutations. A: Missense, T1311G, to produce an amino acid 
change I424S. B: truncating, replacement of a C1238T, producing a truncated protein 
Q400X. C: insertion of a C in position 1348, producing a frame shift with extra48aa. D: 







   
The clinical characteristics of patients with SQSTM1 mutations differed significantly from 
those without mutations as summarised in Table 3.2.  
 




p Value n=80 n=657 
Male 38  
(47.5%
) 356  
(54.2%
) .13 
Age at recruitment 
71.
1 ± 8.1 
73.
4 ± 7.8 .19 
Alkaline phosphatase 
1.2
5 ± 1.02 
1.4
5 ± 1.51 .12 
Previous courses of 
Bisphosphonate           
  0 11  
(13.7%
) 163  
(24.8%
)   
  1 28  (35%) 269  
(40.1%
) .01 
  2 24  (30%) 150  
(22.8%
)   
  3 or more 17  
(21.2%
) 75  
(11.4%
)   
Age at diagnosis 
59.
4 ± 11.5 65 ± 10.4 <.0001 
Family history of PDB 34  
(42.5%
) 74  
(11.3%
) <.001 
Number of bones affected 3.2 ± 2 2.1 ± 1.3 <.0001 
Patients with bone deformity 34  
(42.5%
) 234  
(35.7%
) .23 
Any fracture 31  
(38.7%









   
Fracture in unaffected bone 20  (25%) 200  
(30.4%
) .31 
fracture in Pagetic bone 11  
(13.7%
) 65  (9.8%) .28 
Orthopaedic surgery 21  
(26.2%
) 106  
(16.1%
) .024 
Skull disease and hearing aid 8  (10%) 46  (7%) .33 
SF-36 bodily pain 
38.
6 ± 11 
40.
4 ± 11.4 .18 
SF-36 physical summary score 34 ± 11.3 
37.
1 ± 11.4 .036 
SF-36 mental summary score 
49.
2 ± 11.7 
49.
4 ± 11.5 .90 
Composite disease severity score 7.9 ± 3.3 6 ± 2.6 <.0001 
Values are mean SD or number (%). The p values refer to the differences between the 
genotype groups assessed by Student’s test or chi-square test. The ALP values have been 
standardized to the upper limit of the reference range, which was set at 1.0. 
 
There was no difference between the genotype groups in terms of age, gender or total ALP at 
baseline although it should be noted that a high proportion of patients had previously been 
treated with bisphosphonates. Patients with SQSTM1 mutations had an earlier age at first 
diagnosis than those without mutations (59.4 ± 11.5 vs. 65.0 ± 10.4; p<0.0001), had previously 
required more courses of bisphosphonate therapy for PDB (86.3% vs. 75.2%; p=0.01), had a 
greater number of affected bones (p<0.0001) and had required orthopaedic surgery more 
frequently (26.2% vs. 16.1%; p=0.024). Several other complications of the disease tended to 
be more common in carriers of SQSTM1 mutations including bone deformity, previous 
fractures through affected bone and patients with skull disease who used a hearing aid for 
deafness but the difference between the groups was not significant for these variables (Fig.3.1). 
Overall disease severity, as assessed by the composite score described in the methods section 
was significantly greater in SQSTM1 mutation carriers (7.9 ± 3.3 vs. 6.0 ± 2.6; p<0.0001). In 







   
(34.0 ± 11.3 vs. 37.1 ± 11.4; p=0.036), although there was no difference in SF36 bodily pain 
score or SF36 mental summary score between SQSTM1 mutation carriers and non-carriers. 
 



































   





(n=637) p Value 
Intensive treatment 38 (47.5%) 338 (51.5%) 0.5 
Any fracture 10 (12.5%)   35 (5.3%) 0.011 
Fracture in unaffected bone 10 (12.5%)   26 (4.0%) 0.001 
Fracture in affected bone   0 (0%)   10 (1.8%) 0.25 
Orthopaedic surgery   8 (10.0%)   39 (5.9%) 0.16 
Bisphosphonate therapy 49 (61.2%) 402 (61.0%) 0.97 
Bisphosphonate dose (mg)*    
   Alendronate     259±1462   106±802 0.15 
   Etidronate   2610±21488 1046±8207 0.2 
   Pamidronate    46.9±118  53.5±176 0.74 
   Risedronate    2013±3253 2113±3436 0.79 
   Tiludronate    6640±27129 6283±23065 0.86 
Alkaline phosphatase. 24 months     1.01±0.70  0.93±0.71 0.34 
SF-36 bodily pain, 24 months     38.0±9.8  41.0±11.0 0.04 
SF-36 physical summary, 24 
months     32.7±9.4  36.8±11.3 0.007 
SF-36 mental summary, 24 months     47.2±12.5  48.1±11.2 0.55 
Values are mean SD or number (%). The p values refer to the differences between the 
genotype groups assessed by Student’s t test, chi-square test, or (in the case of 
bisphosphonate dose) Kruskall-Wallis test. The ALP values have been standardized to 
the upper limit of the reference range, which was set at 1.0. 
*Total dose of bisphosphonate given during the study, in milligrams. 
 
 
The proportion of patients allocated to intensive and symptomatic treatment was similar in the 
two genotype groups and there was no difference between the groups in the doses of 
bisphosphonates administered, the number of patients who required orthopaedic surgery or the 
level of total ALP at 24 months. Fractures were significantly more common in patients with 







   
Pagetic bone. The SF36 physical summary score at 24 months was lower in SQSTM1 mutation 
carriers as compared with non-carriers (32.7 ± 9.4vs. 36.8 ± 11.3; p=0.007). Bodily pain as 
assessed by SF36 was also significantly worse in SQSTM1 mutation carriers at 24 months 
(38.0 ± 9.8 vs. 41.0 ± 11.0; p=0.04) but there was no significant difference in the SF36 mental 
summary score between the groups. 
 
In order to identify the predictors of a poor clinical outcome in PDB we used univariate and 
multivariate regression analysis to identify factors that were associated with the composite 
disease severity score at baseline. Univariate analysis showed that age (p=0.01), age at 
diagnosis (p<0.001), family history (p<0.001), and the presence of a SQSTM1 mutations 
(P<0.001) were all significant predictors of disease severity score (Fig.3.2). None of the 
environmental variables studied including dietary calcium intake, occupation, or previous 
musculoskeletal injury predicted disease severity score (all p values > 0.4). Multivariate 
analysis (Table 3. 4) identified four independent predictors of disease severity score which 
together accounted for 29.1% of the variance in disease severity score. These were SQSTM1 













   
 
Figure 3.2: SQSTM1 Mutation status in relation with age at recruitment, age at diagnosis, 
family history and composite disease severity score. Panel A showing relation between 
the presence of the SQSTM1 mutations and the age of recruitment. Panel B showing the 
relation between the age at diagnosis and the occurrence of the SQSTM1 mutations. The 
error bars are mean ±SD. In the panel C, represent the percentage of cases with family 
history, the values are expressed on percentage (%). The panel D represent the relation 
between the severity score and the occurrence of SQSTM1 mutations. The p values refer 


















   
Table 3.4: Independent Predictors of Baseline Disease Severity Score in the PRISM 
Study. 
Predictor Coefficient SD T p Value 
Constant 9.746 0.888 10.97 <.0001 
SQSTM1 mutation 0.863 0.285 3.03    .003    
Family history 0.862 0.249 3.47    .001 
Age at diagnosis -0.160 0.010 -15.60 <.0001 
Age at baseline 0.112 0.013 8.29  <.000 
Regression equation severity=9.746+0.863 (mutation) +0.863 (family history)-0.160 (age 





This study has shown that SQSTM1 mutations are an important marker of disease severity and 
complications in PDB patients attending secondary referral centres in the UK. In keeping with 
previous smaller studies  ( Collet et al. 2007;  Hocking et al. 2004) we found that patients who 
carried SQSTM1 mutations had a younger age at diagnosis and more extensive disease than 
those without mutations. We have now shown for the first time that SQSTM1 mutation carriers 
are at greater risk of developing disease complications and have greater impairment of quality 
of life than non-carriers. It is interesting to note however that the reduction in quality of life 
was restricted to the physical summary score of SF36, which were between 12 and 16 points 
below the population normal values of 50 whereas the SF36 mental summary scores were 
completely normal in both screened groups. This suggests that whilst PDB adversely affects 
physical functioning, those patients who are affected seem to be able to overcome adversity 
and cope with their disability. 
 
Analysis of the relationship with treatment response showed no significant difference between 
SQSTM1 mutation carriers and non-carriers with regard to the biochemical response to 
bisphosphonate therapy. The amounts of bisphosphonate administered during the study were 







   
requirement for orthopaedic surgery was similar. Quality of life remained lower in SQSTM1 
mutation carriers than non-carriers after 24 months of treatment, however, suggesting that once 
complications of PDB and physical impairment have developed, they are not influenced 
substantially by therapeutic intervention. This is in keeping with the results reported for the 
PRISM study as a whole where we found that neither symptomatic management nor intensive 
management had a significant impact on quality of life or disease complications  ( Langston 
et al. 2007a). We were interested to note that fractures were significantly more frequent in 
patients with SQSTM1 mutations during the study although these predominantly occurred 
through unaffected bone. Previous studies have shown that fracture risk is increased in PDB  ( 
Melton, III et al. 2000b;  van Staa et al. 2002a), and in the PRISM study we found that about 
80% of these fractures are in unaffected bone. 
 
Whilst the increased risk of fractures in Pagetic bone is easily explained on the basis of reduced 
bone quality, the reason for the increased risk in unaffected bone is less clear. Previous studies 
have shown that PDB is associated with an increased risk of osteoarthritis  ( Helliwell 1995;  
Melton, III et al. 2000a;  van Staa et al. 2002b). This condition is known to be associated with 
an increased risk of fracture  ( Arden et al. 2006). Another potential reason for an increased 
fracture risk of unaffected bone in PDB would be deformity with resulting postural instability. 
This would be in keeping with the trend for patients with SQSTM1 mutations to have worse 
bone deformity than those without mutations. 
 
Epidemiological studies have suggested that low dietary calcium intake during childhood is 
associated with an increased risk of developing PDB  ( Siris 1994). In this study we observed 
no association between disease severity and consumption of dairy products during childhood 
or at other points in life. Repetitive mechanical loading has also been suggested to play a role 
in targeting of Paget’s disease to specific bones in the skeleton although this is mainly based 
on anecdote  ( Solomon 1979). Based upon this observation, we looked at the relationship 
between occupation and disease severity, but no significant association was observed, nor did 
we observe an association between previous musculoskeletal injury and severity of PDB. 
 
A limitation of our study is that the conclusions only hold true for participants in whom DNA 







   
patients being treated in a secondary care setting however, since the characteristics of subjects 
who provided DNA samples were broadly similar to those who did not. 
 
Previous studies have shown that intervention with potent bisphosphonates such as Zoledronic 
acid and Risedronate are very effective at suppressing bone turnover in PDB          ( Reid et 
al. 2005;  Siris et al. 1998). The effects of these agents on quality of life and disease 
complications are modest, however, probably because many patients have already developed 
irreversible skeletal damage by the time treatment is initiated. Our data raise the possibility 
that genetic testing for SQSTM1 mutations in patients with a family history of the disease 
might be warranted so that carriers of these mutations can be kept under close surveillance for 
early signs of the disease developing. 
 
It is important to emphasise that if a programme of genetic testing was to be implemented, 
then properly designed studies would need to be conducted to examine whether prophylactic 
bisphosphonate therapy would be of clinical benefit in asymptomatic SQSTM1 gene carriers. 
In this regard it is relevant to point out that the current generation of SQSTM1 gene carriers 
seems to have a delayed onset of PDB as compared with their parents  ( Bolland et al. 2007). 
Accordingly, the timing of any intervention would need to be carefully chosen to take the 
likely age at onset into account. Other issues such as anxiety associated with having a genetic 
test and cost-effectiveness would also need to be addressed to determine if the potential clinical 
benefit of genetic testing and intervention out-weigh the costs of mutation screening and drug 
treatment. A Trial is now in progress, called the ZiPP study (Zoledronate in the Prevention of 
Paget’s disease; ISRCTN11616770) in which we are addressing these issues. The ZiPP study 
aims to explore the risk and benefits of prophylactic zoledronic acid therapy versus placebo in 
asymptomatic patients with SQSTM1 mutations who have not yet been diagnosed with PDB. 
The primary aim of the ZiPP study is to determine whether bisphosphonate therapy can prevent 
the development of elevated bone turnover and bone lesions in mutation carriers but 
information is also being gathered on clinically relevant outcomes such as pain, quality of life, 
and anxiety and depression. At present, we do not feel that SQSTM1 Mutation screening is 
indicated in routine clinical practice but it will be important to re-evaluate this in the light of 








   
Chapter 4: 
 Identification of Novel Genetic Markers that predict Disease 
severity and Complications in Paget’s disease of Bone 
 
ABSTRACT 
PDB is a common skeletal disorder affecting about 2% of people over the age of 55 in the UK. 
Some patients develop progressive disease complicated by deafness, bone deformity, fractures 
and osteoarthritis. Mutations of SQSTM1 are found in about 10% of PDB patients and are 
significantly associated with disease severity  ( Visconti et al. 2010). Recently, seven 
additional susceptibility loci for PDB have been identified by GWAS in patients without 
SQSTM1 mutations. The aim of this study was to determine if these novel loci are also 
associated with clinical severity and extent of PDB, either alone or in combination with 
SQSTM1 mutations. 
 
Genotyping was conducted for the seven PDB susceptibility SNPs (rs10494112, rs4294134, 
rs2458413, rs1561570, rs10498635, rs5742915, rs3018362) and previous results of 
genotyping for SQSTM1 was used. The samples used were 770 participants of the PRISM 
study and in a replication sample of 1170 PDB patients from centres in Italy, Western Australia 
and Spain. For statistical analysis, the patients were divided into tertiles based on the 
cumulative number of risk allele carried and the association between carriage of the alleles, 
extent of PDB, disease complications and a composite disease severity score (previously 













   
4.1. Materials and Methods 
In this chapter, the primary analysis for PRISM samples was done by the candidate. The 
sequencing of the PCR products was done by the MRC sequencing service. Genotyping for 
the other SNPs that attained genome wide significance for association with PDB (rs10494112, 
rs4294134, rs2458413, rs1561570, rs10498635, rs5742915, rs3018362) was performed 
externally at the genetics core of the Wellcome Trust Clinical Research Facility. 
Genotypes for cases and controls were called using BeadStudio v3.2 (Illumina, Inc.) by 
following the manufacturer’s recommended protocol and the meta-analysis was performed 




As mentioned on the materials and methods chapter, the primary analysis was conducted in 
participants of the Paget’s 
 Disease, Randomised Trial of Intensive versus Symptomatic Management (PRISM) study 
9ISRCTN12989577) which was a randomised comparative trial of two treatment strategies for 
PDB  ( Langston et al. 2007c). The present study is based on a subgroup of 770 study 
participants who consented to provide a blood sample for genetic analysis. For replication, 
four separate clinic based cohorts of PDB patients were used. The GenePage cohort, 
comprising 384 unrelated Italian patients with Paget’s disease recruited from 13  Italian centres 
as previously described  ( Falchetti et al. 2009); the Naples/Siena cohort comprised a non-
overlapping cohort of 363 unrelated Italian patients with Paget’s disease recruited from 
northern, central and southern Italy as described  ( Gennari et al. 2010); the Salamanca cohort 
comprising 191 unrelated patients attending a specialist clinic for Paget’s disease in 
Salamanca, Spain  ( Corral-Gudino et al. 2012); and the Western Australian cohort comprising 
232 unrelated patients attending a specialist clinic in Perth  ( Rea et al. 2009). 
 
 







   
 In all cohorts, disease extent was assessed on the basis of radionuclide bone scan by counting 
the number of affected sites as explained previously. Clinical assessment, have been also 




Genotyping for SQSTM1 has been described in detail on the Materials and Methods chapter. 
Genotyping for the other SNPs that attained genome wide significance for association with 
PDB (rs10494112, rs4294134, rs2458413, rs1561570, rs10498635, rs5742915, rs3018362) 
was performed externally at the genetics core of the Wellcome Trust Clinical Research 
Facility using either using the Illumina HumanHap300-Duo BeadChip v2 array or the 
Sequenom MassARRAY iPLEX plattaform  ( Albagha et al. 2011). Genotypes for cases and 
controls were called using BeadStudio v3.2 (Illumina, Inc.) by following the manufacturer’s 
recommended protocol.  All the analysis was performed by Dr. Omar Albagha using 
BeadStudio and quality-control metrics such as cluster separation, AB T mean (the mean 
normalized theta values of the heterozygote cluster) and AB R mean (the mean normalized 
intensity of the heterozygote cluster) to exclude badly performing SNPs. Samples with a call 
rate of less than 90% were excluded (n=30). A number of randomly selected samples were 
genotyped on the different genotyping platforms (n=96 on Illumina and Sequenom; n=12 on 
all three platforms) and the cross-platform genotype concordance rate was >99.9%. The data 
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4.1.5. Statistical analysis 
The meta-analysis was performed by Dr. Omar Albagha. In this case meta-analysis 
was used for comparing, contrasting and combining results from different studies or 
cohorts, in the hope of getting results on a wider group or population, identifying 
patterns among study results, sources of disagreement among those results, or other 
interesting relationships that may come to light in the context of multiple studies.  
 
Data were synthesized across cohorts by the meta-analysis using Review Manager 
software, we use the results from 5 different cohorts to examine the relation between 
risk allele score and markers of disease severity in the study group as a whole. No 
heterogeneity was found. The total size on this study adding all the cases used for each 
study is N=1940; but more specific details of the cohorts are in the table 4.1.  
 
As mention on figure 4.1 case we used the fixed effects model. The figure is referring 
to Standard mean difference which is calculated using the means from tertile 1 and 
tertile 2 in panel A, tertile 1 and tertile 3 in panel B taking in account the weigh. 
Basically the figure 4.1 is showing that it is not heterogeneity between the results or in 
other words, the results are similar between the cohorts. The total size on this study 
adding all the cases used for each study is N=1940; but more specific details of the 
cohorts are in the table 4.1. The Mantel-Haenszel method was used to calculate odds 
ratios and confidence intervals for categorical variables, and the inverse variance 
method was used to calculate standardized mean differences for continuous variables. 
 
 
For each individual in each cohort, we assigned a score of 0, 1 or 2 to genotypes at the 
rs10494112, rs4294134, rs2458413, rs1561570, rs10498635, rs5742915, and rs3018362 loci, 
depending on whether subjects where homozygous or were heterozygous or homozygous for 
the allele that was associated with PDB. The score was adjusted for each locus depending on 
the strength of the association with PDB derived from the odds ratio for association with PDB 







   
was 1.72 for rs10494112; 1.45 for rs4294134, 1.40 for rs2458413, 1.67 for rs1561570, 1.44 
for rs10498635, 1.34 for rs5742915, and 1.45 for rs3018362.  
The scores were then added across all seven loci to create a cumulative allelic risk score and 
divided subjects from each cohort into tertiles based on the cumulative risk score. The 
cumulative allelic risk score was created as described on previous publication  ( 
Albagha et al. 2013). A cumulative risk allele score was constructed by adding the 
variants together and relating this to markers of disease severity, alone and in 
combination with SQSTM1 mutations. The use of tertiles is justified also by the need 
of summarizing the data. Tertiles split the data into three (approximately) equally sized 
groups. This approach is particularly useful because the data was not symmetrically 
distributed.  
 For SQSTM1 mutations, a score of 0 or 1 was assigned depending on whether or not a mutation 
was present. We also devised a genetic risk score in which patients were classified into three 
groups based on their risk allele score and SQSTM1 mutation status. Low risk patients were 
defined as those in the lowest two tertiles of risk allele score who were negative for SQSTM1 
mutations. Medium risk patients were defined as those in the highest tertile of risk allele score 
or those with SQSTM1 mutations. High risk patients were defined as those in the top tertile of 
risk allele score and positive for SQSTM1 mutation. 
 
 Analysis of variance (ANOVA) and general linear model ANOVA were used to evaluate 
differences between the genotype groups for continuous variables and the chi-square test was 
used for categorical variables. Data was synthesized across cohorts by meta-analysis using 
Review Manager software. The Mantel-Haenszel method was used to calculate odds ratios and 
confidence intervals for categorical variables and the inverse variance method was used to 












   
4.2. Results 
 
4.2.1. Characteristics of study cohorts 
The characteristics of the cohorts included in the study are summarised in Table 4.1. The 
average age at recruitment ranged from 67 to 75 years and the average age at diagnosis from 
58 to 68 years. There was a predominance of male subjects in each cohort ranging from 53% 
to 60% and between 8.6% and 19.8% of patients reported a family history of the disease. The 
frequency of complications varied between cohorts. Fractures through Pagetic bone ranged 
from 3.1% in Salamanca to 12.7% in the GenePage cohort whereas the prevalence of bone 
deformity ranged from 0.5% in the GenePage cohort to 59.7% in the Salamanca cohort. The 
frequency of deafness with skull involvement ranged from 5.9% in the GenePage cohort to 
17.3% in the Naples/Siena cohort and the frequency with which orthopaedic surgery had been 
required for PDB ranged from 6.1% in the Naples/Siena cohort to 16.9% in the PRISM cohort. 
The frequency with which patients had previously been given bisphosphonates therapy for 























   
Table 4.1: Characteristics of Included studies.  
 PRISM Naples/ 
Siena 
GenePage Salamanca Perth 
Number 770 363 384 191 232 
SQSTM1 +ve 82 (10.6%) 37 (10.2%) 30 (7.8%) 14 (7.3%) 17 (7.3%) 
Age (9years) 73.0 ± 8.0 67.4 ± 11.5 75.8 ± 10.0 74.4 ± 9.9 72.9 ± 9.9 




210 (57.8%) 206 
(53.6%) 
114 (59.8%) 133 
(57.3%) 
Family History 113 
(14.6%) 
72 (19.8%) 33 (8.6%) 28 (14.6%) 46 
(19.8%) 
Affected bones 1.8 ± 1.05 2.4 ± 2.02 1.5 ± 0.91 2.8 ± 2.0 2.6 ± 2.2 
Disease severity 5.1 ± 2.5 7.1 ± 3.11 5.7 ± 1.52 6.6 ± 3.3 6.4 ± 2.8 
Pagetic 
Fracture 
81 (10.5%) 29 (7.9%) 49 (12.7%) 6 (3.1%) 15 (6.4%) 
Bone deformity 280 
(36.3%) 
162 (44.6%) 2 (0.5%) 114 (59.7%) N/A 






225 (62.0%) 329 
(85.6%) 






22 (6.1%) 38 (9.8%) 23 (12.0%) N/A 
The first row is the total number of cases used in each study. The percentage are 











   
The association between PDB susceptibility alleles, disease extent and complications in the 
PRISM cohort are shown in Table.4.2. There was a significant association between risk allele 
score and number of affected bones with evidence of an allele dose effect (p=0.04). A similar 
trend was observed for disease severity score, but the differences were not significant. Family 
history of PDB was significantly associated with risk allele score in this subgroup of patients 
(p=0.01) as was the number of previous courses of bisphosphonates received for PDB 
(p=0.04). There was no significant association between allele risk score and sex, age, age at 
diagnosis of PDB, quality of life measures, the presence of deafness owing to PDB (reflected 
by use of a hearing aid and skull involvement), fractures through Pagetic bone, orthopaedic 





























   
Table 4.2.: Susceptibility alleles and severity of PDB in PRISM study at baseline visit.  
 
 
Values are mean ± SD or number (%). The p-values refer to the differences between the 
genotype groups assessed by ANOVA or Chi-square test. The ALP values have been 
standardised to the upper limit of the reference range which was set at 1.0 







Age (years) 73.3 ± 7.8 73.7 ± 8.1 72.7 ± 7.8 0.47 
Male 121 (53.1%) 131 (57.0%) 117 (50.9%) 0.39 
Age at diagnosis 65.2 ± 10.4 65.7 ± 10.4 64.0 ± 10.5 0.19 
Family History of PDB 18 (7.9%) 23 (10.0%) 38 (16.5%) 0.01 
Patients with Bone deformity 84 (36.8%) 75 (32.6%) 90 (39.1%) 0.33 
Fracture in Pagetic Bone 17 (7.5%) 29 (12.6%) 25 (10.9%) 0.18 
Orthopaedic surgery for PDB 36 (15.8%) 38 (16.5%) 37 (16.1%) 0.97 
Deafness and skull PDB 17 (7.5%) 17 (7.4%) 14 (6.1%) 0.80 
Number of affected bones 1.66 ± 0.92 1.82 ± 0.98 1.87 ± 0.98 0.04 
Disease severity score 4.82 ± 2.18 4.87 ± 2.34 5.19 ± 2.22 0.17 
Previous 
bisphosphonates 
0 69 (30.3%) 68 (29.6%) 41 (17.7%)  
 
0.04 
1 87 (38.2%) 91 (39.6%) 98 (42.6%) 
2 47 (20.6%) 48 (20.9%) 57 (24.8%) 
3 or more 25 (10.9%) 23 (10.0%) 34 (14.7%) 








37.7 ± 11.0 37.0 ± 11.6 37.1 ± 11.8 0.77 
SF36 mental 
summary 
49.4 ± 10.7 49.5 ± 11.9 49.7 ± 11.5 0.94 
Alkaline 
Phosphatase 
1.18 ± 0.85 1.37 ± 1.25 1.21 ± o.91 0.10 







   
4.2.3. Meta-analysis of PDB susceptibility alleles in relation to disease severity 
In order to determine if risk alleles were associated with disease severity in other populations 
we employed meta-analysis to examine the relation between risk allele score and markers of 
disease severity in the study group as a whole. There was a highly significant association 
between risk allele score and both disease extent and severity with evidence of an allele dose 
effect. The number of affected bones was significantly greater in tertile 2 compare with tertile 
1 (standardized mean difference 0.20 [0.08-0.31], p=0.0007) and greater still in tertile 3 
compared with tertile 1 (standardized mean difference 0.27 [0.15-0.38], p=0.00001) (Fig. 4.1). 
 
 
Fig. 4.1: Risk Allele Score and Number of affected bones. 
 
 
Meta-analysis of association between Risk allele score and number of affected bones on 
pagetic SQSTM1-mutation-negative individuals, using a fixed effects model, comparing 
tertile 1 with tertile 2 (panel A) and tertile 1 with tertile 3 (panel B). 
 
A similar effect was noted for disease severity score, which was greater in tertile 2 than in 
tertile 1 (0.15 [0.03-0.26], p=0.01) and greater still in tertile 3 compared with tertile 1 







   
association between fractures through Pagetic bone, use of a hearing aid and Paget’s disease 
of the skull, orthopaedic surgery for Paget’s disease, or bone deformity and risk allele score. 
However, he number of previous courses of bisphosphonates received for was also 
significantly greater for those within tertile 3 as opposed to tertile 1 (0.22 [0.10-0.33], 
p=0.0002) (Fig. 4.3). 
 
Analysis of individual loci for PDB susceptibility in relation to disease extent and severity in 
the whole cohort of SQSTM1 negative subjects, revealed weakly positive associations for 
some markers. These included rs104941, rs2458413, rs1561570, and rs3018362 with the 
number of affected bones (p=0.048, p=0.012 and p=0.030 and p=0.043 respectively); and 
rs2458413 for disease severity (p=0.041).  
 
 
Fig. 4.2: Risk allele score and disease severity score.  
 
Meta-analysis of association between risk alleles and severity score on pagetic 
SQSTM1-mutation negative individuals, using a fixed effects model, comparing tertile 









   
 
Fig. 4.3: Risk allele score and previous courses of bisphophonates. 
 
Meta-analysis of association between risk alleles and previous courses of bisphophonates 
on pagetic SQSTM1-mutation negative individuals, using a fixed effects model, 
comparing tertile 1 with tertile 2 (panel a) and tertile 1 with tertile 3 (panel b). 
 
 
4.2.4. Interaction between SQSTM1 mutations, risk alleles and disease severity. 
Since we and others have previously reported that SQSTM1 mutations influence severity of 
PDB  ( Collet et al. 2007;  Hocking et al. 2004;  Visconti et al. 2010) we looked for evidence 
of an interaction between risk allele score and SQSTM1 mutations in predicting disease 
severity. We analysed the relationship between risk allele score (lowest two tertiles versus 
highest tertile), SQSTM1 mutations, number of affected bones and overall severity using 
general linear model ANOVA, also entering age, gender and study site into the model for the 
whole study population. The results are summarized in Table 4.3. For number of affected 
bones, male gender (p < 0.0001), risk allele category (p < 0.0001), SQSTM1 mutations 
(p < 0.0001), and study center (p < 0.0001) were all significant predictors. For disease severity 
score, significant predictors were male gender (p < 0.0001), family history of Paget's 







   
(p = 0.002 to 0.0001), and age (p = 0.01, beta coefficient 0.005). The effect size of SQSTM1 
mutations on number of affected bones and overall disease severity as reflected by the β-
coefficients was about three times larger than that of the risk allele score. 
Because both risk allele score and SQSTM1 were independent predictors of disease extent and 
severity, we combined information from both markers to create a genetic risk score, dividing 
patients into three groups: group 1 (SQSTM1 negative and tertile 1 of risk allele score); group 
2 (SQSTM1 negative and tertiles 2 and 3 of risk allele score); and group 3 (SQSTM1 positive 
and tertiles 1 to 3 of risk allele score). 
 
 Analysis of various markers of disease severity in the whole study population showed a highly 
significant and stepwise increase in disease extent, severity, and number of previous 
bisphosphonates given for Paget's in relation to the genetic risk score (Table 4.4). When we 
defined “severe disease” as a disease severity score of 7 or greater (representing the top 20% 
of the whole population), there was a stepwise increase in severity according to genetic risk 
score. In terms of specificity and sensitivity, the highest category of genetic risk score had 























   
Table 4.3.: Predictors of Disease Severity and Extent in the Whole Study Population. 
 No. of affected bones Disease Severity score 
Mean±SD Beta p Value Mean±SD       β p Value 
Gender 
Female 2.67±0.07 -0.137 <0.0001 6.88±0.12 -0.199 <0.0001 
Male 2.95±0.07 _  7.28±0.12 _  
Family history 
No 2.72±0.06 -0.092 0.055 6.80±0.11 -0.277 0.001 
Yes 2.90±0.09 _  7.36±0.15 _  
SQSTM1+ve 
No 2.15±0.05 -0.659 <0.0001 6.20±0.09 -0.883 <0.0001 
Yes 3.47±0.11 _  7.97±0.18 _  
Risk allele category 
Tertile 1 2.61±0.08 -0.200 <0.0001 6.80±0.13 -0.282 <0.0001 
Tertile 2 2.91±0.08 0.105 0.025 7.16±0.13 0.080 0.303 
Tertile 3 2.90±0.08 _  7.28±0.13 _  
Center 
Florence 2.10±0.09 -0.709 <0.0001 6.72±0.16 -0.365 0.002 
PRISM 2.42±0.07 -0.386 <0.0001 5.98±0.12 -1.105 <0.0001 
Salamanca 3.38±0.12 0.566 <0.0001 7.57±0.19 0.490 0.001 
Naples/Siena 3.00±0.09 0.188 0.009 7.82±0.16 0.740 <0.0001 
Western 
Australia 
3.15±0.10 _  7.32±0.18 _  
The data shown are least square means (SD) from a general linear model analysis of 
predictors of disease extent in the whole study population. The beta-coefficients (Beta) 
refer to the effect size of the indicated variable on the response variable (no. of affected 
bones or disease severity score). The p values refer to differences between subgroups in 










   










Number of affected bones 1.74 ± 1.19 2.04 ± 1.48 3.20 ± 2.48 <0.0001 
Disease severity score 5.44 ± 2.15 5.86 ± 2.59 7.58 ± 3.67 <0.0001 
Severe disease (score >7.0) 
146 
(25.6%) 
378 (31.7%) 99 (55.0%) <0.0001 
Number of previous 
bisphosphonates 




346 (33.1%) 58 (35.6%) 0.46 
Deafness due to Paget's 49 (9.8%) 95 (9.1%) 23 (14.1%) 0.13 
Fracture in Pagetic bone 45 (7.9%) 113 (9.5%) 22 (12.2%) 0.20 
Orthopaedic surgery 57 (11.4%) 133 (12.7%) 23 (14.1%) 0.59 
Values are mean ± SD or number (%). The p values refer to the differences between the 
genotype groups assessed by ANOVA or chi-square test. Those in the low risk group 
were SQSTM1 negative and tertile 1 of the risk allele score; the medium risk group 
SQSTM1 negative and tertiles 2 to 3 of the risk allele score; and the high-risk group 
SQSTM1 positive and tertiles 1 to 3 of the risk allele score. 
 
 
4.2.5. Role of SQSTM1 mutations and risk alleles as predictors of clinical severity and 
treatment response 
In view of the fact that the genetic risk score was a strong predictor of disease extent and 
severity we wanted to determine if we could use this information to identify “high risk” 
patients and to determine if the response to treatment was influenced by the genetic markers. 
This analysis was restricted to the PRISM study where we had full information on disease 
complications including the presence of Pagetic bone pain and prospective data on treatment 
response. The results are shown in Table 4.5. Although genetic risk predicted severity at 
baseline, there was no difference in the response to treatment in terms the change in ALP levels 
or changes in quality of life measures as assessed by the SF36 score according to genetic risk. 
This illustrates that patients at increased genetic risk of severe disease do not have an impaired 











   











Symptomatic treatment 105 (47.7%) 229 (48.9%) 43 (52.4%) 0.76 
Number of affected bones at 
baseline 
1.66 ± 0.92 1.83± 0.97 2.48± 1.22 <0.0001 
Disease severity score at 
baseline 
4.85 ± 2.27 4.99 ± 2.29 6.22 ± 2.63 <0.0001 
Received bisphosphonate 
during study 
134 (60.9%) 289 (61.7%) 50 (62.2%) 0.97 
Total dose risedronate (g) 2.18 ± 3.24 2.00 ± 3.34 2.17 ± 3.64 0.79 
Total dose etidronate (g) 0.29 ± 3.12 1.19 ± 8.72 2.98 ± 21.5 0.10 
Total dose pamidronate (mg) 45.0± 156 66.9 ± 202.8 39.7 ± 107.5 0.21 
Total dose tiludronate (g) 4.94 ± 20.0 6.51 ± 23.5 7.56 ± 28.2 0.60 
Change in ALP -0.34 ± 0.90 -0.32 ± 0.97 -0.39 ± 1.11 0.39 
Change in SF36 pain score -0.53 ± 8.81 +0.12 ± 9.7 -0.88 ± 11.2 0.59 
Change in SF36 physical 
summary 
-4.27 ± 9.0 -4.62 ± 9.7 -4.98 ± 10.6 0.86 
Change in SF36 mental 
summary 
-1.56 ± 10.1 -2.41 ± 10.8 -3.74 ± 12.1 0.39 
Values are mean ± SD or number (%). The p values refer to the differences between the 
genotype groups assessed by ANOVA or chi-square test. The ALP values have been 







   
4.3. Discussion 
 
Genetics factors play an important role in regulating susceptibility to PDB and the findings 
reported here when combined with other evidence indicate that susceptibility alleles are also 
associated with disease severity. We previously reported that in the PRISM study, SQSTM1 
mutations were associated with more severe and extensive disease and a higher incidence of 
certain complications  ( Visconti et al. 2010). Associations between SQSTM1 mutations and 
disease extent have also been observed in other studies  ( Collet et al. 2007;  Hocking et al. 
2004). In the present study we have confirmed and extended these observations to show that 
the risk alleles which we previously found to predispose to  PDB by genome wide association 
study  ( Albagha et al. 2010;  Albagha et al. 2011) are also associated with disease extent and 
severity. 
 
When we analysed the association between PDB susceptibility alleles and markers of disease 
in the PRISM study we found that patients in the highest tertile of risk alleles group has 
significantly more extensive disease and a higher disease severity score as compared with 
those in the lower two tertiles. The positive association between risk allele score, disease extent 
and disease severity score was confirmed by meta-analysis of data from independent cohorts 
in Italy, Spain and Western Australia where we also found that highest tertile group had more 
extensive disease. In addition we found that in the extended sample, subjects in the highest 
tertile were more likely to have required previous bisphosphonates therapy than those in the 
lowest category, consistent with the fact that they had more severe disease. 
 
In all cohorts we found that the new risk alleles acted in an additive manner with SQSTM1 
mutations to regulate disease extent and severity but found that mutations of SQSTM1 had a 
quantitatively greater effect than the risk allele score. By combining information from 
SQSTM1 status and the new risk alleles however we were able to develop a genetic risk score 
which delineated three distinct groups with markedly differing effects on disease extent and 
severity. 
 
Although the genetic risk score was strongly associated with disease extent, there was no 







   
treatment. This is an important observation since it indicates that patients at high genetic risk 
of severe PDB show no evidence of resistance to the therapeutic effects of bisphosphonates, 
raising the possibility that complications associated with increased disease severity could be 
preventable. 
 
In this regard, previous studies have shown that potent bisphosphonates such as Zoledronic 
acid and Risedronate are highly effective at suppressing bone turnover in PDB  ( Reid et al. 
2005;  Singer et al. 1998) and that Zoledronic acid gives prolonged suppression of ALP levels 
for up to 6.5 years after a single infusion. The effects of bisphosphonate therapy on symptoms 
of PDB and quality of life are inconsistent however. Several randomised controlled trials of 
bisphosphonate therapy for PDB have shown a poor correlation between response of ALP and 
response of bone  ( Langston et al. 2007b;  Miller et al. 1999;  Reid et al. 1996). An exception 
is the HORIZON study where, Zoledronic acid was superior to residronate at controlling ALP 
levels and improving some aspects of quality of life in the short term  ( Reid et al. 2005) and 
longer term  ( Reid et al. 2011) . Although this indicates that effective control of elevated bone 
turnover can give symptomatic improvements, the overall effects of Zoledronic acid on quality 
of life in HORIZON were modest and the difference between Zoledronic acid and risedronate 
were less than the 5-point margin which is considered clinically significant. We speculate that 
these inconsistencies in biochemical and clinical response are attributable to the fact that many 
patients with PDB have already developed complications before the diagnosis is made and 
treatment is initiated. This was certainly true in the PRISM study where at baseline, 35% of 
patients already had bone deformity; 17% had previously required orthopaedic surgery for the 
disease and 22% had deafness associated with skull involvement. 
 
The results presented here shows that it is possible to predict the severity and extent of PDB 
by genetic testing for SQSTM1 mutations and other susceptibility alleles and further research 
will now be required to define how this information should be beneficially used in clinical 
practice. One possibility is that patients in the highest genetic risk categories could be 
prioritised for enhanced surveillance for the development of complications or even 
prophylactic bisphosphonate therapy. It is important to emphasise however that use of 
prophylactic bisphosphonate therapy in the absence of symptoms would need to be carefully 







   
is relevant to point out that a trial is now in progress, the ZiPP trial (Zoledronate in the 
Prevention of Paget’s disease; ISRCTN11616770) which aims to explore the risk and benefits 
of prophylactic zoledronic acid therapy versus placebo in patients with SQSTM1 mutations 
who have not yet been diagnosed with PDB and it would be of great interest to evaluate the 
effect of these new markers within this study to determine if they affect penetrance of and 































   
Chapter 5: Association between Viral Antibodies and PDB 
 
ABSTRACT 
Previous studies suggested that PDB may arise as the result of a slow virus infection with one 
of Paramyxoviridae virus family. It has more recently been proposed that measles virus 
infection might act as a trigger for disease occurrence and severity in people who are 
genetically predisposed to develop PDB. Although there is evidence that over-expression of 
measles virus protein can stimulate osteoclastogenesis and cause PDB-like lesions in mice, 
attempts to detect viral antigens and nucleic acids from bone and blood samples from affected 
patients have yielded conflicting results but there have been no previous studies of the immune 
response to viruses in PDB. 
 In this chapter circulating antibodies of the IgG class weremeasured for several viruses in 
patients with PDB and healthy controls using commercially available enzyme linked 
immunosorbent assays. Additionally levels of antiviral antibodies were related to markers of 
disease severity in the PDB cases in relation to other potential determinants of disease severity 
including age, gender, SQSTM1 mutation status and allelic score generated by genotypes at 
other susceptibility loci for PDB.  
The case control analysis showed no significant difference in antibody titres directed against 
rubella, varicella zoster, canice distemper, respiratory syncytial virus or measles in PDB 
patients as compared with controls. However, circulating antibodies to mumps virus were 
significantly higher in PDB cases as compared with controls (mean ± SD = 3.1± 0.84 vs 2.62 
±0.86. p<0.001), a difference remained significant when corrected for age and gender. 
and we study the association between antibody titers and markers of disease severity in PDB 
cases. There was no significant association between circulating levels of antibody to measles 
and mumps virus and age of diagnosis, such that subjects in the highest antibody tertile were 
diagnosed later in life (p0.01 and p<0.0001 respectively). There was a weak negative 
association between disease severity score and antibodies to mumps virus (p=0.047) and 
between number of affected bones and antibodies to distemper virus (p=0.049). There was no 
evidence of an interaction between predisposing susceptibility alleles for PDB and markers of 
disease severity for any of the antibodies tested. 
These observations suggest that PDB is associated with dysregulation in the antibody response 







   
with some markers of disease severity. There was no evidence for an interaction between 
antibody responses to any of the viruses tested and genetic determinants of PDB in predicting 
disease extent, severity or age at onset. The results are consistent with the hypothesis that PDB 
may be associated with abnormalities of the immune response but there was no evidence of a 
specific defect in response to measles virus which has been most implicated in the 






























   
5.1. Materials and Methods 
 
5.1.1. Patients 
The patients studied comprised of patients with PDB who took part in the PRISM study where 
samples were available from the baseline visit for genetic analysis and for analysis of anti-
virus antibodies. Due to the fact that a limited volume of serum was available, antibody testing 
was prioritised for measles virus antibodies, since this virus has been most implicated in the 
pathogenesis of PDB and samples for the other viruses were analysed where there was enough 
serum available for testing. As a result, testing for measles virus antibodies was conducted in 
709 patients with PDB as compared with 463 subjects for rubella virus, varicella zoster virus, 
distemper virus, and respiratory syncytial virus. The controls subjects comprised 220 subjects 
not known to have PDB who mainly comprised of the spouses of PDB subjects in the PRISM 
study. 
 
5.1.2. Clinical phenotype 
In the PDB patients, information was collected on previous fractures, orthopaedic procedures, 
use of a hearing aid, bone pain, bone deformity as assessed clinically, gender, age at entry to 
the study, the age at which PDB was first diagnosed, and the number of affected bones as 
assessed by radionuclide bone scan. From these data an overall disease severity score was 
calculated. This is a composite measure of severity taking into account the number of affected 
bones, and the presence of complications. In summary, one point was assigned for each 
affected bone and additional points were assigned for the following: previous fractures 
throught Pagetic bone (0=no or 1=yes), previous orthopaedic surgery (0=no or 1=yes), history 
of osteosarcoma (0=no or 1=yes); bone deformity (0=no deformity; 1=mild or moderate 
deformity, 2=severe deformity, for each bone affected); use of a hearing aid if the patient had 
PDB of the skull bones (excluding mandible and maxilla) (0=no or 1=yes);bisphosphonate 
treatment in the previous 12 months (0=no; 1=yes); bisphosphonate treatment >12 months ago 









   
5.1.3. Serum 
Serum was extracted from whole blood as described in chapter 2.  
 
5.1.4. Genotyping 
Genotyping for mutations of SQSTM1 was carried out by DNA sequencing of PCR-amplified 
DNA fragments of exons 7 and 8 and the intron-exon boundaries of SQSTM1 as described in 
chapter 3. Genotyping for the other SNP that attained genome wide significance for association 
with PDB in the studies of Albagha  ( Albagha et al. 2009;  Albagha et al. 2010) was performed 
either using the Illumina HumanHapDuo300 array; the Sequenom MassARRAY iPLEX 
platform as previously described, or using TaqMan SNP genotyping assays. A number of 
randomly selected samples were genotyped on the different genotyping platforms (n=96 on 
Illumina and Sequenom, n=12 on all three platforms) and the cross-platform genotype 





5.1.5. Measurement of anti-viral antibodies  
Testing for immunoglobulin G (IgG) antibodies to viruses was carried out on serum samples 
collected at the baseline visit using a variety of commercially available enzyme linked 
immunosorbent assays (ELISA). For measles virus, mumps virus, rubella virus, and varicella 
zoster virus antibodies the Trinity Biotech Captia assays TM was used (catalogue number 
2326000, measles; 2325900, mumps; 2325300, rubella; 2325600, varicella zoster). For 
respiratory syncytial virus the MP Biomedical RSV IgG ELISA was used (catalogue number 
071-516002) and for distemper virus the ImmunoComb® antibody test kit was used. All of 
the assays were performed according to manufacturer’s instructions. Inter-assay and intra-
assay CV for each ELISA is available on table 5.1. The reproducibility of the ELISAS is assess 
to determine the precision of the test results. Is performed by the manufacturers over 5 sera, 
run in 20 replicates for intra-assay, five replicates for 3 days for inter-day and 3 replicates of 







   
The results of the ELISA assays were read on a Synergy HT Multi-Mode Micro plate reader 
(Bio-Tek), 450nm filter. Dual wavelength was used and the reference filter set to 600-650nm. 
All samples were tested in duplicate and the mean value of the two samples calculated. 
Duplicate samples that yielded values that differed by more than 20% were repeated. 
 Using a calibrator in each run of ELISA, a mean Optical Density (OD) value is obtained, and 
to account for day to day fluctuations in the assay performance due to room temperature and 
timing a Correction Factor is determined by the manufacturers for each lot of kits and printed 
on the kit; the cut-off calibrator value for each assay is determined by multiplying the 
correction factor by the mean calibrator OD previously calculated. The Inmune Status Ratio 
(ISR) for each specimen is calculated by dividing the specimen OD value by the cutoff 
calibrator value determined previously; to transform all the data to International Units (IU) we 
use the natural exponential function f (x) = ex , where the results will be transformed into 
IU/ml as indicated by the manufacturer’s instructions. Details of the reference ranges for each 
assay are summarised in Table 5.2. Canine Distemper values are calculated on a different way, 
based on a colour scale or CombScale provided with the kit, the values range go from S0 to 
≥S5 which mean High Positive (Fig.  5.1); the comb can be read manually or as done in this 
case, using CombScan. Comb Scan is a software program that use a computer connected to an 
scanner; when a Comb is placed on the scanner, the program translate the colour results on the 
comb into numerical values. 
 













Table 5.1.: Reproducibility; Inter-assay and intra-assay CV for each ELISA, Sensitivity 















Measles 3.8-17.9 3.7-25.7 4.6-15.2 99.3 91.0 
Mumps 4.1-38.1 8.3-14.3 8.3-17.7 99.3 96.6 
Rubella 5.1-10.6 4.0-14.5 6.1-16.0 100 97.1 
Varicella-Zoster 3.7-18.3 7.0-23.7 6.3-16.3 99.4 97.0 
Respiratory 
Syncytial virus 
0.0-6.4 4.8-12.1 0.0-10.7 100 100 
Canine 
distemper 





Table 5.2 ELISA kits for viral antibody detection: Reference values and Range. The 
values are on International Units (IU) with the exception of Canine Distemper. 
Virus Negative Indeterminate Positive  
Measles ≤0.06 0.061-0.09 ≥0.091 
Mumps ≤0.9 0.91-1.09 ≥1.10 
Rubella ≤6.5 6.6-8.1 ≥8.2 
Varicella-Zoster ≤0.11 0.12-0.14 ≥0.15 
Respiratory Syncytial virus ≤0.54 0.55-1.09 ≥1.10 









   
5.1.6. Statistical analysis 
Differences between the levels of antibodies in cases and controls were assessed by 
analysis of variance when the data were normally distributed or by Mann-Whitney test 
when the data were not normally distributed. Differences in the proportion of PDB 
patients and controls that tested positive for antibodies were assessed by the chi-square 
test. The relation between viral antibody concentrations and markers of disease 
severity was assessed by analysis of variance after categorising patients into tertiles of 
low, medium and high antibody levels for each virus.  Additional analyses were 
performed in which the relationship between genotype and disease severity were 
analysed in relation to circulating viral antibodies. This analysis employed a general 
linear model analysis of variance, entering genotype, tertile of antiviral antibodies, 
gender and age into the model with calculation of least square means for the categorical 
variables. The significance level was set at 0.008 to account for the fact that antibodies 




















   
 
5.2. Results 
5.2.1 Demographic characteristics of PDB cases and controls 
The characteristics of PDB cases and controls are summarised in Table 5.3. The 
proportion of males was higher in PDB cases (53.4% vs 40.0%, p<0.001) and the cases 
were slightly older than the controls (73.1 vs 71.1 years, p=0.002).  
 






Age  73.1 ± 8.0 71.1 ± 9.2 p=0.002 
Male 379 (53.4%) 88 (40%) 2, df=1, p<0.001 
Age at diagnosis  64.4 ± 0.4   
Number of affected bones 1.83 ± 0.04   
Disease Severity Score 5.79 ± 0.09   
Values are mean SD or number (%). The p-value for the difference between groups was 
assessed by ANOVA for continuous variables or chi-square test for categorical variables.  
 
5.2.2 Qualitative testing for viral antibodies in cases and controls 
The results of qualitative testing for the presence or absence of anti-viral antibodies in 
cases and controls are summarised in Table 5.4. For this analysis patients were 
categorised as testing, negative, equivocal or positive for anti-viral antibodies 
according to the manufacturer’s reference range (Table 5.2). This analysis showed that 
a very high proportion of PDB cases and controls tested positive for measles virus, 
rubella, VZV, mumps and RSV. Antibodies were also detected that cross-reacted with 
distemper virus in PDB cases and controls but less than 5% were strongly positive.  
The only difference between cases and controls were for RSV where 91.7% of PDB 







   
5.4 Qualitative testing for viral antibodies in PDB cases and controls 
 PDB Control Significance  
Measles n=720 n=220  
Negative 2 (0.3%) 2 (0.9%)  
Equivocal 5 (0.7%) 2 (0.9%) 2 1.04, df=1, p=0.31 
Positive 216 (99.0%) 216 (98.2%)  
Rubella n=463 n=202  
Negative 1 (0.3%) 1 (0.5%)  
Equivocal 11 (0.7%) 8 (4.0%) 2 1.59, df=1, p=0.20 
Positive 451 (97.4%) 193 (95.4%)  
VZV    
Negative 4 (0.9%) 1 (0.5%)  
Equivocal 11 (2.4%) 2 (1.0%) 2 1.68, df=2, p=0.43 
Positive 448 (96.8%) 199 (98.5%)  
Mumps    
Negative 8 (1.7%) 3 (1.5%)  
Equivocal 4 (0.9%) 5 (2.5%) 2 2.77, df=2, p= 
0.25 
Positive 451 (97.4%) 194 (96.0%)  
Distemper    
Negative 2 (0.4%) 3 (1.5%)  
Weak positive 252 (54.5%) 101 (50.0%) 2 3.57, df=2, p=0.31 
Positive 194 (41.2%) 89 (44.1%)  
Strong positive 14 (3.0%) 9 (4.5%)  
RSV    
Negative 30 (6.4%) 6 (2.9%)  
Equivocal 8 (1.7%) 0 (0%) 2 6.23, df=1, p=0.01 







   
Differences in the proportions of patients in each category were assessed by chi-square test. 
Where necessary, data were combined for categories where the numbers of observations were 
too small to provide a valid chi-square statistic.   
 
5.2.3. Antibody concentrations in PDB cases and controls. 
The serum levels of anti-virus antibodies in cases and controls were then compared are 
summarised in Table 5.5. The only significant difference between antibody titres in 
cases and controls was for mumps virus when levels were significantly higher in PDB 
cases.  
 
Table 5.5. Levels of antivirus antibodies in PDB cases and controls  




2.38 ± 10.9 
(n=219) 






29.0 ± 11.4 
(n=202) 






0.87 ± 0.72 
(n=202) 






3.00 ± 0.84 
(n=202) 






2.36 ± 1.08 
(n=202) 






226.7 ± 143.4 
(n=205) 
243.3 ± 137.4 
 
0.16 
The values shown are mean ± SD. The number of observations for each virus in cases 
and controls are indicated.  The p-values refer to the differences between groups assessed 
by ANOVA 
 
Since the gender distribution and age of cases and controls differed significantly (Table 







   
differences between cases and controls. The results are summarised in Table 5.6. After 
adjusting for differences in age and gender the only significant difference between 
cases and controls was for mumps virus. 
 
Table 5.6 Age and gender adjusted levels of antivirus antibodies in PDB cases and 
controls  




2.37 ± 0.37 
(n=219) 






29.1 ± 0.52 
(n=202) 






0.87 ± 0.05 
(n=202) 






3.00 ± 0.04 
(n=202) 






2.36 ± 0.05 
(n=202) 






226.6 ± 6.5 
(n=205) 
244.8 ± 10.0 
 
0.13 
The values shown are least square means adjusted for age and gender  ± SD. The number of 
observations for each virus in cases and controls are indicated.  The p-values refer to the 
differences between groups assessed by GLM-ANOVA. 
 
5.2.3 Relation between viral antibodies and severity of PDB 
For this analysis patients were divided into tertiles on the basis of circulating levels of viral 
antibodies and antibody levels were related to age at diagnosis, number of affected bones and 
overall disease severity score which takes account of the number of affected bones and 
complications of the disease (section 5.1.2). The associations are summarised separately for 









   
Table 5.7. Markers of disease severity in relation to measles virus antibodies 
 Antibody Tertile  
 Low Middle High p-value 
Number 234 237 238  
Antibody level 0.2 ± 0.08 0.5 ± 0.13 6.3 ± 18.3 <0.0001 
Age at diagnosis 64.5 ± 10.8 63.5 ± 11.4 65.1 ± 10.0 0.26 
Affected bones  1.8 ± 1.0 1.8 ± 1.0 1.8 ± 1.1 0.95 
Total Severity score  5.8 ± 2.6 5.7 ± 2.4 5.8± 2.5 0.92 
Values are means ± SD. Differences between groups as assessed by ANOVA are indicated 
 
Table 5.8. Markers of disease severity in relation to rubella virus antibodies 
 Antibody Tertile  
 Low Middle High p-value 
Number 153 154 156  
Antibody level 17.6 ± 5.44 27.7 ± 2.51 41.7 ± 7.9 <0.0001 
Age at diagnosis 63.7 ± 11.3 64.3 ± 10.6 64.8 ± 9.8 0.65 
Affected bones  1.9 ± 1.1 1.8 ± 1.1 1.7 ± 0.9 0.12 
Total Severity score  5.9 ± 2.8 5.7 ± 2.3 5.7± 2.2 0.84 
Values are means ± SD. Differences between groups as assessed by ANOVA are indicated 
 
Table 5.9. Markers of disease severity in relation to varicella zoster virus antibodies 
 Antibody Tertile  
 Low Middle High p-value 
Number 157 152 154  
Antibody level 0.3 ± 0.1 0.7 ± 0.1 1.6 ± 0.8 <0.0001 
Age at diagnosis 63.2 ± 11.4 64.8 ± 10.1 64.8 ± 10.0 0.27 
Affected bones  1.7± 0.9 1.8 ± 1.0 1.9 ± 1.1 0.35 
Total Severity score  5.6 ± 2.3 5.7 ± 2.4 5.9± 2.7 0.47 








   
Table 5.10. Markers of disease severity in relation to mumps virus antibodies 
 Antibody Tertile  
 Low Middle High p-value 
Number 153 156 154  
Antibody level 0.3 ± 0.1 0.7 ± 0.1 1.6 ± 0.8 <0.0001 
Age at diagnosis 64.2 ± 10.3 63.7 ± 11.1 64.9 ± 10.3 0.55 
Affected bones  1.7± 1.0 1.9 ± 1.1 1.7 ± 0.9 0.34 
Total Severity score  5.4 ± 2.2 6.3 ± 2.8 5.5± 2.2 0.002 
Values are means ± SD. Differences between groups as assessed by ANOVA are indicated 
 
Table 5.11. Markers of disease severity in relation to distemper virus antibodies 
 Antibody Tertile*  
 Low Middle High p-value 
Number 115 139 208  
Antibody level 0.98± 0.1 2 ± 0.0 3.4 ± 0.6 <0.0001 
Age at diagnosis 62.6 ± 10.3 64.0 ± 10.1 65.3 ± 10.8 0.087 
Affected bones  1.7± 0.9 1.9 ± 1.1 1.7 ± 1.0 0.156 
Total Severity score  6.0 ± 2.7 5.9 ± 2.5 5.6± 2.3 0.229 
Values are means ± SD. Differences between groups as assessed by ANOVA are 
indicated. * It was not possible to categorise patients into tertiles for distemper virus due 















   
Table 5.12. Markers of disease severity in relation to respiratory syncytial virus 
antibodies 
 Antibody Tertile  
 Low Middle High p-value 
Number 157 156 157  
Antibody level 103.6±63.2 195.0±13.2 381.1±131.8 <0.0001 
Age at diagnosis 63.9±11.0 64.5±10.7 64.5±10.1 0.88 
Affected bones  1.7±1.0 1.9±1.0 1.8±1.1 0.25 
Total Severity score  5.7±2.4 5.7±2.5 6.0±2.6 0.37 
Values are means ± SD. Differences between groups as assessed by ANOVA are indicated 
 
5.2.4 Interaction between SQSTM1 mutations, viral antibodies and severity of PDB 
Since it has been suggested that viral infection might trigger PDB in patients who have 
SQSTM1 mutations, the relation between SQSTM1 mutations, viral antibody titres 
and markers of PDB severity were studied.  For this analysis patients were categorised 
by presence or absence of SQSTM1 mutations; the concentrations of antibody to each 




Measles virus levels were nominally associated with age at onset in that patients in the 
highest tertile were diagnosed about 3 years older than those in the lower tertile 
(p=0.01) (table 5.5, table 5.6 and table 5.7).  However this was not significant taking 
into account the Bonferroni adjusted threshold of significance of 0.008. There was no 
significant interaction between measles virus and SQSTM1 mutations for age at 
diagnosis (F=2.44, p=0.08), number of affected bones (F=0.32, p=0.72) or disease 
severity score (F=0.62, p=0.54).  However, as previously reported in chapter 3, 
SQSTM1 mutation status was a significant predictors of age at diagnosis (64.8 ± 0.4 







   
and disease severity score (7.03 ± 0.2 vs 5.67 ± 0.2, p<0.0001). Age at entry to PRISM 
also was associated with age at diagnosis (F=460.8, p<0.0001), with number of 
affected bones (F=18.54, p=0.002) and with total disease severity score (F=29.6, 
p=0.028). Gender was not significantly associated with age at diagnosis, number of 
affected bones and disease severity score (data not shown).  
 
Table 5.13. Measles virus antibody levels, SQSTM1 mutations, age, gender and the 
severity of Paget’s disease. 
 Antibody Tertile  
Measles Low Middle High p-value 
Age at diagnosis 61.4 ± 0.90 60.9 ± 0.92 64.2 ± 
0.80 
0.01 
Number of affected bones 2.1 ± 0.1 2.0 ± 0.1 2.1 ± 0.1 0.71 
Disease Severity score 6.5 ± 0.3 6.1 ± 0.3 6.2 ± 0.2 0.53 
Values are least square means ± SD. Differences between groups as assessed by GLM 




Rubella virus levels were not associated with any marker of disease severity and there 
was no significant interaction between rubella viral antibody titres and SQSTM1 
mutations in predicting age at diagnosis (F=0.28, p=0.758), number of affected bones 
(F=0.67, p=0.51) or disease severity score (F=0.04, p=0.958). As with the measles 
virus analysis, SQSTM1 mutation status was a significant predictors of age at 
diagnosis (65.8±9.6 vs 56.55±9.47 p˂0.0001), number of affected bones (1.76±0.96 vs 
2.52±1.2 p˂0.0001) and disease severity score (5.6±2.3 vs 7.4±2.8 p=0.001) after 
adjusting for antibody titre. Age at entry to PRISM also was associated with age at 
diagnosis (F=17.44, p<0.0001), with number of affected bones (F=5.52, p˂0.0001) 
and with total disease severity score (F=4.25, p˂0.001). Gender was not significantly 
associated with age at diagnosis, number of affected bones and disease severity score 








   
Table 5.14. Rubella virus antibody levels, SQSTM1 mutations, age, gender and the 
severity of Paget’s disease. 
 Antibody Tertile  
 Low Middle High p-value 
Age at diagnosis 61.87±1.36 61.11±1.07 62.23±1.07 0.76 
Number of affected bones 2.19±0.17 2.02±0.14 2.01±0.14 0.68 
Disease Severity score 6.55±0.42 6.28±0.33 6.24±0.33 0.83 
Values are least square means ± SD. Differences between groups as assessed by GLM 
ANOVA are indicated.  
 
 
Varicella Zoster Virus 
The results are shown in Table 5.15. Varicella zoster virus levels were not associated 
with any marker of disease severity and there was no significant interaction between 
rubella viral antibody titres and SQSTM1 mutations in predicting age at diagnosis 
(F=0.34, p=0.71), number of affected bones (F=0.09, p=0.92) or disease severity score 
(F=0.45, p=0.64). As with the measles virus analysis, SQSTM1 mutation status was a 
significant predictors of age at diagnosis (64.8 ± 0.4 vs 58.5 ± 1.3, p<0.0001), number 
of affected bones (2.39 ± 0.2 vs 1.74 ± 0.05 p<0.0001) and disease severity score (7.01 
± 0.4 vs 5.68 ± 0.1, p<0.0001) after adjusting for antibody titre. Age at entry to PRISM 
also was associated with age at diagnosis (F=329.3, p<0.0001), with number of 
affected bones (F=14.12, p<0.0001) and with total disease severity score (F=10.5, 
p=0.001). Gender was not significantly associated with age at diagnosis, number of 













   
Table 5.15. Varicella zoster virus antibody levels, SQSTM1 mutations, age, 
gender and severity of Paget’s disease. 
 Antibody Tertile  
 Low Middle High p-value 
Age at diagnosis 61.43±1.11 61.54±1.19 61.97±1.15 0.94 
Number of affected 
bones 
1.96±0.14 2.15±0.15 2.10±0.15 0.66 
Disease Severity score 6.05±0.34 6.54±0.37 6.44±0.35 0.57 
Values are least square means ± SD. Differences between groups as assessed by GLM 




Mumps virus antibody levels were significantly associated with age at diagnosis 
(p<0.001) and weakly with total disease severity score (p=0.047) but not with number 
of affected bones. Since age at diagnosis forms a component of the total disease 
severity score it seems likely that the greater age at diagnosis in the group with the 
highest tertile of mumps virus antibodies may have been driving this association. There 
was a significant interaction between mumps viral antibody titres and SQSTM1 
mutations in predicting age at diagnosis (F=9.46, p<0.001). The least square means for 
age at diagnosis for the different combinations in Table 5.16. This shows that patients 
with the highest levels of mumps virus antibodies who are SQSTM1 positive have an 
increased age at onset when compared with the lower tertiles suggesting of a gene – 













   
Table 5.16. Mumps Virus Least Squares Means for Age of Diagnosis. 
 SQSTM1 negative SQSTM1 positive 
Mumps tertile 1  65.1 ± 0.6 52.8 ± 2.3 
Mumps tertile 2 64.4 ± 0.6 54.6 ± 2.2 
Mumps tertile 3 64.9 ± 0.7 65.3 ± 1.9 
 
 However there was no interaction for the number of affected bones (F=0.18, p=0.83) 
or disease severity score (F=12.67, p=0.047). As with the measles virus analysis, 
SQSTM1 mutation status was a significant predictors of age at diagnosis (64.8 ± 0.4 
vs 58.5 ± 1.3, p<0.0001), number of affected bones (2.41 ± 0.2 vs 1.74 ± 0.5 p<0.0001) 
and disease severity score (7.12 ± 0.4 vs 5.67 ± 0.1, p<0.0001) after adjusting for 
antibody titre. Age at entry to PRISM also was associated with age at diagnosis 
(F=337.34, p<0.0001), with number of affected bones (F=8.41, p=0.004) and with total 
disease severity score (F=3.89, p=0.049). Gender was not significantly associated with 
age at diagnosis, number of affected bones and disease severity score (data not shown).  
 
Table 5.17. Mumps virus antibody levels, SQSTM1 mutations, age, gender and severity 
of Paget’s disease. 
 Antibody Tertile  
 Low Middle High p-value 
Age at diagnosis 59.01±1.21 59.51±1.17 65.09±1.02 0.0001 
Number of affected bones 2.12±0.16 2.09±0.15 2.00±0.13 0.83 
Disease Severity score 6.58±0.37 6.87±0.36 5.74±0.32 0.047 
Values are least square means ± SD. Differences between groups as assessed by GLM 




Distemper virus levels were nominally associated with number of affected bones in 
that those with the highest tertile of antibodies had fewer bones affected (p=0.047) 







   
adjusted threshold of significance of 0.008. There was no significant interaction 
between distemper virus and SQSTM1 mutations for age at diagnosis (F=1.99, 
p=0.138), number of affected bones (F=3.09, p=0.05) or disease severity score 
(F=1.44, p=0.24).  However, as for the previous analyses SQSTM1 mutation status was 
a significant predictors of age at diagnosis (64.8 ± 0.4 vs 58.6 ± 1.3, p<0.0001), number 
of affected bones (2.41 ± 0.2 vs 1.74 ± 0.5 p<0.0001) and disease severity score (7.12 
± 0.4 vs 5.71 ± 0.1, p=0.01). Age at entry to PRISM also was associated with age at 
diagnosis (F=323.05, p<0.0001), with number of affected bones (F=9.09, p=0.003). 
Gender was not significantly associated with age at diagnosis, number of affected 
bones and disease severity score (data not shown).  
 
Table 5.18. Distemper virus antibody levels, SQSTM1 mutations, age, gender and the 
severity of Paget’s disease. 
 Antibody Tertile  
Measles Low Middle High p-value 
Age at diagnosis 61.4 ± 0.90 60.9 ± 0.92 64.2 ± 0.80 0.01 
Number of affected bones 2.1 ± 0.1 2.0 ± 0.1 2.1 ± 0.1 0.71 
Disease Severity score 6.5 ± 0.3 6.1 ± 0.3 6.2 ± 0.2 0.53 
Values are least square means ± SD. Differences between groups as assessed by GLM 
ANOVA are indicated.  
 
 
Respiratory syncytial virus 
Respiratory syncytial virus (RSV) levels were not associated with any marker of 
disease severity and there was no significant interaction between RSV antibody titres 
and SQSTM1 mutations in predicting age at diagnosis (F=1.03, p=0.358), number of 
affected bones (F=0.52, p=0.59) or disease severity score (F=0.77, p=0.46). As with 
the measles virus analysis, SQSTM1 mutation status was a significant predictors of 
age at diagnosis (64.8 ± 0.4 vs 58.4 ± 1.3, p<0.0001), number of affected bones (2.37 
± 0.2 vs 1.75 ± 0.04 p<0.0001) and disease severity score (6.92 ± 0.2 vs 5.69 ± 0.2, 







   
with age at diagnosis (F=358.7, p<0.0001), with number of affected bones (F=9.37, 
p=0.002) and with total disease severity score (F=4.39, p=0.03). Gender was not 
significantly associated with age at diagnosis, number of affected bones and disease 
severity score (data not shown). 
  
Table 5.19. Respiratory syncytial virus antibody levels, SQSTM1 mutations, age, gender 
and the severity of Paget’s disease. 
 Antibody Tertile  
Measles Low Middle High p-value 
Age at diagnosis 60.64±1.28 61.32±1.1 62.89±1.06 0.358 
Number of affected bones 1.98±0.17 2.09±0.14 2.18±0.13 0.593 
Disease Severity score 6.07±0.40 6.19±0.34 6.66±0.33 0.462 
Values are least square means ± SD. Differences between groups as assessed by GLM 























   
5.3. Discussion 
 
The aim of this study was to determine if antibody response to measles virus, RSV and 
distemper virus which have been implicated in the pathogenesis of PDB  ( Basle et al. 1985;  
Friedrichs et al. 2002;  Gordon et al. 1993;  Hoyland et al. 2003;  Mills et al. 1981;  Ralston et 
al. 1997) was associated with disease occurrence or severity. In addition to testing these viruses 
I also measured antibody titres to other viruses such as mumps, rubella and varicella zoster 
virus which have not been implicated in the pathogenesis of Paget’s disease. 
 The results showed that a very high proportion of patients in both the PDB group and controls 
had circulating antibodies to the human viruses tested. In most cases the prevalance of those 
that tested positive was greater than 95% with only a small number of individuals that tested 
negative or where the results were intermediate. For distemper virus about 50% tested weakly 
positive, with 40% positive and only 5% strongly positive. Since there is homology between 
distemper virus and other members of the paramyxovirus family  ( Kallajoki et al. 1991;  Orvell 
and Norrby 1980;  Sheshberadaran et al. 1986), it’s unclear if these antibodies truly represented 
previous distemper virus infection or whether antibodies within the patient’s serum were cross-
reacting with the distemper ELISA. Further studies will be required to assess this.  
On qualitative testing there was no significant difference between cases and controls in the 
proportion of those that tested positive for any of the viruses studied except RSV where a 
greater proportion of PDB patients tested negative for antibodies than controls (6.4% vs 
2.69%, p=0.01).  
On quantitative testing the only difference between groups was observed for mumps virus. In 
this case PDB patients had a significantly higher titre of antibodies than controls (3.0 ± 0.8 vs 
2.6 ± 0.8, p<0.001).  
Another aim of the study was to determine if the levels of virus antibody were related to 
markers of severity of PDB. For this analysis patients were divided into three groups on the 
basis of viral antibody titre and this was related to age at diagnosis, number of affected bones 
and the overall disease severity score which takes into account the number of affected bones, 
along with other complications of the disease and age at onset. The only significant difference 
that was observed was in relation to mumps virus where the overall disease severity score was 
related to mumps antibody level. Specifically subjects with mumps virus titres in the middle 







   
respectively). However this was at the borderline of significance (p=0.002) and could have 
represented a false positive result.  
Given that genetic factors play an important role in PDB a further analysis was conducted to 
determine if SQSTM1 mutation status and viral antibody titres interacted to influence severity. 
This analysis showed that SQSTM1 mutations strongly predicted age at onset, number of 
affected bones and overall disease severity score. However we found little evidence of an 
interaction between viral antibody titres and SQSTM1 in predicting disease severity with the 
notable exception of mumps virus where subjects with the highest levels of antibodies that 
were SQSTM1 positive had in increased age at diagnosis than the other genotype / viral 
antibody groups.   
Overall the studies do provide no support for the notion that patients with PDB have an 
abnormal antibody response to paramyxovirus or have had previous infections with these 
viruses more frequently than controls. This of course does not exclude the possibility that PDB 
patients might have a clinically occult slow virus infection which is not accompanied by an 
abnormality in the immune response. Having said that, subacute sclerosing pan-encephalitis, 
the archetypical slow virus infection with measles is associated with abnormal immune 
response with increased levels of antibody production in blood (≥1:256) and the CSF (≥1:4)  ( 
Garg 2002). 
Interestingly evidence for an abnormality in the immune response to mumps virus was 
detected both in respect to the occurrence of PDB and disease severity score. Given that greater 
disease severity was only detected in participants within the middle tertile of mumps virus 
antibodies it is possible that this may represent a false positive result. Previous studies have 
shown evidence to suggest that immunoglobulin levels are abnormal in PDB compared with 
controls, although this study was small  ( Buxbaum and Kammerman 1984). This raises the 
possibility that PDB might be associated with subtle abnormalities in the immune response 
which would not be surprising given that many of the genes implicated in the pathogenesis of 
PDB such as RANK, OPG and OPTN also play a role in regulating immune function  ( 
Bengtsson and Ryan 2002;  Boyce and Xing 2007;  Mori et al. 2013;  Walsh and Choi 2014). 
Further studies would be of interest to determine if the abnormal antibody production to 
mumps virus that was observed here is a feature specific to mumps or might represent a wider 












































   
Chapter 6: Future Work 
 
For a long time PDB has been thought to have a genetic cause due to the observation 
of a pattern of familial transmission in many studies  ( Eekhoff et al. 2004a;  Hocking 
et al. 2000;  Laurin et al. 2001;  Morissette et al. 2006). Additionally, linkage studies 
have identified a number of chromosomal regions which are linked to disease in such 
families  ( Good et al. 2001;  Hocking et al. 2001;  Laurin et al. 2001). In chapter 3, 
genotyping the prism population, exon 7 and exon 8, for SQSTM1 mutations, allowed 
us to identify common mutations and even identify some novel mutations which also 
open the possibility of the future study of novel mutations, structural and 
functional studies as well as the opportunity of using animal models. This could 
be achieve by: studying and defining the complexity of (poly) ubiquitin modifications 
in vivo by the application of proteomics-based methods; also crating robust animal 
models carrying the mutations, will allow fully described and understand the genetics 
consequences of the mutations and possibly to provide a high-throughput genetically 
modifiable platform for preclinical evaluation of new therapeutics. 
Additionally we related the presence of the mutations with the severity of the disease 
and found that cases with the mutations on SQSTM1 have an earlier age of diagnosis, 
more bones affected, are more likely to have orthopaedic surgery, more often to have 
pagetic bones fractures and in general a more severe presentation of the disease than 
the patients without the mutation.  
 
Mutations in SQSTM1 gene are found in around a third of families with PDB, and 10 
to 11% of sporadic cases. There is a high percentage of cases were SQSTM1 mutations 
are not present. Other potential loci linked to the disease have also been identified and 
are currently under study. In Chapter 4 we mention the identification of novel genetic 
markers that predict disease severity and complications in PDB. Genetics factors play 







   
Chapter 4, when combined with other evidence, indicate that susceptibility alleles are 
also associated with disease severity. Associations between SQSTM1 mutations and 
disease extent have also been observed in other studies  ( Collet et al. 2007;  Hocking 
et al. 2004). In the present study we have confirmed and extended these observations 
to show that the risk alleles which we previously found to predispose to PDB by 
genome wide association study  ( Albagha et al. 2010;  Albagha et al. 2011) are also 
associated with disease extent and severity. More work has already been published 
recently, extending the dimension of this study  ( Albagha et al. 2013;  Obaid et al. 
2011). 
 
 A number of environmental factors have been suggested to be involved in the disease. 
Changes in severity and occurrence of the disease have been found together with 
variable penetrance of Paget’s disease within families with a genetic predisposition, 
demonstrating that an environmental factor may be operative. The concentration of 
cases in Lancashire, England  ( Barker et al. 1980) and in Australia  ( Gardner et al. 
1978)strongly suggests an important environmental factor in the aetiology. However, 
the focal nature of Paget’s is still unexplained, in the fact that the disease remains 
highly localized to a particular bone or bones rather than affecting the whole skeleton. 
The leading hypothesis for an infectious aetiology in Paget’s disease of bone is the 
slow virus infection theory which we explored on Chapter 5. 
 
In chapter 5, I discussed the study of a variety of virus. The data showed that Rubella, 
RSV, Distemper, VZV and Measles IgG levels are not different between cases and 
controls; but what is still interesting are the levels of antibodies found against specific 
virus. Additionally, we found that there is a significant difference between cases and 
controls with regard to IgG levels specific to Mumps virus, where the people with PDB 
showed higher levels than the controls. Also in Chapter 5, studying further into the 
cases, I found that for Mumps virus IgG levels, the cases are diagnosed earlier, suffered 
from deafness and have a higher risk of fractures if the levels of IgG against Mumps 







   
protective levels did not have records of pagetic fractures. If PDB is related to a viral 
infection, this study corroborated the fact that it may be Mumps virus, not measles or 
other paramixovirus. However, further studies will be required to clearly establish 
the relationship between PDB and MUMPS virus such as analysis of local Pagetic 
lesions and RT-PCR for specific viral particles in pagetic cases. 
 
It has been reported previously, that bisphosphonates such as Pamidronate may cause 
reduction in serum of IgG levels  ( Zhang et al. 2007); our data suggested some similar 
happening when we analysed the levels of IgG against measles in the cases. More 
recently it has been published that the oral administration of soluble proteins with first 
generation clodronate, zoledronate and neridronate induced transient specific soluble 
protein serum IgG  ( Tonti et al. 2013); recognizing that these drugs may enhance B 
cell responses in humans (transiently). We used a very small number of cases and 
controls. A bigger number study will clearly answer this question. Perhaps also 
studying the production of Immunoglobulins in-vitro in cases and controls will give 
us an idea of the functioning of the Immune System on the PDB meaning that a 
comparative study of the synthesis of Immunoglobulin on PDB cases and controls 
is required. Further studies on different bisphosphonates effect on the production of 
Immunoglobulins and the immune response in general will be also complement and 
















   
Electronic Database Information 
 
URLs for databases used in this study are as follows: 
 
 
Human Genome Mapping Project, http://www.hgmp.mrc.ac.uk/ (software or conducting 
SimWalk analysis) 
 
National Centre for Biotechnology Information (NCBI), http://www.ncbi.nlm.nih.gov/ 
(source of genomic and mRNA sequence information) 
 
Official Rebase Website, The http://rebase.neb.com (data base for restriction enzymes which 
could be use to genotype C1215T) 
 
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim 
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